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A key component of drug development is to establish the compound’s dose-response 
relationship, and identify all effective doses of the drug with a general goal of selecting the 
minimum effective dose (MED).  
A new closed testing procedure is proposed for identifying the MED for a single 
component drug. This procedure is based on constructing simultaneous one-sided confidence 
bands for the response surface of each dose’s effect relative to placebo. Our methodology utilizes 
a stepwise closed testing to test the ordered hypotheses of equality of mean dose-responses. The 
pattern of the rejected and accepted null hypotheses provides the estimate of the MED, if it 
exists. 
In the case of a combination drug, in addition to demonstrating safety and efficacy the 
FDA requires demonstrating that each component makes a contribution to the claimed effects. A 
combination which satisfies the last requirement is called an efficacious combination.  
In the most common case both single drugs are approved ones, and therefore, the 
efficacious combinations are effective, that is, they produce a therapeutic effect which is superior 
to placebo. 
We propose a closed testing procedure for estimating the minimum efficacious 
combinations (MeD’s) in a two-drug study and introduce a notion of the MeD-set. 
The main advantage of a closed testing procedure is the strong control of the familywise 
error at level of significance α and allowing testing individual hypotheses at the same 
significance level α without multiplicity adjustments. 
The proposed procedure is based on two main steps. In the first step, all possible 
structures of the population MeD-set are identified and the related closed family of hypotheses is 
constructed, and the proper step-down testing partial order is established. The second step is the 
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“α-testing” step. Using the closed testing principle, we test the hypotheses by constructing the 
AVE-test statistic. The pattern of the rejected null hypotheses identifies the MeD-set.  
In order to assess the performance of our procedure, we define several statistical 
measures. These notions are used in a large simulation study to examine the goodness of the 
estimation procedures and to identify the population configurations when the procedure performs 
the best. 
 
Keywords: Minimum effective dose; Dose-response; Combination drug; AVE-test; Closed 
testing; Step-down procedure. 
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PREFACE 
 
My father says that “there are just a few important decisions that a person must make during his 
life but upon these decisions his whole life depends.” Choosing a field of the major interest and a 
school where one can get an excellent education in this field have a great effect on the person’s 
life-time career and are two of these choices.  
My first choice to become a mathematician was made while I was in the middle school 
by my whole family. Since my mother and my sister are chemists and my father is an engineer, 
this decision was purely my father’s idea. It is never easy to argue with a woman, and it is almost 
impossible to argue with two of them at once, so the battle was a hard one but my father won it! 
More likely, he provided a very complex proof that his choice is the only correct one. Moreover, 
I suspect that the proof was so numerically intense that no one wanted to spend time to verify it, 
so the decision was made. This is how I chose the field of my interest! 
Next, my sister chose the only university for me to go to, Moscow State University. And 
again, my whole family helped me a lot so I could pass the exams and get admitted at such a 
famous school. This is how I made the second important decision in my life! 
I am really thankful to the faculty members of the Department of Computational 
Mathematics and Cybernetics of Moscow State University for their unique teaching style and 
creating an atmosphere stimulating a self-education and individual growth as a scientist of each 
student. 
My second school, Wayne State University, was also chosen for me by my sister. While I 
was an undergraduate student, my sister decided to continue her graduate education in the United 
States. No one in my family had ever thought about leaving Russia but my sister who is very 
brave and enthusiastic about favoring new opportunities. Following her steps, I started working 
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on my Masters’ at Wayne State University. This is how I made the third important decision in 
my life! 
I am very thankful to all faculty members of the Department of Mathematics at the 
Wayne State University. Especially, I want to thank two Professors, Rafail Khasminskii and 
Alex Korostelev who helped me make a decision to continue my education in the field of 
statistics. 
My third school, the University of Pittsburgh was not chosen for me by my sister. This 
time I had to make my own choice and I made a very right one. During my second year as a 
graduate student at the Department of Statistics I asked Professor Allan R. Sampson to become 
my research advisor. I was and I am very lucky to have his support and time for more than four 
years. And the most importantly, I am very thankful to Allan R. Sampson for helping me in 
selecting a dissertation topic, guiding me during my research and playing the leading role in my 
early career achievements as a young statistician.  
I also would like to acknowledge the help of other faculty members of the Department of 
Statistics, particularly, Professors Leon J. Gleser and Henry W. Block for being the dissertation 
committee members and giving me a professional advice, and the Chair of the department, 
Professor Satish Iyengar, for creating an educational atmosphere at the department. I also would 
like to thank two Professors of the Department of Biostatistics, John Bryant and Lisa Weissfeld, 
for their valuable comments regarding my research.  
Finally, I would like to thank my very closest family members: my husband, Alex 
Goponenko, for his love, patience, support, and motivation, and two of my loving children, 
Ksenia and Ivan, for filling every moment of my life with joy and happiness.  
“There are just a few important decisions that a person must make during his life;” and 
maybe, the majority of these decisions were made for me, I do not regret any of them. I believe 
that without my family and my teachers I would not accomplish that much and I would not 
become a proud owner of a Philosophiæ Doctor degree. 
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1.0 INTRODUCTION 
Modern drug development focuses on assessing the biological activity of a chemical or 
biological compound and investigating the significant health benefits and adverse effects, due to 
the compound. The Food and Drug Administration (FDA) requires demonstrating the safety and 
efficacy of the drug for approval for marketing. A key component of drug development is to 
establish the compound’s dose-response relationship, and based on this relationship identify all 
effective doses of the drug with a general goal of selecting the lowest dose among the effective 
ones. This information is of significance, particularly as increasing dosage tends to lead to the 
increased serious side effects. The recent actions concerning Vioxx® (Merck) or Celebrex® 
(Pfizer) illustrate the importance of understanding the dose-response relationship, particularly 
with respect to safety. The problems in establishing the correct dose-response relationships are 
even more complex when combination drugs are considered, such as the cholesterol drug 
Vytorin® (Merck/Schering-Plough), which is a combination of Zocor and Zetia®. 
The first results presented in this dissertation deal with single drug studies. The statistical 
analyses of single drug dose-response studies, while well developed, are still challenging. In a 
typical clinical trial, subjects are randomly assigned to one of the several dose groups and 
administered a drug at the assigned dose level. The patients in the control group receive placebo. 
All patients are treated and observed over the same amount of time. The main goal of the trial is 
to draw statistical inferences concerning the behavior of the population dose response function. 
Of particular importance is to determine the dose range where the drug is effective and then to 
obtain the lowest dose that is still effective. If the true dose-response were known then all of 
those notions would be simple. Data from clinical trials are used to estimate the shape of the 
dose-response. After the dose-response relationship is estimated, another goal is to estimate all 
effective doses, with a primary emphasis on estimation of the minimum effective dose (MED) 
and to characterize the uncertainty of this estimate.  
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There are a number of well known statistical procedures that are used to estimate the 
MED, but there is no one best procedure since the properties of the procedure depend on the 
shape of the true, but unknown, dose-response curve. A literature review (given in Section 2.1) 
discusses various hypothesis testing procedures and methods involving suitable confidence bands 
for the dose-response curve. We present a new procedure for identifying the MED in single drug 
studies. In doing so, we develop a new procedure for constructing simultaneous one-sided and 
two-sided confidence bands for the dose-response curve of each dose’s effect relative to placebo. 
Our methodology utilizes a method similar to the approach given by Lee (1996). By generalizing 
Lee’s method to handle dependent random variables, we first construct two-sided confidence 
bands for the differences between responses to the active dose levels and placebo (see Section 
2.3). Next, we construct the lower bands for the differences between responses to the active dose 
levels and placebo. Then we use stepwise closed testing to test the ordered hypotheses of 
equality of mean dose-responses. The pattern of the rejected and accepted null hypotheses 
provides the estimate of the MED, if it exists. The detailed step-down procedure is given in 
Section 2.4. We perform simulation studies to assess the goodness of the parameter estimates 
provided by the procedure. We also compare the proposed procedure with two well known 
procedures: William’s (1971, 1972) procedure and the Step-Down with Pairwise Contrasts 
procedure considered by Tamhane et al. (1996) in order to identify in comparison dose-response 
patterns where our procedure performs well in identifying the MED and has a smaller bias. The 
results of these studies are presented in Section 2.5. 
A much more complicated issue concerning dose-response studies deals with compounds 
obtained as a combination of two known effective drugs. There are many reasons why it may be 
desirable to produce a drug combination. There is a particular advantage to consider a drug 
combination for the treatment of infectious diseases. Wertheiner and Morrison (2002) note that 
simplifying the treatment regiment is crucial in the case of infectious diseases, because “partial 
adherence can lead to the development of drug-resistant strains and a threat to public health.” 
In the case of a combination drug, the FDA requires demonstrating that each component 
makes a contribution to the claimed effects. A combination which satisfies this requirement is 
called efficacious. The lowest efficacious combinations are called the minimum efficacious 
combinations (MeD’s). In the most commonly occurring case, both single drugs are approved 
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ones. In such a case the MeD is effective, that is, it produces a therapeutic effect which is 
superior to placebo. 
Since the MeD is not usually unique in a combination drug study, we define the notion of 
the MeD-set. It turns out that the population MeD-set has a very complicated structure and has a 
number of interesting properties, which are discussed in Section 3.2. 
Due to the increased attention directed toward combining two or more therapeutic agents 
to produce better treatments, several procedures have recently been proposed by Hung (1992, 
1993) for detecting the superior combinations and by Hellmich and Lehmacher (2005) for 
detecting the minimum effective combinations, i.e., the combinations with higher mean dose-
responses than the placebo. These procedures are discussed in a literature review provided in 
Section 4.1. But none of these methods was extended to find the MeD’s.  
As in a single drug study, in a two-drug study subjects are randomly allocated to the 
different groups, each group receiving a particular combination of the drugs. The increasing dose 
levels of both drugs are specified prior to the experiment. The patients in the control groups get 
either placebo or a particular dose of the component drug alone. All patients are treated and 
observed over the same amount of time. Because we are assuming in our research that each 
component drug is effective we do not use the data of the placebo group other than for the 
variance estimate.  
We propose a step-down procedure for estimating the minimum efficacious doses 
(MeD’s) in such a two-drug study. For each active compound, the expected gain from combining 
the drugs at the given levels is defined. Next, the appropriate estimator of the expected gain is 
constructed in order to test the hypotheses of the expected gains being zero versus at least one 
positive gain. The pattern of the rejected null hypotheses identifies all the combinations, i.e., the 
MeD’s, such that decreasing at least one component’s dose leads to a no-gain compound. Our 
approach focuses on developing criteria necessary for proper ordering of the hypotheses of 
homogeneity of mean dose-responses and applying a suitable closed testing procedure. A general 
method for constructing a closed hypothesis family and ordering the hypotheses is discussed in 
Section 4.2. Since the set of hypotheses to be tested depends on the number of dose levels of 
each drug considered in the study, we focus on the methods for the 2 by 2 case, 2 by 3 case, and 
3 by 3 case, which are presented, respectively, in Sections 4.3-4.5. 
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In order to assess the performance of the proposed procedure and any other procedure 
which identifies the MeD-set, several measures are considered. Some of them are generalizations 
of the measures used in a single drug case, such as the Familywise Error, Power and Lack of 
Power. In addition we define a number of other measures that can be used to assess the goodness 
of the parameter estimates. Chapter 5.0 is devoted to the criteria for evaluating procedures and 
presents the definitions of these measures.  
We perform simulation studies to examine the performance of the proposed procedure. 
The design and results of the studies are presented in Chapter 6.0. For different population mean 
dose-response patterns for the 2 by 2 and 2 by 3 cases, the strong control of familywise error is 
confirmed. Also for the 2 by 3 case we compare two proposed step-down procedures, the regular 
and modified, and obtain the criteria when one procedure dominates the other in terms of the 
measures proposed in Chapter 5.0. 
In summary, the contents of this dissertation are as follows. Chapter 2.0 is devoted to the 
single drug case. The literature review and introduction are presented in Section 2.1. Then the 
research problem is stated in Section 2.2. Section 2.3 presents the method for constructing 
simultaneous two-sided max-min confidence bands. A similar approach used to obtain one-sided 
bands is briefly discussed and then is utilized in the proposed procedure presented in Section 2.4. 
Section 2.5 concludes the single drug case by presenting the results of the simulation studies with 
regard to the proposed procedure. 
The combination drug case is presented in Chapters 3.0-6.0. First, the design of 
combination drug studies and the related statistical parameters are discussed in Chapter 3.0. Then 
the proposed testing procedure is presented in Chapter 4.0 starting with the literature review 
given in Section 4.1. Chapter 5.0 discusses the criteria for evaluating the performance of a testing 
procedure applied in a combination drug setting. Chapter 6.0 presents the details of the design 
and results of the simulation studies. Finally, Chapter 7.0 discusses the findings presented in this 
dissertation and provides the main goals of the future research. 
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2.0 SINGLE DRUG STUDY 
2.1 INTRODUCTION AND LITERATURE REVIEW 
There are a number of different dose-response curves considered for modeling and analyses in a 
single drug study. Among the potential shapes, the monotone one is by far the most commonly 
discussed in the literature. Figure 1 illustrates two examples of monotone population dose-
response functions: linear and step functions. 
 Drug Effect 
Dose Level 
Step 
Linear 
0 1 2 3 4
 
Figure 1. Examples of monotone dose-response curves 
One of the most important statistical summaries of a single drug trial is the estimated 
dose-response curve along with the upper and lower confidence bands for the population curve. 
There are a number of procedures for estimation of the dose-response curve and obtaining those 
bounds. Lee (1996) proposed a procedure which uses the assumption of the monotone dose-
response function and does not rely on a specified parametric model for the population curves. 
Before we discuss this procedure we introduce the basic notation and assumptions which we use. 
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In a single drug trial, subjects are randomly allocated to one of 1+K  groups. Let ,in  
Ki ,...,1,0=  denote the number of patients being allocated to the thi −  group. Subjects in each 
group receive a particular dose ix  of the drug, and the increasing dose levels Ki ,...,1,0=  are 
specified prior to the experiment. Patients in the control group receive placebo, denoted by dose 
00 =x . Let ( )ii xf=μ  denote the population mean dose-response for the thi −  group. Then the 
assumption of a monotone non-decreasing dose-response function )(xf  can be written as  
)(...)()( 10 Kxfxfxf ≤≤≤                                                          (2.1) 
Let ijy  denote the response of the thj −  subject in the thi −  group, Ki ,...,1,0=  and 
inj ,...,2,1= . We assume that the following hold. 
1) All observations ijy  are mutually independent.                                                             (2.2) 
2) ),(~ 2σμiij Ny , with )( ii xf=μ  for Kii ,...,1,0, =  and inj ,...,2,1= .                       (2.3) 
Let )/,(~ 2 iii nNy σμ , Ki ,...,1,0=  denote the sample means of the observations at 
each dose level Kii ,...,1,0, = . Let 2σˆ  be an unbiased estimate of the variance 2σ  such that 
2σˆ  is independent of iy , Ki ,...,1,0=  and  
νχσσ ν /~ˆ 222 , with )1(
0
+−= ∑
=
Kn
K
i
iν  degrees of freedom.                     (2.4) 
Sometimes it is convenient to assume that the same numbers of subjects are allocated to 
each treatment group, i.e., 
nnnn K ==== ...21 .                                                              (2.5) 
Under the conditions (2.1)-(2.4) Lee’s (1996) simultaneous max-min confidence bands 
are given by  
)(1ˆmax
, i
q
pj
jK
q
pj
jjiqp
xfnpqtyn ≤⎥⎥⎦
⎤
⎢⎢⎣
⎡ ÷⎟⎟⎠
⎞
⎜⎜⎝
⎛ +−− ∑∑
==≤≤
σα ν  
⎥⎥⎦
⎤
⎢⎢⎣
⎡ ÷⎟⎟⎠
⎞
⎜⎜⎝
⎛ +−+≤ ∑∑
==≤≤
s
rj
jK
s
rj
jjsri
nrstyn 1ˆmin
,
σα ν  
where Ki ,...,1,0=  and α ν,Kt  denotes the α−1  percentile of the distribution function of 
generalized studentized maximum modulus statistic T , defined as 
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σ
σˆ
1
max
0 +−=
∑
=
≤≤≤ ij
z
T
j
ih
h
Kji
,                                                    (2.6) 
where )1,0(~ Nzh  for Kh ,...,1,0=  and are independent random variables. 
We use ideas based on Lee’s (1996) approach to construct max-min simultaneous 
confidence bounds for the differences between responses to the active dose levels and placebo. 
These two-sided bands can be used to assess the behavior of the dose response differences of a 
certain drug.  
Jia (2004) introduces a method for obtaining the simultaneous confidence bands for the 
monotone mean differences )()( 00 xfxf iii −=−= μμν , Ki ,...,2,1=  for independent 
)/,(~ 2 iiii nNy σμ , Ki ,...,1,0= . To construct such intervals, Jia (2004) applies a max-min 
procedure introduced by Korn (1982) and constructs a step-down testing procedure for analyzing 
dose study data, which incorporates the adaptive sampling nature of the data. 
Sampson et al. (2005) further develop the ideas of Lee (1996) and Korn (1982) by 
providing a unified presentation of Lee’s and Korn’s univariate simultaneous inference 
procedures for monotone functions. The graphical representation of simultaneous confidence 
bands allows for the exploration of the geometry of the procedures in the regression setting and, 
therefore, illustrates their feasibility and applicability. These authors also suggest several cases 
when the procedures can be extended and propose a new bandwidth procedure which generalizes 
Lee’s and Korn’s methods. 
Next, let us consider two procedures for identifying the minimum effective dose (MED) 
presented in the literature, one of them assumes the monotone dose-response and the other does 
not. Both procedures use the following definitions of effective doses and MED.  
The active drug dose ix  is considered effective if it has a mean dose-response higher than 
the placebo mean dose-response, i.e., )()( 0 ixfxf < , Ki ≤≤1 . If there is at least one effective 
dose among doses considered in the trial, then there is a minimum effective dose (MED), which 
is defined as follows. The dose mx , Km ≤≤1  is the MED if ( ) ( ) 00 >− xfxf m  and 
( ) ( ) 00 ≤− xfxf i  mifor < , i.e., { }01 :min μμ >= ≤≤ iKi iMED . One approach to the problem of 
identifying the MED is to formulate it as a sequence of hypothesis testing problems: 
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iiH μμμ === ...: 100 ,                                                      (2.7) 
versus the alternative iiaiH μμμμ <=== −110 ...: , Ki ≤≤1 . In this approach, if *i  is the 
smallest i  such that iH 0  is rejected, then thi −*  dose is declared to be the MED. 
The main advantage of formulating the problem as a sequence of the above hypotheses is 
that the hypothesis family },...2,1,{ 0 KiH i ==Η  is a family that is closed under intersection, i.e., 
any hypothesis which is obtained as an intersection of any number of the hypotheses belonging 
to the family belongs to Η . Indeed, as shown by Tamhane et al. (1996), for any set of indexes 
Kiii m ≤≤≤≤≤ ...1 21 , and any msH si ,...,2,1,0 =Η∈  it follows that 
Η∈=
mm ioiii
HHHH 000 ...21 III , so that the family is closed under intersection.  
Marcus, Peritz and Gabriel (1976) propose a general method (hereafter denoted as the 
MPG principle) for testing hypotheses from a closed family. This method permits testing each 
hypothesis at level of significance α  and states that a hypothesis is rejected at level α  if and 
only if all hypotheses implying it, including itself, are significant at level α . This method has the 
nice property of strong control of familywise error (FWE) at level α . The FWE is defined as the 
probability of rejecting at least one true null hypothesis iH0 . Next, we review two procedures 
that use the MPG principle and, therefore, strongly control the FWE. 
The problem of identifying the MED formulated by (2.7) can be handled by using 
Williams’ (1971) procedure. This is a step-down procedure for dose-response functions 
satisfying (2.1). Under assumptions (2.2)-(2.4), the isotonic (maximum likelihood) estimates for 
the population mean responses are given by 
1
minmaxˆ
11 +−=
∑
=
≤≤≤≤ uv
y
v
ui
i
Kviui
μ , Ki ≤≤1 . 
Next, under assumption of (2.5), pairwise t -type statistics are calculated as 
nn
yt iWi /1/1ˆ
ˆ
0
0
+
−= σ
μ
, Ki ≤≤1 .                                              (2.8) 
Hypotheses (2.7) are tested in a step-down manner by comparing the test statistics stWi '  
with the corresponding critical values. The critical values depend on the dose level i , degrees of 
freedom ν  and level of significance α , and are given by Williams (1971, 1972). Starting from 
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Ki = , KH 0  is tested against aKH  at a level of significance α , if WKt  is greater than or equal to 
the corresponding critical value, then KH 0  is rejected and 10 −KH  is tested. If KH 0  is accepted 
then the testing is completed and all null hypotheses are accepted, otherwise 10 −KH  is tested at 
level α . Similarly, if WKt 1−  is greater than or equal to its corresponding critical value, then 10 −KH  
is also rejected and so on; unless mH0  is accepted for some Km ,...,2,1= , then all 
mHHH 00201 ,...,,  are accepted and MED is estimated as 1
* += mMED . 
Tamhane et al. (1996) mention the above procedure and also consider a class of stepwise 
closed testing procedures based on contrasts among the sample means. None of these latter 
procedures require the monotonicity assumption (2.1) and all of them strongly control the FWE. 
Here, we illustrate the step-down procedure under the assumptions of (2.2)-(2.5) which is based 
on the pairwise contrasts 
nn
yyt ii /1/1ˆ 0
0
+
−= σ ,  Ki ,...,2,1= .                                            (2.9) 
The joint distribution of these statistics is the multivariate −t distribution with ν  degrees 
of freedom and correlation matrix }{ ijρ , where )/( 0 nnnij +=ρ . In order to use the stepwise 
procedures, first, the statistics are ordered as )()2()1( ... Kttt ≤≤≤ . Next, the hypotheses are also 
reordered as )(0)2(0)1(0 ,...,, KHHH , so that )(0 iH  corresponds to the statistic )(it , Ki ≤≤1 . The 
critical values α ρν ,,ic  for testing )(0 iH  are obtained as the upper α  equicoordinate critical points 
of the −i variate −t distribution with ν  degrees of freedom and common correlation ijρρ = . 
The step-down procedure based on the pairwise contrasts (SDPC) is then applied in the same 
manner as the Williams’ procedure but the order in which hypotheses are to be tested at the 1st 
step is specified by the )1(0)1(0)(0 ,...,, HHH KK −  instead of 01100 ,...,, HHH KK − . If 
α
ρν ,,)( KK ct ≥ , then 
reject )(0 KH  and all hypotheses whose rejection is implied by it, e.g., if mK HH 0)(0 =  then reject 
all KmmjH j ,...,1,,0 +=  and proceed to the 2nd step to test 100201 ,...,, −mHHH . If α ρν ,,)( KK ct <  
then accept )(0 KH  and complete the testing. In general, in the thi −  step let ik  be the number of 
hypotheses still to be tested. Reorder the statistics )()2()1( ... ikttt ≤≤≤  and the corresponding 
hypotheses as )(0)2(0)1(0 ,...,, ikHHH . Test )(0 ikH  by comparing )( ikt  with 
α
ρν ,,ikc . If 
α
ρν ,,ii kk ct ≥ , 
 10 
then reject )(0 ikH  and all hypotheses whose rejection is implied by it and go to the next step, 
otherwise, stop testing. When the testing procedure stops, the MED is estimated as the minimum 
index of the rejected hypotheses. 
2.2 PROBLEM SET-UP 
We are going to consider the problem of identifying the lowest dose level for which the mean 
response differs from the mean response at the placebo (zero) dose under the assumption of a 
monotone dose-response curve (2.1). At first, in addition to (2.2)-(2.4), we assume that 2σ  is 
known and that both of the following conditions hold 
nnnn K ==== ...)1 10 ,                                                     (2.10a) 
                                         1/2)2 2 =nσ .                                                                    (2.10b) 
Let us construct the mean differences )()( 00 xfxf iii −=−= μμν , Ki ,...,2,1=  with 
00 =ν . 
Note that si 'ν  satisfy the monotonicity assumption 
                                                  Kννν ≤≤≤≤ ...0 21 .                                                      (2.11) 
Then the minimum effective dose (MED) is defined as             
                                { } { }0:min:min 0 >=>= ii iiMED νμμ .                                      (2.12) 
And the problem of identifying the MED is formulated as a sequence of hypothesis 
testing problems 
llH ννν ==== ...0: 210 , versus the alternative 
                      KlH llal ,...,2,1,...0: 121 =<==== − νννν .                              (2.13) 
Obviously, the above family of hypotheses },...,2,1,{ 0 KlHH l ==  is closed under 
intersection; the proof is identical to the one for hypothesis family (2.7) and is given in the 
preceding section. The last fact allows us to apply the MPG principle, and test each hypothesis at 
a level of significance α . As we mentioned above, such a testing procedure guarantees the 
strong control of the FWE. The detailed proposed procedure for identifying the MED is 
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described later on in Section 2.4.2. The next section illustrates our generalization of Lee’s 
method to handle dependent random variables to construct two-sided confidence bands for the 
differences between responses to the active dose levels and placebo. 
2.3 TWO-SIDED CONFIDENCE BANDS FOR MEAN DOSE-RESPONSE 
DIFFERENCES 
2.3.1 Test Statistic and its Distributional Properties 
Consider a vector of K  random variables )',...,,( 21 Kzzz  with hz  distributed marginally as 
standard normal, Kh ,...,2,1= , and covariance 
2
1),( =ji zzCov  for ji ≠ , i.e., 
),0(~)',...,,( 21 ΣKK MVNzzz
r
, where K0
r
 is the K -dimensional zero-vector and Σ  is the KK ×  
matrix 
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
=Σ
1....5.05.05.0
..............................
5.0....5.015.0
5.0....5.05.01
. 
Next, we compute the test statistics 
1
max
1 +−=
∑
=
≤≤≤ ij
z
T
j
ih
h
Kji
.                                                 (2.14) 
The distribution of this statistic is different from the distribution of the generalized 
standardized maximum modulus (2.6) because the szh '  are no longer independent. Note that T  
takes only positive values, and its distribution depends on K , the total number of szh ' . For 
1=K , the statistic T  reduces to the absolute value of the standard normal random variable and 
its distribution function can be expressed as 
 12 
⎪⎩
⎪⎨⎧ <
≥−Φ⋅=
0,0
0,1)(2
)(
a
aa
aFT  
where )(aΦ  is the distribution function of a standard normal random variable evaluated at 
),(, +∞−∞∈aa .  
For 1>>K , the statistic does not have an easy expression for the density or the 
distribution function. The graph in Figure 2 illustrates the approximate density function obtained 
by simulation (based on 100,000 replications) for 10=K  under the assumptions (2.2)-(2.4) and 
(2.10). 
0 2 4 6 8 10 
0.0 
0.1 
0.2 
0.3 
0.4 
0.5 Φ(T) 
 
Figure 2. Approximated density function of T  statistic (2.14) for K = 10 
2.3.2 Constructing Two-Sided Simultaneous Max-Min Confidence Bands for the 
Case of Equal Sample Sizes and Known Variance 
To construct the confidence bands, first we need to determine the percentage points of the 
distribution of T  statistic. Let α
K
c  denote the upper α−1  percentile of the distribution of T  for 
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K  active dose levels. Since the distribution function does not have a simple expression, we 
approximate the percentiles by solving the equation below for α
K
c  
                                       αα −=≤ 1)(
K
cTP .                                                  (2.15) 
The R code for obtaining the critical values based on a simulation study is given in 
Appendix A. The results for up to ten dose levels for 1.0=α , 05.0=α  and 01.0=α  are given 
in Table 1. The number of replications for each case is 100,000. 
Table 1. α -level critical values of T  statistic given by (2.14) 
Number of Active                  Significance Level 
     Dose Levels               1.0=α      05.0=α      01.0=α  
           K=1                         1.64            1.96            2.58 
           K=2                         2.12            2.47            3.19 
           K=3                         2.45            2.85            3.67 
           K=4                         2.73            3.18            4.09 
           K=5                         2.97            3.47            4.49 
           K=6                         3.20            3.73            4.86 
           K=7                         3.39            3.99            5.18 
           K=8                         3.59            4.21            5.49 
           K=9                         3.78            4.45            5.77 
           K=10                       3.94            4.65            6.08 
 
Under conditions (2.2)-(2.4) and (2.10), the random variables 
n
yyz hhh
/2 2
0
σ
ν−−=  
are distributed as standard normal for each Kh ,...,2,1= . The covariance of these random 
variables can be calculated as 
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2
1)(
/2
1),(
/2
1),( 02002 =⋅=−−= yVarnyyyyCovnzzCov jiji σσ  for ji ≠ . 
Then, two-sided simultaneous confidence intervals for 0μμν −= ll , Kl ,...2,1=  under the 
assumption of (2.11) for the case of K  active doses can be obtained as follows. 
The T  statistic is bounded by α
K
c  if and only if α
K
j
ih
h
Kji
c
ij
z
≤+−
∑
=
≤≤≤ 1
max
1
, i.e., if and only if 
Kjiallforijcyyijc
K
j
ih
h
j
ih
hK
≤≤≤+−≤−−≤+−− ∑∑
==
1,1)(1 0
αα ν , which can be written 
as  
Kjiallforijcyyijcyy
K
j
ih
h
j
ih
hK
j
ih
h ≤≤≤+−+−≤≤+−−− ∑∑∑
===
1,1)(1)( 00
αα ν . 
Dividing the last inequality by 01 >+− ij , we obtain 
Kjiallfor
ij
c
ij
yy
ijij
c
ij
yy
K
j
ih
h
j
ih
h
K
j
ih
h
≤≤≤+−++−
−
≤+−≤+−−+−
− ∑∑∑
=== 1,
11
)(
111
)( 00 αα ν
. 
Taking the maximum of the left hand side over all indexes less or equal to l , and the 
minimum of the right hand side over all indexes greater or equal to l , we obtain two inequalities: 
Kl
pqpq
c
pq
yy
q
ph
h
lqp
K
q
ph
h
lqp
,...,2,1,
1
max
11
)(
max
1
0
1
=+−≤
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
+−−+−
− ∑∑
=
≤≤≤
=
≤≤≤
να
                            (2.15.1) 
Kl
rs
c
rs
yy
rs
K
s
rh
h
Ksrl
s
rh
h
Ksrl
,...,2,1,
11
)(
min
1
min
0
=
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛
+−−+−
−
≤+−
∑∑
=
≤≤≤
=
≤≤≤
αν
.                             (2.15.2) 
Next, from (2.11) it follows that 
Klallfor
rspq l
s
rh
h
Ksrll
q
ph
h
lqp
,...,2,1,
1
min,
1
max
1
==+−=+−
∑∑
=
≤≤≤
=
≤≤≤
ν
ν
ν
ν
, 
so the inequalities (2.15.1) and (2.15.2) can be combined to provide simultaneous confidence 
bands 
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Kl
rs
c
rs
yy
pq
c
pq
yy
K
s
rh
h
Ksrll
K
q
ph
h
lqp
,...,2,1,
11
)(
min
11
)(
max
00
1
=
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛
+−−+−
−
≤≤
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
+−−+−
− ∑∑
=
≤≤≤
=
≤≤≤
αα
ν .   (2.16) 
2.3.3 Constructing Two-Sided Simultaneous Max-Min Confidence Bands for the 
General Case 
The confidence bands above are constructed under the conditions of equal group sample sizes 
and equal known group variances. To generalize the bands to the case of arbitrary sample sizes 
and unknown (but common) variances, we omit assumption (2.10) and construct the procedure 
based on (2.1)-(2.4) only. Then )/,(~ 2 iii nNy σμ , Ki ,...,1,0=  are the sample means of the 
observations at each dose level i  and 
0
22
0
nn
yyz
i
hi
h σσ
ν
+
−−=  is distributed as standard normal for each 
Kh ,...,2,1= . Since the group sample means are independent for Ki ,...,1,0= , the covariance 
can be calculated as  
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
+
−
+
−=
0
22
0
0
22
0 ,),(
nn
yy
nn
yyCovzzCov
j
j
i
i
ji σσσσ  
                   
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
+
−
+
−=
0
22
0
0
22
0 ,
nn
y
nn
yCov
ji
σσσσ  
                   )(1 0
0
02
0
02
yVar
nn
nn
nn
nn
j
j
i
i
⋅++= σσ
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0
2
0
02
0
02
1
n
nn
nn
nn
nn
j
j
i
i
σ
σσ
⋅++=   
                   
))(( 00 ji
ji
nnnn
nn
++=  for ji ≠ . 
Next, we compute the test statistic 
σ
σˆ
1
max
1 +−=
∑
=
≤≤≤ ij
z
T
j
ih
h
Kjigen
, 
where 22
2
~
ˆ
νχσ
σν ⋅  with )1(
0
+−= ∑
=
Kn
K
i
iν  and σ
σˆ  is independent of hz , Kh ,...,2,1= . The 
critical values of the distribution of genT , 
α
ν,Kc , can be obtained by simulation for given α , K  
and ν . Then two-sided simultaneous confidence intervals for 0μμν −= ll , Kl ,...,2,1=  can be 
obtained similarly as in the simple case with a few modifications. First, we consider the 
inequality α ν,Kgen cT ≤  which has probability α−1  and is identical to 
α
νσ
σ
σσ
ν
,
0
22
0
1
ˆ
1
max
K
h
j
ih
hh
Kji
c
ij
nn
yy
≤
+−⋅+
−−∑
=
≤≤≤
, or α ν
σ
ν
,
0
0
1
111ˆ
max
K
j
ih
h
hh
Kji
c
ij
nn
yy ≤
+−⋅+⋅
−−∑
=≤≤≤
.
 
This can be rewritten as  
α
ν
σ
ν
,
0
0
111ˆ
K
j
ih
h
hh c
ij
nn
yy ≤
+−⋅+⋅
−−∑
=
, Kjiallfor ≤≤≤1 , or equivalently,  
1ˆ
11 ,
0
0 +−⋅⋅≤
+
−−∑
=
ijc
nn
yy
K
j
ih
h
hh σν α ν , Kjiallfor ≤≤≤1 , so that 
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1ˆ
11
1ˆ
,
0
0
,
+−⋅⋅≤
+
−−≤+−⋅⋅− ∑
=
ijc
nn
yyijc
K
j
ih
h
hh
K
σνσ α να ν
r
, Kjiallfor ≤≤≤1 , which 
yields 
1ˆ
1111
1ˆ
11 ,
0
0
0
,
0
0 +−⋅⋅+
+
−≤
+
≤+−⋅⋅−
+
− ∑∑∑
===
ijc
nn
yy
nn
ijc
nn
yy
K
j
ih
h
h
j
ih
h
h
K
j
ih
h
h σνσ α να ν .    (2.17) 
Next, we apply the following simple lemma. 
Lemma 2.1. Let hλ , Kh ,...,2,1=  be any non-negative constants. Then under monotonicity 
assumption (2.11),  
sq
ph
h
q
ph
hh
sqp
ν
λ
νλ
=
∑
∑
=
=
≤≤≤1
max  and sq
ph
h
q
ph
hh
Kqps
ν
λ
νλ
=
∑
∑
=
=
≤≤≤
min , where Ks ,...,2,1= . 
Proof: Since Kshallforsh ≤≤≤ ,νν  and ∑∑∑
===
=≤
q
ph
hs
q
ph
sh
q
ph
hh λννλνλ , 
sqpallfor ≤≤≤1  then  
sq
ph
h
q
ph
hh
ν
λ
νλ
≤
∑
∑
=
=  sqpallfor ≤≤≤1 . 
The last inequality becomes an equality when sqp == , which completes the proof of the first 
statement. The second statement can be proved similarly. 
■ 
To use Lemma 2.1 for 
0
1 11
nnh
h +=−λ , we first divide (2.17) by 
2/1
0
11
−
=
∑ ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
j
ih h nn
 and 
then take the maximum of the left hand side over all indexes less or equal to s , to obtain 
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⎞
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≤≤≤ q
ph h
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q
ph
h
h
sqp
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pqc
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nn
yy
1
0
,1
0
0
0
1 11
11ˆ
11
11
max σα ν  
s
q
ph h
q
ph
h
h
sqp
nn
nn ν
ν
=
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
+
≤
∑
∑
=
−
=
≤≤≤ 1
0
0
1 11
11
max . 
                                                                                                                                     (2.18) 
Similarly,  
⎟⎟
⎟⎟
⎟⎟
⎟⎟
⎠
⎞
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⎜⎜
⎜⎜
⎜⎜
⎝
⎛
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⎞
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1
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11
11ˆ
11
11
min σα ν . 
(2.19) 
Finally, combining (2.18) and (2.19), we obtain the confidence bands for sν , 
Ks ,...,2,1= : 
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σα ν .  
(2.20) 
Although we do not provide the formal proof that the two-sided intervals given by (2.16) 
and (2.20) are indeed the simultaneous confidence bands with α−1  confidence level, the proof 
is similar to the one provided for the one-sided confidence bands, which is given as the proof of 
Lemma 2.2 in Section 2.4.1.  
The confidence bands given by (2.16) and (2.20) can be used in clinical studies to 
examine the behavior of a test drug and to characterize the differences between the active 
treatment effects and the placebo effect. These bands are constructed under an assumption of a 
non-decreasing mean dose-response and can be modified for the case of a non-increasing 
function. Next, we illustrate how to construct the lower bands for the differences between 
responses to the active dose levels and placebo and discuss two procedures for identifying the 
minimum effective doses based on the lower bands. 
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2.4 MINIMUM EFFECTIVE DOSE DERIVED FROM ONE-SIDED 
CONFIDENCE BANDS 
2.4.1 Constructing One-Sided Simultaneous Max-Min Confidence Bands 
To construct one-sided confidence bands we consider the procedure similar to the one for 
obtaining the two-sided confidence intervals, but instead of the test statistics T  and genT  we use 
the statistics  
1
max
1
0
+−=
∑
=
≤≤≤ ij
z
T
j
ih
h
kji
                                                         (2.21) 
for the case when assumption (2.10) holds and  
σ
σˆ
1
max
1
0
+−=
∑
=
≤≤≤ ij
z
T
j
ih
h
kjigen
,                                                  (2.22) 
for more general case of Section 2.3.3. The distributions of both statistics, 0T  and 0genT  depend 
on the number k . For 1=k , 0T  is distributed as a standard normal random variable and 0genT  has 
the −t distribution with 210 −+= nnν  degrees of freedom. The graph in Figure 3 illustrates the 
approximated distribution of 0T , obtained by simulation based on 100,000 replications for 
10=k  under the assumptions (2.2)-(2.4) and (2.10). 
The critical values of both distribution functions can be also obtained by the simulation 
studies as the solutions α
k
m  and αν,' km  to the equations αα −=≤ 1)( 0 kmTP  and 
ααν −=≤ 1)'( ,0 kgen mTP  for the specified values of α , k  and ν . Table 2 contains the critical 
values of 0T  statistic (based on 100,000 replications) for up to ten active dose levels for 1.0=α , 
05.0=α  and 01.0=α . 
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Figure 3. Approximated density function of 0T  statistic (2.21) for k =10 
The simultaneous one-sided max-min confidence bands for mean response differences, 
si 'ν , are given by  
i
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based on the statistic 0T , and by  
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max' ,  ki ,...,2,1=            (2.24) 
based on the statistic 0genT . Next, we prove the following lemma.   
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Table 2. α -level critical values of 0T  statistic given by (2.21) 
Number of Active                  Significance Level 
     Dose Levels               1.0=α      05.0=α      01.0=α  
           K=1                         1.28              1.64             2.33 
           K=2                         1.72              2.12             2.89 
           K=3                         2.01              2.45             3.34 
           K=4                         2.24              2.73             3.72 
           K=5                         2.42              2.96             4.06 
           K=6                         2.59              3.19             4.38 
           K=7                         2.76              3.39             4.71 
           K=8                         2.89              3.59             4.99 
           K=9                         3.04              3.79             5.23 
           K=10                       3.17              3.94             5.50 
 
Lemma 2.2. Let )(νC  be the confidence level of the max-min simultaneous confidence intervals 
(2.23) and (2.24). Then )(νC  is at least α−1 . 
Proof: We prove the lemma for the confidence bands given by (2.23). Similar proof can 
be used for the bands given by (2.24). First, from Lemma 2.1 it follows that  
1
max
1 +−=
∑
=
≤≤≤ pq
q
ph
h
iqpi
ν
ν . 
Then the confidence level is defined as  
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which is a true statement, because the critical value is calculated as the solution to this equation 
for α
k
m . 
■ 
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2.4.2 Procedure for Identifying the Minimum Effective Dose 
Before we propose a closed step-down procedure based on the MPG principle, let us mention 
that the lower bands given by (2.23) and (2.24) can readily be used to provide the simultaneous 
lower confidence statements for the mean response differences at all dose levels. For any given 
number of active drug levels, K , and confidence level, α−1 , the positive values of the lower 
bands indicate effective doses of the drug and the smallest such dose can be used as an MED 
estimate. Doses where the lower bounds are negative indicate non-effective doses. Next, we 
construct a more powerful procedure for estimating the MED. 
We propose a step-down procedure to test the hypotheses (2.13) based on constructing 
α−1  simultaneous one-sided max-min confidence bands for mean response differences, si 'ν , 
given by (2.23) and (2.24). For simplicity, we illustrate the proposed step-down procedure using 
the intervals (2.23)  
l
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, kl ,...,2,1= , Kk ≤≤1 . 
This method uses only the lower bands for the thkl −=  mean dose-response difference. 
Starting with Kkl == , KH 0  is tested against aKH  at a level of significance α  by computing 
KL  using the corresponding critical value 
α
K
m , where KH 0  and aKH  are given by (2.13). 
Positive KL  suggests that at least one of the K  mean response differences is positive so the 
corresponding null hypothesis KH 0  is rejected. Next, the highest dose is omitted from 
consideration and the first 1−= Kk  doses are considered and the lower bound for 1−=Kkν  is 
calculated based on α
1−=Kkm . If 0>kL  then 10 −=KkH  is rejected and the testing is continued with 
2−= Kk  and so on unless 0≤mL  for some Km ,...,2,1= , then mH0  is accepted and testing is 
completed. The MED is estimated as 1* += mMED . If Km =  then 1* += KMED , meaning 
that there are no effective doses in the study. If such Km ,...,2,1=  can not be found, i.e., all 
hypotheses are rejected, then all of the active doses are estimated being effective and the smallest 
active dose corresponds to the minimum effective dose, i.e., 1* =MED . 
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The above procedure is given for the closed family of hypotheses (2.13) (See Section 2.2) 
and uses the MPG testing principle. Indeed, each hypothesis is tested at a fixed level of 
significance and a hypothesis is tested and rejected if and only if it is significant and all 
hypotheses implying it are also significant. For example, the hypothesis mH0  for some Km <  is 
tested if and only if all hypotheses with higher indexes Kmm HHH 02010 ,...,, ++  are rejected. Since 
the set of hypotheses Kmm HHH 02010 ,...,, ++  contains all of the hypotheses implying mH0 , mH0  is 
tested if and only if all hypotheses implying it are significant. Moreover, mH0  is rejected if and 
only if it is significant along with all hypotheses implying it. 
A simpler one-step alternative approach would be to construct the simultaneous lower 
bounds for lL , kl ,...,2,1=  with Kk = . Then starting with the highest dose difference Kl = , if 
0>lL  then lH0  is rejected and 10 −lH  is tested for some Kll ≤≤2, . The maximum 
Kll ≤≤2,  such that 10 −lH  is accepted provides the estimated MED. If all lower bounds are 
positive then MED is estimated as the first dose and if 0≤KL  then we conclude that the MED 
does not exist. 
The proposed procedure is more powerful than the above alternative approach. The latter 
one uses a single critical value, α
K
m , for constructing the bands. Since the critical value 
αα
lK mm >  for Kl <≤1 , the proposed procedure is more powerful. Note that the procedures 
perform similarly only in the case when the lower bound for the highest mean dose-response 
difference is negative, therefore, there are no effective doses detected by the procedures.  
Example 2.1. To illustrate the proposed step-down procedure, let us consider hypothetical data 
given by Tamhane et al. (1996). These authors suppose that in a single drug trial with five active 
dose levels and a placebo the same number of subjects are allocated to each of the six groups. 
The sample group means are given by                   
0y  1y  2y  3y  4y  5y  
0.0 1.5 2.1 1.9 2.3 2.1 
 
They further assume that (2.10) holds, i.e., 1/2 2 =nσ  with ∞=ν  degrees of freedom. 
The problem of identifying the MED is considered subject to the condition that the FWE is 
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controlled at 0.05. Among the results of several procedures presented by Tamhane et al. (1996), 
the results of Williams’ procedure (2.8) and the results of SDPC procedure based on (2.9) are 
presented. Both methods provide the estimate 2* =MED . 
Now we illustrate the proposed step-down procedure. Since the placebo sample group 
mean is zero, the confidence bounds (2.23) reduce to  
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Table 3. Calculation of 5L  for example of Section 2.4.2 
p q 1S  q-p+1 2S  3S  4S  
1 1 1.50 1.00 1.50 2.96 -1.46 
1 2 3.60 2.00 1.80 2.09 -0.29 
1 3 5.50 3.00 1.83 1.71 0.12 
1 4 7.80 4.00 1.95 1.48 0.47 
1 5 9.90 5.00 1.98 1.32 0.66 
2 2 2.10 1.00 2.10 2.96 -0.86 
2 3 4.00 2.00 2.00 2.09 -0.09 
2 4 6.30 3.00 2.10 1.71 0.39 
2 5 8.40 4.00 2.10 1.48 0.62 
3 3 1.90 1.00 1.90 2.96 -1.06 
3 4 4.20 2.00 2.10 2.09 0.01 
3 5 6.30 3.00 2.10 1.71 0.39 
4 4 2.30 1.00 2.30 2.96 -0.66 
4 5 4.40 2.00 2.20 2.09 0.11 
5 5 2.10 1.00 2.10 2.96 -0.86 
Max = 0.66 
 
First, we need to calculate 5L , based on 96.2
05.0
5
=m  (see Table 2). We start with 
computing ∑
=
=
q
ph
hyS1  for all possible combinations of indexes p  and q  and then, we find 
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1
1
2 +−= pq
SS  and 
1
96.2
3 +−= pqS  and finally, calculate 324 SSS −= . The detailed 
calculations based on this notation are given in Table 3. Since 066.05 >=L  we reject 05H  and 
test 04H . Similarly, for 73.2
05.0
4
=m  we obtain 059.04 >=L  so we reject 04H  and test 03H  
based on 45.205.0
3
=m . 042.03 >=L  so we reject 03H  and test 02H  with 12.205.02 =m . Finally, 
030.02 >=L  and 014.01 ≤−=L  based on 64.105.01 =m . So we accept 01H  and estimate 
2* =MED . 
2.5 SIMULATION STUDY 
Tamhane et al. (1996) consider a simulation study to compare the results of a number of 
procedures. For the monotone dose-response, the studies assume two types of population 
response functions: linear and step (the examples of such types of the response functions are 
given in Figure 1). We consider a similar set up for the simulation studies to compare the 
performance of our proposed procedure with the Williams’ (2.8) and the SDPC (2.9) procedures. 
The critical values under the assumption (2.10) for the latter two test procedures are given by 
Tamhane et al. (1996). 
We assume a single drug study with a placebo response fixed at zero and 5=K  active 
dose levels with the significance level 05.0=α . Under the assumption (2.10) of known variance 
and equal group sample sizes, we consider two types of monotone (non-decreasing) dose-
response curves, linear and step. Let δ  denote the largest value of the response function, this 
value corresponds to the 5th dose level. Tamhane et al. (1996) uses 3=δ  and 5=δ ; in addition 
to these values, we consider 4=δ . For each combination of the type of response and its 
maximum value, we vary the true MED over the five dose levels. Note that for 5=MED  the 
linear and step functions provide the same values of means. For each case of given mean values, 
we generate the sample mean responses )2/1,(~ ii Ny μ , 5,...,1,0=i , 00 =μ  and apply the 
proposed step-down procedure, together with Williams’ (WILM) procedure and the step-down 
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procedure based on pairwise contrasts (SDPC) to estimate the MED. Based on 10,000 
replications for each case, we obtain the proportion when each dose is estimated as the MED. 
Since we know a priori the true MED and what doses correspond to the effective and non-
effective doses, we can simulate the values of FWE, Power, Lack of Power and Bias in each 
case, based on the formulas below, given by Tamhane et al. (1996). 
N
NFWE 1* = , 
N
NPower 2* = , 
N
N
PowerofLack 3* = , MEDMEDEBias −= *)(* ,     (2.25) 
where 1N  is the number of non-effective doses estimated as the MED’s; 2N  is the number of 
doses, correctly estimated as the MED’s; 3N  is the number of doses, higher than the MED being 
estimated as the MED, including the cases, when none of the doses is estimated as the MED; 
*)(MEDE  is the expected value of the estimated MED, based on the observed probabilities; if 
none of the five doses is estimated as the MED then 6* =MED  is used to calculate the 
expectation and 000,10=N  is the total number of replications.  
Example 2.2. Suppose we consider the linear response with its maximum value 5=δ  and the 
true 3=MED , then the population means are given by 0210 === μμμ , .3/53 =μ  3/104 =μ  
and 55 =μ . Next, we generate )2/1,(~ ii Ny μ , 5,...,1,0=i  and apply each of the three 
procedures. Each one provides an MED-estimate, }6,5,4,3,2,1{*∈MED . If we repeat the 
above steps 10,000 times, then each procedure produces the estimated MED’s with the 
corresponding frequencies. For example, if we let id  denote the number of times when a certain 
procedure provides the estimate iMED =*  for 6,5,4,3,2,1=i , then 000,10
6
1
=∑
=i
id . In this 
example with 3=MED , we can calculate 211 ddN += , 32 dN = , 6543 dddN ++= , 
∑
=
⋅=
6
1000,10
1*)(
i
idiMEDE . 
The R Code for the simulation studies is given in Appendix B. It contains the procedures 
for calculating all of the above measures. Table 4 summarizes the familywise error, power and 
bias of three procedures. Since the simulation results are based on 10,000 replications, the 
standard error of estimation is 005.0000,10/)5.0(5.0 = .  
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Note that in the case of true 1=MED , there are no non-effective doses, so there can be 
no FWE. We also note that the results of our simulation studies agree with the results presented 
by Tamhane et al. (1996) for WILM and SDPC for 3=δ  and 5=δ .  
First, as the theory establishes, all three procedures strongly control the FWE at 
05.0=α . Indeed, in order to conclude that significance level would be higher than 05.0 , the 
estimated FWE must be greater than 054.0000,10/)95.005.0(96.105.0 =⋅+ . The largest 
simulated value of FWE across all considered population configurations corresponds to the 
Williams’ procedure for linear shape of the mean dose-response with 3=δ . But since it equals 
054.0052.0 < , we conclude that all procedures strongly control the FWE, which agrees with the 
theoretical results. 
When the true MED is relatively large then WILM and SDPC seem to perform better in 
terms of power and bias than the proposed procedure. The power of the proposed procedure is 
0.378, which is less than the power of WILM (0.492) and the power of SDPC (0.443).  
The above ranking is confirmed by the corresponding values of bias. The average bias of 
the WILM procedure is 0.097, followed by 0.109 of SDPC and by 0.197 of the proposed 
procedure.  
In the cases with the true 1=MED , the proposed procedure performs the best. The 
average power across such configurations equals 473.0  for the proposed procedure, followed by 
451.0  for the SDPC procedure and by 437.0  for the WILM procedure. The average biases 
corresponding to such designs are 655.1  for the proposed procedure, followed by 756.1  for the 
SDPC procedure and by 676.1  for the WILM procedure. 
Based on these results we can conclude that the proposed procedure performs the best 
when the true MED is low, which is the most common case in the dose-response studies. And 
our procedure performs worse than the Williams’ procedure and the SDPC procedure when the 
true MED is high.  
If we compare the results corresponding to the same shape of the mean dose-response 
function for different values of δ , then, obviously, all procedures perform better in the case of 
5=δ , because the larger the mean dose-response difference the easier it can be detected by a 
statistical procedure.  
If we compare the results corresponding to the same value of δ  but different shapes of 
the mean dose-response function, then the average power of the procedures is higher for the step 
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function. It can be explained by the flat shape of the step function with zero mean difference for 
the consecutive non-effective dose levels and a relatively large positive difference associated 
with the dose effectiveness.  
The performed simulation studies are limited to the equal sample size case, and its 
conclusion may be different for unequal sample size case. Moreover, only two shapes of the 
dose-response function are considered so additional studies are suggested for more detailed 
investigation of the performance of the procedures. 
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Table 4. Familywise error, power and bias 
Estimated FWE (upper entry), power 
(middle entry) and bias (lower entry) 
with standard error of 0.005 Response 
function  
True 
MED 
Williams’ 
Step-down 
with pairwise 
contrasts 
Proposed 
1 0.000 0.000 0.000 
  0.062 0.069 0.087 
  3.316 3.553 3.487 
2 0.026 0.029 0.034 
  0.061 0.052 0.053 
  2.541 2.814 2.863 
3 0.030 0.034 0.039 
  0.092 0.059 0.051 
  1.816 2.097 2.225 
4 0.042 0.042 0.049 
  0.195 0.103 0.062 
  1.032 1.285 1.448 
5 0.052 0.049 0.049 
  0.599 0.415 0.193 
Linear 
3=δ  
 
  0.253 0.390 0.613 
1 0.000 0.000 0.000 
  0.096 0.102 0.121 
  2.563 2.833 2.787 
2 0.025 0.026 0.034 
  0.100 0.079 0.077 
  1.942 2.257 2.329 
3 0.040 0.039 0.045 
  0.155 0.103 0.078 
  1.320 1.616 1.796 
4 0.042 0.043 0.046 
  0.318 0.188 0.103 
  0.705 0.938 1.187 
5 0.048 0.045 0.048 
  0.813 0.681 0.407 
Linear 
4=δ  
 
  0.051 0.142 0.408 
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Table 4 continued 
Estimated FWE (upper entry), power 
(middle entry) and bias (lower entry) Response 
function  
True 
MED 
Williams’ 
Step-down 
with pairwise 
contrasts 
Proposed 
1 0.000 0.000 0.000 
  0.134 0.134 0.154 
  1.977 2.213 2.181 
2 0.035 0.038 0.043 
  0.144 0.111 0.100 
  1.460 1.730 1.824 
3 0.041 0.042 0.045 
  0.232 0.149 0.108 
  0.965 1.218 1.420 
4 0.045 0.043 0.047 
  0.462 0.307 0.172 
  0.456 0.644 0.879 
5 0.047 0.046 0.049 
  0.915 0.857 0.664 
Linear 
5=δ  
 
  -0.052 -0.036 0.146 
1 0.000 0.000 0.000 
  0.543 0.588 0.636 
  1.637 1.446 1.139 
2 0.046 0.044 0.047 
  0.496 0.489 0.449 
  1.282 1.281 1.220 
3 0.050 0.049 0.050 
  0.500 0.446 0.333 
  0.949 1.083 1.241 
4 0.048 0.049 0.048 
  0.536 0.426 0.258 
Step 
3=δ  
 
  0.604 0.793 1.055 
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Table 4 continued 
Estimated FWE (upper entry), power 
(middle entry) and bias (lower entry) Response 
function  
True 
MED 
Williams’ 
Step-down 
with pairwise 
contrasts 
Proposed 
1 0.000 0.000 0.000 
  0.829 0.846 0.869 
  0.478 0.416 0.286 
2 0.049 0.049 0.049 
  0.776 0.753 0.715 
  0.367 0.396 0.388 
3 0.049 0.047 0.049 
  0.769 0.715 0.600 
  0.282 0.378 0.504 
4 0.048 0.048 0.049 
  0.786 0.691 0.504 
Step 
4=δ  
 
  0.169 0.291 0.536 
1 0.000 0.000 0.000 
  0.960 0.964 0.969 
  0.087 0.075 0.048 
2 0.051 0.051 0.051 
  0.906 0.894 0.869 
  0.029 0.051 0.058 
3 0.051 0.051 0.050 
  0.904 0.875 0.814 
  0.001 0.038 0.101 
4 0.051 0.051 0.049 
  0.907 0.863 0.748 
Step 
5=δ  
 
  -0.026 0.000 0.142 
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3.0 COMBINATION DRUG STUDY FOUNDATIONS 
3.1 INTRODUCTION 
Combination products, also known as fixed-dose combinations are combinations of two or more 
active drugs produced in a single tablet. Usually, these active drugs come from different classes 
of drugs with the same therapeutic effect. For example, the drug VICOPROFEN® (Abbott) is 
indicated for a short-term management of acute pain. This drug is a fixed-dose combination of 
the opioid analgesic agent, hydrocodone bitartrate (7.5 mg) and the nonsteroidal anti-
inflammatory agent, ibuprofen (200 mg).  
There are many reasons why it is desirable to combine drugs. The main rationale for 
combining drugs is to produce a better treatment. As in the case of VICOPROFEN®, the 
component drugs, opioid and ibuprofen, have different mechanisms of action. When these drugs 
are combined, then the combination produces an analgestic effect, which is significantly greater 
than the effect produced by each component drug alone (Palangio et al. (2000)).  
Another rationale for combining drugs is to simplify treatment regiments for patients. 
Wertheimer and Morrison (2002) mention that the combination products are especially beneficial 
in the treating of infectious diseases, when exact compliance is crucial. These authors emphasize 
that “partial adherence can lead to the development of drug-resistant strains and a threat to public 
health”. 
In order for a new combination drug to be approved for human use, the FDA requires 
demonstrating that “each component makes a contribution to the claimed effects and the dosage 
of each component (amount, frequency, duration) is such that the combination is safe and 
effective for a significant patient population requiring such concurrent therapy as defined in the 
labeling for the drug” (21 CFR 300.50). In order to satisfy these requirements, safety and 
efficacy studies are performed.  
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Efficacy studies are needed to assess the dose-response relationship and characterize the 
effectiveness of combination drugs. There are two primary goals of such studies. The first one is 
to obtain the information about all effective doses and the second one is to demonstrate that each 
component makes a contribution to the claimed effects, i.e., to show that there is a gain in effect 
of combining drugs at certain fixed doses. 
Our research is devoted to the analysis of efficacy of combination drug studies. We 
assume the most commonly occurring case, when both single drugs are known to be effective at 
the considered doses. So if we identify all combinations which produce a therapeutic effect 
higher than the effect produced by each component alone, then all such superior combinations 
are considered by regulatory agencies to be effective. Our primary research goal is to detect the 
“lowest” doses among such superior combinations. Selecting of the lowest combination is crucial 
especially when administering higher doses of the drug can cause serious side effects so it is 
beneficial to administer lower (safer) doses.  
The problem stated above is different from the problem of identifying the effective 
combinations, because the effective combinations do not necessarily produce a greater effect 
than the single drugs alone so additional analysis is needed to satisfy the FDA regulations 
regarding combination efficacy. Because we assume both individual components are effective, 
by demonstrating the FDA requirements, we also show effectiveness of drug combination. In 
theory, if one were using a component drug which is not known to be effective then in addition 
to showing the combination is superior to each component, one would need to demonstrate that 
the combination is also superior to placebo. Combination drugs of the latter type are not very 
common, and as such are not covered by our methodology. 
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3.2 POPULATION PARAMETERS USED IN COMBINATION DRUG 
STUDIES 
3.2.1 Design of Combination Drug Studies and Matrix Representation of 
Population Parameters  
In a NK ×  combination drug trial, subjects are randomly allocated to one of )1()1( +×+ NK  
groups. Subjects of each group receive a combination ),( ji yx  of drug A at dose level 
Kii ,...,0, =  and drug B at dose level Njj ,...,0, = , where ),0( jy  and )0,( ix  are the thj −  
dose of drug B, and the thi −  dose of drug A alone, respectively. We are assuming in our 
research that both component drugs are effective.  
There is another way to code the drug doses. If instead of the actual amounts of the doses, 
the dose levels are used for identifying the combination, then a drug combination ),( ji yx  can be 
recorded as the combination ),( ji . For example, if the first active dose of drug A is 3mg and the 
second active dose of drug B is 4mg, then the combination )4,3(),( 21 mgmgyx =  can be 
referred to as a combination )2,1( . We are going to use both representations. 
Let ijμ  be the population mean dose response to a drug combination ),( ji yx , i.e., the 
population therapeutic effect produced by the combination ),( ji yx . 
The expected gain from combining the thi −  active dose of drug A with the thj −  active 
dose of drug B, is defined as },min{ 00 jijiijij μμμμθ −−= , Ki ,...,1=  and Nj ,...,1= . Hung et 
al. (1993) states that if this gain is positive, then the combination is considered to be superior in 
terms of greater effect over its individual components alone. And since both component drugs 
are assumed to be effective, we are able to claim since the gain is positive that this combination 
is efficacious. Let E  be the set of all such efficacious doses, i.e.,  
{ }0:,...,1,,...,1),,( >=== ijji NjKiyxE θ . 
We use the matrix notation to represent the response structure of the NK ×  trial. The 
matrix of mean dose-responses is a )1()1( +×+ NK  matrix where the thij −  entry corresponding 
to the population mean response of the drug combination ),( ji yx  is given by 
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⎟⎟
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎜⎜
⎝
⎛
=
KNKK
N
N
R
μμμ
μμμ
μμμ
...
.......................
...
...
21
11110
00100
 
The first row and first column of the matrix correspond to the controls: drug B alone and 
drug A alone respectively, 00μ  is the placebo mean response.  
Next, let us construct two NK ×  matrices of partial effects.  
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
−−−
−−−
−−−
=Θ
NKNKK
NN
NN
A
0022011
0202220121
0102120111
...
....................
..
...
μμμμμμ
μμμμμμ
μμμμμμ
, 
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
−−−
−−−
−−−
=Θ
00201
20220222021
10110121011
...
....................
..
...
KKNKKKK
N
N
B
μμμμμμ
μμμμμμ
μμμμμμ
. 
The partial effects matrix AΘ  is obtained by subtracting the 1st row of matrix R  from the 
rest of the rows, so AΘ  stores the differences between the combination drug mean response and 
the mean response of drug B alone taken at the same dose levels, i.e., the partial effects due to 
agent A. Similarly, the partial effects matrix BΘ  is obtained by subtracting the 1st column of 
matrix R  from the rest of the columns and it stores the partial effects due to drug B.  
By taking the minimum of two thij −  elements of AΘ  and BΘ , we obtain the element ijθ  
of matrix of expected gains { }ijθ=Θ , Ki ,...,1=  and Nj ,...,1= . Using the fact that 
),max(),min(),min( 000000 jiijjiijjijiijij μμμμμμμμμμθ −=−−+=−−= , where Ki ,...,1=  and 
Nj ,...,1= , we obtain the expected gains matrix 
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
−−−
−−−
−−−
=Θ
),max(...),max(),max(
....................
),max(...),max(),max(
),max(...),max(),max(
0002020101
0202022022012021
0101021012100111
NKKNKKKK
NN
NN
μμμμμμμμμ
μμμμμμμμμ
μμμμμμμμμ
. 
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The matrices AΘ , BΘ  will be referred to as the partial effect matrices and Θ  will be 
referred to as the gain matrix. 
3.2.2 Definitions of Matrix Partial Order and Isotonic Responses 
We start examining the properties of the above matrices by first making the assumption of 
isotonic responses with respect to the matrix partial order. If the doses of drug A and drug B are 
coded as Kii ,...,0, =  and Njj ,...,0, =  respectively, then the matrix partial order p  on the 
grid { }NjKiji ,...,0,,...,0),,( ==  is defined as )','(),( jiji p  if and only if 'ii ≤  and 'jj ≤ . 
Then a )1()1( +×+ NK  matrix }{ ijaA =  is said to be isotonic with respect to the matrix partial 
order if )','(),( jiji p  implies that '' jiij aa ≤  for all Kii ,...,0, =  and Njj ,...,0, = . The 
assumption that ijμ  are isotonic with respect to the matrix partial order states that for all 
Kii ,...,0, =  and Njj ,...,0, =  if )','(),( jiji p  then '' jiij μμ ≤ . 
The last is equivalent to saying that both drugs A and B have the monotone responses 
when the level of the other drug is fixed, i.e., iNii μμμ ≤≤≤ ...10  and Kjjj μμμ ≤≤≤ ...10  for all 
Ki ,...,0=  and Nj ,...,0= . 
Under the assumption of isotonic structure, the matrix R  has the following properties: 
1) all elements are non-decreasing in each column, 
2) all elements are non-decreasing in each row. 
Matrix AΘ  ( BΘ ) satisfies only the first (the second) property and nothing can be said 
about matrix Θ , except for that it consists of non-negative elements. In order to guarantee that 
both properties hold for partial effect matrices, we need additional assumptions on the sij 'μ . 
For convenience, let us fix the dose level of drug A and consider all of the 1+N  doses of 
drug B, then the mean response function can be represented by a univariate function 
ijjii ygg μ== )( , Nj ,...,0=  for each fixed drug A dose level Kii ,...,0, = . The matrix of 
partial effects AΘ  consists of non-decreasing in each row elements if and only if 
NsNss 0022011 ... μμμμμμ −≤≤−≤−  for any Ks ,...,1= . 
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Since the means are isotonic, all of the above mean differences are bounded by zero from 
below. The above set of inequalities is identical to 1,01,00 ++ −≤−≤ ttstst μμμμ  for all Ks ,...,1=  
and 1,...,1 −= Nt , which can be rewritten as sttstt μμμμ −≤−≤ ++ 1,01,00  or as 
)()()()(0 1010 tststt ygygygyg −≤−≤ ++  for all Ks ,...,1=  and 1,...,1 −= Nt . 
So the elements of the partial effect matrix AΘ  are non-decreasing in each row if and 
only if the non-negative difference between mean responses to two consecutive doses of drug B 
for any fixed dose level of drug A is at least as big as the non-negative difference between mean 
responses to the same consecutive doses of drug B taken alone. Hence, this condition guarantees 
that AΘ  satisfies both properties, 1) and 2). 
Moreover, if )( ji yg , Nj ,...,0=  can be assumed linear for each fixed drug A dose level 
Kii ,...,0, = , then the condition becomes smm ≤≤ 00  for all Ks ,...,1= , where im  is the slope 
of ig , Ki ,...,0= . So the rate at which the linear mean response corresponding to any fixed 
active drug A dose level increases is at least the rate at which the linear mean response 
corresponding to the placebo of drug A increases.  
In a similar manner one can obtain the necessary and sufficient conditions to guarantee 
that partial effect matrix BΘ  consists of non-decreasing elements in each column, that is the non-
negative difference between mean responses to two consecutive doses of drug A for any fixed 
dose level of drug B must be at least as big as the non-negative difference between man 
responses to the same consecutive doses of drug A taken alone. And in addition, if the mean 
response function to the combination is linear for each fixed dose level of drug B, then it is 
equivalent to the requirement that the linear mean response function for any fixed active dose of 
drug B increases at least as fast as the linear mean response corresponding to the placebo of A. 
Next, we are going to examine the structure of matrix Θ  under the assumption that each matrix 
of partial effects has an isotonic structure. 
Result 3.1. If the partial effect matrices AΘ  and BΘ  are isotonic then the matrix of gains Θ  is 
isotonic.  
Proof: Let us consider an arbitrary row, say the thk −  row, Kk ≤≤1  of matrix Θ . If 
both matrices of partial effects consist of non-decreasing elements in each row and each column, 
then ),min(...),min(),min(0 000220201101 NkNkkNkkkkkk μμμμμμμμμμμμ −−≤≤−−≤−−≤ , 
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i.e., kNkk θθθ ≤≤≤≤ ...0 21 . Since we fix an arbitrary row index, the last fact is true for all 
Kk ,...,1= , which proves that Θ  is non-decreasing in each row. 
Similarly, it can be shown that Θ  is non-decreasing in each column. So the matrix of 
gains consists of non-negative elements and has an isotonic structure.  
■ 
The following example illustrates that the converse to the statement is not true. Consider 
the matrix of mean responses R  given by  
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛×
=
0.14.00.0
1.12.01.0
0.00.0
R ,
 
where ""×  indicates that this dose is not evaluated. 
So that  
⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ=Θ
0.14.0
0.11.0
B  and ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
0.14.0
1.12.0
A . 
Then, obviously, matrix Θ  is isotonic but AΘ  is not. 
In the case of an isotonic non-negative matrix Θ , the behavior of the combination drug 
under investigation has a number of nice properties. First, since the gains are non-decreasing in 
each row and each column, each combination effect is at least as big as the corresponding effect 
of a single drug. Next, the combination expected gain non-decreases with increasing dose levels. 
The other advantages of an isotonic structure of the gain matrix are discussed later on, when the 
notion of the minimum efficacious combination is introduced. 
3.2.3 Pharmaceutical Meaning of Negative and Zero Expected Gains 
In the previous section we made some assumptions about the population dose-responses. 
Without these assumptions, the matrix Θ  has a very general structure. This fact is illustrated by 
the following example. Suppose there are two active dose levels of each drug A and B and the 
population gains are ,011 ≤θ  ,012 >θ  021 >θ  and ,022 ≤θ . In this case superiority of a dose 
compound ),( 21 yx  or ),( 12 yx  does not imply the superiority of the higher dose combination 
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),( 22 yx . The reason for this is that the single drug effects are not necessarily synergistic or 
additive, i.e., the effect of one single drug is not enhanced by another single drug taken at the 
given doses. This can be the consequence of pharmacodynamic and/or pharmacokinetic 
interaction. So for such drugs the assumption of the isotonic structure of the indicator gain matrix 
does not hold. But since, usually, a number of the single drug properties are established before 
the combination drug trial is conducted; some additional assumptions about the drug behavior 
can be made. In our research from now on we assume that all combination mean responses are at 
least as large as each of the single drug mean response taken at the same dose levels, i.e., all 
0≥ijθ  with 0=ijθ  corresponding to dose combination with no gain. As it is discussed in 
literature review, given in Section 4.1, Hung et al. (1993) make the same assumption of non-
negative gains. 
3.2.4 Isotonic and General Structures of the Indicator Gain Matrix 
For convenience, together with matrix Θ  we use the “indicator gain matrix” 'Θ  which is NK ×  
and has entries of 0 and 1 only. For any given gain matrix Θ , the elements of the indicator gain 
matrix 'Θ  are defined as 
⎪⎩
⎪⎨
⎧
>
==
.0,1
0,0
'
ij
ij
ij if
if
θ
θθ  
There are two cases we are interested in examining. In the first case, we assume that the 
indicator gain matrix has an isotonic structure. The second case corresponds to a general 
structure of the indicator gain matrix.  
In the isotonic case, the elements of each row and each column of 'Θ  create non-
decreasing sequences, i.e., 'Θ  has the property: if 1' =ijθ  for some Ki ,...,1=  and Nj ,...,1= , 
then 1' =rsθ  for all jsandir >> : 
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⎟⎟
⎟⎟
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜⎜
⎜⎜
⎜
⎝
⎛
=Θ
............
1...110....000
......
1...110....000
0...000...000
...........
' ij . 
Such structure of the indicator gain matrix implies that if there is a positive gain 
combination, then all combinations with higher row or column indexes are also more beneficial 
than the corresponding single components. Note that one of the sufficient conditions for this to 
hold is when the matrix Θ  itself is isotonic.  
In the general case, 1' =ijθ  for some Ki ,...,1=  and Nj ,...,1=  does not imply 1' =rsθ  for 
jsandir >>  and 'Θ  could look like  
⎟⎟
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜⎜
⎜
⎝
⎛
=Θ
............
...0...1.....00......
......
...1...0...10....0
...........
'
ij
. 
Next, we are going to introduce the notion of the minimum efficacious dose in the 
combination drug study and examine its properties with regard to isotonic and general cases of 
the indicator gain matrix.  
3.2.5 Definition of the Minimum Efficacious Combination, Non-Uniqueness and 
Definition of the MeD-Set 
We define the minimum efficacious dose (MeD) using the Food and Drug Administration’s 
policy (21 CFR 300.50) which states that “two or more drugs may be combined in a single 
dosage form when each component makes a contribution to the claimed effects.” We appear to 
be the first to consider minimum efficacious doses in terms of the lowest combinations that 
produce an effect greater than each of the single drugs taken alone. We note that in those rare 
instances when the components themselves are not effective in the dose range being studied, 
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establishing that the combination is superior to each component while necessary under FDA 
regulation (21 CFR 300.50) is not sufficient to establish efficacy. That would require, in 
addition, showing superiority to placebo. In these special instances our minimum efficacious 
dose notion would need to be reinterpreted as finding the minimum doses which produce positive 
gain.  
Definition of the MeD. A positive gain dose, such that decreasing any agent dose leads to a no-
gain compound is called the minimum efficacious dose (MeD), i.e., the dose ),( sr yx  for some 
NsKr ≤≤≤≤ 1,1  is the MeD if all of the following are true:  
                                    
.,,0
;0
sjriallforisrjij
rs
<<===
>
θθθ
θ
 
The set of all such doses is called the MeD-set. We introduce the notion of the MeD-set, 
because the MeD is not necessarily unique. Non-uniqueness can be illustrated by considering the 
example of Section 3.2.3 for the 22×  case. There are 2 active dose levels of each drug and the 
population expected gains are 011 ≤θ , 012 >θ , 021 >θ , 022 >θ , then ),( 21 yx  and ),( 12 yx  are 
both the MeD’s, because both of these drug combinations produce a positive expected gain and 
the combination ),( 11 yx  is a no-gain combination.. 
Although, the above definition of the MeD given for the case when all 0≥ijθ , it can be 
easily generalized when this assumption does not hold by replacing all equality signs with the 
""≤  sign and rewriting the last equality as three inequalities.  
3.3 POPULATION MeD-SET 
3.3.1 Matrix Representation and Properties of the Population MeD-Set 
Since by definition, the MeD-set is the collection of all the efficacious doses, such that 
decreasing of at least one agent dose leads to a no-gain compound, the matrix representation of 
the MeD-set can be easily obtained from Θ  or 'Θ . The MeD-matrix is defined as an NK ×  
matrix }{ ijλ=Λ  where for NjKi ,...,1,,...1 ==  
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⎪⎩
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⎧
=≤≤=
==
.1',,0',1
0',0
ijrs
ij
ij
forexceptjsirforif
if
θθ
θλ  
There is a one-to-one correspondence between the elements of the MeD-set and the 
elements of Λ : setMeDyx ji −∈),(  if and only if 1=ijλ . So the properties of the population 
MeD-set can be described in terms of the MeD-matrix Λ . 
From the definition of }{ ijλ=Λ  it follows that each row and each column of this matrix 
has at most a single entry of 1, hence, there is at most one MeD for any fixed dose level of drug 
A and at most one MeD for each fixed dose level of drug B. For the NK ×  design, the MeD-set 
can be empty; it can contain a single element; two elements; etc., up to { }NK ,min  elements. For 
each fixed cardinality of the MeD-set there is a collection of different MeD-sets. The 
cardinalities of these collections are calculated later on. For example, in the 22×  case, the 
following are all possible MeD-matrices: 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
00
, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
01
, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
10
, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
01
00
,  ⎟⎟⎠
⎞
⎜⎜⎝
⎛
10
00
 and ⎟⎟⎠
⎞
⎜⎜⎝
⎛
01
10
.                               (3.1) 
Here, the zero-matrix corresponds to the case when there are no efficacious doses and 
therefore, the MeD-set is empty. The matrices with a single non-zero entry identify the cases 
when the MeD is unique. And therefore, there are four possible MeD-sets of cardinality 1. The 
maximum number of MeD’s is { } 22,2min =  and is represented by the last matrix in (3.1). The 
MeD-set of the example of Section 3.2.3 also corresponds to the last matrix with two MeD’s.  
Next, we present two results which illustrate some basic relationship between the MeD-
matrix and the corresponding indicator gain matrix.  
Result 3.2. For any MeD-matrix there exists a unique isotonic indicator gain matrix.  
Proof: If Λ  is a zero matrix, then there are no efficacious doses among the considered 
combinations and the corresponding indicator matrix is the zero matrix, which is isotonic. For 
non-zero Λ  we construct the corresponding indicator gain matrix using the following approach. 
First, form a matrix Λ=A , then change all elements to the right and below entries of 1 from 
zero to one, i.e., if 1=sta , for some Ks ≤≤1  and Nt ≤≤1  then make 1=ija  for all 
Kssi ,...,1, +=  and Nttj ,...,1, += . The final matrix A  has a property that if an element is 
equal to 1, then all elements with the higher indexes are also 1. So it is isotonic and since all 
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combinations higher than the MeD’s correspond to the efficacious doses (under the assumption 
of isotonic structure), this is the indicator gain matrix and it is unique by construction. 
■ 
If the indicator gain matrix has a general structure, then superiority of some combinations 
does not imply superiority of combinations with higher dose levels, which is stated in the 
following result. 
Result 3.3. If a NK ×  MeD-matrix }{ ijλ=Λ , satisfied 1=stλ  where 2−+≤+ NKts , then 
there exist at least three different non-isotonic indicator gain matrices corresponding to the 
matrix }{ ijλ=Λ . 
Proof: The condition stating that indexes of all non-zero elements stλ  satisfy 
2−+≤+ NKts  guarantees that 0,1,,1 === −− NKNKNK λλλ . So the indicator gain matrices 
}'{' tijt θ=Θ , 3,2,1=t  can be constructed as follows. First, let ijtij λθ =' , for all i  and j  such that 
2−+≤+ NKji  for all 3,2,1=t . The remaining three elements of each matrix }'{' tijt θ=Θ  can 
be specified using the assignments: ,1'' 1 1,
1
,1 == −− NKNK θθ  0'1 , =NKθ , ,0'2 ,1 =− NKθ  ,1'2 1, =−NKθ  
0'2 , =NKθ  and ,1'3 ,1 =− NKθ  0'' 3 ,3 1, ==− NKNK θθ . Then the matrices 1'Θ , 2'Θ  and 3'Θ  are non-
isotonic and each of them corresponds to the given matrix }{ ijλ=Λ .  
■ 
Example 3.1. To illustrate Results 3.2 and 3.3 let us consider a 33×  case and suppose that the 
MeD-matrix is given by  
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛
=Λ
000
010
100
. 
Then, we can claim that the combinations )1,3(),1,2(),2,1(),1,1(  are not efficacious and 
the combinations )2,2(),3,1(  are the MeD’s, so they are superior. This provides the following 
information about the indicator gain matrix:  
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛
∗∗
∗=Θ
0
10
100
' . 
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Next, in the case of the isotonic structure, the last matrix becomes  
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛
=Θ
110
110
100
' , 
but in a general case the elements labeled by "" ∗  stay unspecified and can be either 0 or 1. 
There are eight different possible assignments of 0  and 1 to these three unspecified elements 
and only one of the assignments corresponds to the isotonic indicator gain matrix, which is given 
above. All other assignments (seven of them) produce non-isotonic indicator gain matrices.  
3.3.2 Recursive Algorithm for Identifying the Population MeD-Set for a Given 
Response Matrix 
Using the definition of the MeD-set and the properties of its MeD-matrix Λ , we now provide an 
algorithm for identifying the minimum efficacious doses for the NK ×  case. We assume that the 
mean response matrix R  is given, so the matrices Θ  and 'Θ  can be constructed.  
Algorithm 
Step 1: Construct the indicator gain matrix 'Θ  from the given mean response matrix R . 
The NK ×  matrix 'Θ  has entries of s'0  and s'1  only. 
Step 2 “Identifying the MeD of the combination drug for each fixed dose level of drug 
A”: construct a new NK ×  matrix F  with elements }{ ijf  defined as 
⎪⎩
⎪⎨
⎧
<==
=<∃===
.0'1',1
}1':1'{0',0
jsallforandif
jsandorif
f
isij
isijij
ij θθ
θθθ
 
Thus, matrix F  has at most one non-zero entry in each row; that non-zero entry 
corresponds to the MeD of the combination drug for a fixed dose level of drug A. Let ),( 21 ll  be 
the location of the first (from the left) non-zero element of the first (from the top) non-zero row 
of matrix F . If all rows of the matrix are zero, then stop and conclude that the MeD-set is 
empty, otherwise go to Step 3.  
Step 3 “Identifying the MeD of the combination drug for each fixed dose level of drug 
B”: Matrix F  has at most a single non-zero entry in each row but it might have several non-zero 
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entries in a column, so the matrix must be modified (to a new matrix 'F ) so that each column 
and each row has at most one non-zero column. Define 'F  with elements }'{ ijf  given by 
⎪⎩
⎪⎨
⎧
<==
=<∃===
.01,1
}1:1{0,0
'
irallforfandfif
fsrandforfif
f
rjij
rjijij
ij  
Note that the non-zero entries of matrix 'F  represent only those efficacious combinations 
that become no-gain combinations if the dose level of any one of the drugs is decreased. 
However, it is possible to obtain an efficacious combination from some of those by decreasing 
both indexes. Therefore, not all of the non-zero entries of matrix 'F  represent the MeD’s. The 
next step eliminates the entries that do not represent the MeD’s and constructs the MeD-matrix. 
Let ),( 21 mm  be the location of the non-zero entry of the 1
st non-zero column of matrix 'F  and 
go to Step 4. 
Step 4 “Recursion”: This step is recursive. For the first run, matrix 'F  is the working 
matrix; the working matrix W  for a next run is calculated in the previous run. If the working 
matrix W  has no non-zero entries, the recursion is over and the MeD-set obtained in the 
previous step is returned as the resulting one.  
Let W  be a non-zero working matrix of size BA×  (for the first run, NBKA == , ) 
with elements swij ' . Let ),( 21 ll  be the location of the non-zero entry of the first non-zero row of 
the working matrix and ),( 21 mm  be the location of the non-zero entry of the first non-zero 
column of the working matrix, i.e., 
.1
1
  and  for    0
  and  for    0
21
21
,
,
2,
1,
=
=
<∀∀=
∀<∀=
mm
ll
ji
ji
w
w
mjiw
jliw
 
Note that both ),( 21 ll  and ),( 21 mm  belong to the MeD-set. Moreover, if any other 
MeD’s exist, then they have the first index in the interval 11 lim <<  and the second index in the 
interval 22 mjl << . Thus, if 211 <− lm  or 222 <−ml  then the recursion is finished, and the 
additional elements should be included in the set. If ),(),( 2121 mmll ≠  then two elements, 
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),( 21 ll  and ),( 21 mm , to be included in the set. If ),(),( 2121 mmll =  then a single element is to 
be included. For the first run, these are the only MeD’s included in the MeD-set.  
If 111 >− lm  and 122 >−ml , then more MeD’s might exist in the sub-matrix of 
dimension ( ) ( )11 2211 −−×−− mllm  starting at element 1,1 21 ++ mlw  of matrix W . Let this sub-
matrix be W  and submit the sub-matrix for the next run of the recursion.  
The elements of the resulting MeD-set identify the non-zero entries of the MeD-matrix; 
all other entries of the MeD-matrix must be set to zero.  
■ 
The R-Code and an example of the resulting MeD-matrices are given in Appendix C. 
3.3.3 The Cardinality of the MeD-Set and Number of Different MeD-Sets of Fixed 
Cardinality for the K by N Design 
In the NK ×  setting, the number of elements (cardinality) of an MeD-set is bounded between 
zero (when the MeD-set is empty) and { }NK ,min . Let p  be the cardinality of an MeD-set and 
{ }qMMM ,...,, 21  denote the collection of all different MeD-sets each having p  elements. We 
show that q , the number of elements in { }qMMM ,...,, 21  is a function of p , K  and N  and 
obtain the recursive formula for its calculation.  
Let us start with 1=p , then NKNKq ⋅=),,1( , which corresponds to the number of 
elements of the MeD-matrix. For example, for the 32×  design, there are six different MeD-sets 
of a single element )}1,1{( , )}2,1{( , )}3,1{( , )}1,2{( , )}2,2{(  and )}3,2{( . 
Next, we consider 2=p , then the MeD-set can be written in the form )},(),,{( 2211 jiji . 
By the definition of the MeD, we must have 21 ii <  and 21 jj > . The first element with matrix 
coordinates ),( 11 ji  can be located anywhere except for the last row and the first column of the 
MeD-matrix, i.e., 1,...2,11 −= Ki  and Nj ,...,3,21 = . The second element, with coordinates 
),( 22 ji  must be located to the left and down from the first element, i.e., Kii ,...,112 +=  and 
1,...,2,1 12 −= jj . So there are )1()( 11 −⋅− jiK  choices for the second element. Hence, the total 
number of different choices of such two elements is given by  
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For example, for the 32×  design, the MeD-sets of two elements are given by 
)}1,2(),2,1{( , )}1,2(),3,1{(  and )}2,2(),3,1{( which agrees with 3
4
)2(3)1(2)3,2,2( ==q . 
For the case of 3=p , the MeD-set can be written in the form )},(),,(),,{( 332211 jijiji , 
where 321 iii <<  and 321 jjj >> . Here, 2,...2,11 −= Ki  and Nj ,...,4,31 = . The second and 
third elements must be located in a matrix with 1iK −  rows and 11 −j  columns. There are 
)1,,2( 11 −− jiKq  different ways to choose the second and the third elements given the first 
element. So the total number of different choices of all three elements is given by  
∑∑∑∑ −
= =
−
= =
−−−−−=−−=
2
1 3
2
1 3 4
)2)(1)(1)(()1,,2(),,3(
K
i
N
j
K
i
N
j
jjiKiKjiKqNKq  
So in a general case, the result can be summarized by the following theorem. 
Theorem 3.1. In the NK × case, for any },min{1: NKpp ≤≤ , the number of different MeD-
sets of cardinality p , is given by the recursive formula  
∑ ∑+−
= =
−−−=
1
1
)1,,1(),,(
pK
i
N
pj
jiKpqNKpq  for },min{2 NKp ≤≤  with NKNKq ⋅=),,1(      (3.2) 
The above formula is very helpful if all MeD-sets must be identified for the given design, 
as it provides the total number of different MeD-sets containing the certain number of elements.  
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4.0 HYPOTHESES TESTING APPROACH TO ESTIMATE THE MeD-SET 
4.1 LITERATURE REVIEW 
We have examined the properties of the primary population parameters which are present in a 
combination drug trial. However, as we later note additional parameters also must be considered 
in order to draw some conclusions about the combination drug behavior.  
Let ijty  be the response of the tht −  subject in the thji −),(  dose combination group. 
We are going to introduce the procedure for identifying the MeD-set. This procedure is based on 
the following distributional properties and assumptions: 
Assumption 1. Group sample sizes are equal nnij = , for Ki ,...,0=  and Nj ,...,0= , 
(4.1a) 
Assumption 2. The group sample mean responses are independent and normally distributed with 
the common variance, )/,(~ 2 nNy ijij σμ  for Ki ,...,0=  and Nj ,...,0= . 
 (4.1b) 
The U.S. Food and Drug Administration’s policy (21 CFR 300.50) regarding the use of a 
fixed-dose combination drug requires that each component makes a contribution to the claimed 
effect of the combination. In view of this requirement, a lot of research has been done to study 
the superiority of a combination drug. 
Laska and Meisner (1989) consider the problem of identifying whether the combination 
treatment is better than each of the single component agents of a single fixed-dose combination 
),( ji  using a hypothesis testing approach. They consider the null hypothesis 
ojijiij orH μμμμ ≤≤ 00 :  versus the alternative ojijiij andH μμμμ >> 01 : . They illustrate 
that an α -level test can be constructed by performing two separate statistical tests of 
0
1
0 : iijH μμ ≤  versus 011 : iijH μμ >  and ojijH μμ ≤:20  versus ojijH μμ >:21  each at the same 
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α -level. Under the assumptions (4.1a) and (4.1b), the proposed test statistics are given by 
)(2/ 0
1
iij yynS −⋅=  for testing 10H  and by )(2/ 02 jij yynS −⋅=  for testing 20H  for the 
case when the variance is 12 =σ . The test statistics are jointly distributed as a bivariate normal 
random variable with mean vector )',(2/ 0 ojijiijn μμμμ −−  and covariance matrix  
⎟⎟⎠
⎞
⎜⎜⎝
⎛
15.0
5.01
. 
Then the hypothesis 0H  is tested against 1H  by the “min-test”, which rejects the null 
hypothesis if αcSS >},min{ 21 , where αc  is the upper α -level critical value of the standard 
normal distribution. In the normal case the min-test is a likelihood ratio test. Laska and Meisner 
also show that among the family of test statistics that are monotone non-decreasing functions of 
the two separate tests, the min-test is uniformly most powerful. 
Hung et al. (1993) consider a more general problem of “global superiority”. They 
consider a global null hypothesis associated with all active study combinations stating that all 
combinations in the study are no-gain combinations. The alternative hypothesis states that there 
exists at least one dose combination which is more effective than its respective component doses. 
Under the assumptions (4.1a) and (4.1b) two test statistics are constructed to test these 
hypotheses. The AVE  test statistic, AT , is given by  
σθ ˆˆ
1 1
⋅⋅= ∑∑
= =
NKT
K
i
N
j
ijA  ,                                                    (4.2) 
where ijθˆ , ),max(ˆ 00 jiijij yyy −=θ , is an estimator of ijθ , the expected gain (or gain), for the 
thji −),(  dose combination. The pooled estimator 2σˆ  of 2σ  is given by  
( ) [ ])1()1()1(ˆ
0 0 1
22 −⋅+⋅+−= ∑∑∑
= = =
nNKyy
K
i
N
j
n
t
ijijtσ . 
The second test statistic is the MAX  statistic, MAXT . It is given by 
σθ ˆ)ˆ( ijMAX MAXT = , 
where the maximum operator MAX  is taken over all possible points in the lattice 
},...,1,,...,1),,{( NjKiji == . 
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Both test statistics are then used by authors to test the hypothesis 
1,0:0 ≥= jiallforH ijθ  versus 1,0:1 ≥> jisomeforH ijθ . Note that these hypotheses are 
constructed for the case when the combination of the two drugs is not expected to be less 
effective than either component drug alone, i.e., all 0≥ijθ . 
Using the fact that σμ /)( ijijij ynZ −⋅=  are distributed as standard normal random 
variables and the fact that given NjKiallforyy ji ,...,1,,...,1,, 00 == , the variables ijθˆ  are 
statistically independent and independent of σˆ , the authors obtain the exact distribution 
functions of the test statistics AT  and MAXT . The distribution function of AVE test statistic can be 
written as: 
( ) )(......)()()),;,,((1, 11
10 1
wdQdvdvduduvuwvuhcTP NKj
N
j
i
R
K
i
A
NK
ϕϕθδθδ ∏∫ ∫ ∏
=
∞
=+
⋅Φ−=≤ )))) ,      (4.3) 
where δ)  and θ)  are vectors with components ijij θδ ,  respectively, for ,,...,1 Ki =  Nj ,...,1= ; 
)(⋅Φ  is the distribution function of the standard normal random variable; ϕ  is its density 
function; )(⋅Q  is the distribution function of σσ /ˆ , and NKR +  is the −+ )( NK dimensional 
Euclidean space; the function  
[ ]
KN
nvunvu
cwnKNwvuh
K
i
N
j
ijjiijji
AVE
2
),;,,( 1 1
∑∑
= =
+−+−+
−⎟⎠
⎞⎜⎝
⎛ −−=
δδ
σ
θθδ )) , 
where                 
)(
1 1
NK
K
i
N
j
ijAVE ⋅= ∑∑
= =
θθ , σμμδ /)( 00 jiij −= . 
Note that the distribution function of AT  depends on the parameters ijθ  only through 
AVEθ .  
The distribution function of the MAX test statistic can be written as  
( )θδ )),cTP MAX ≤ )(......)()()),;,,(( 11
10 111
wdQdvdvduduvuwvug NKj
N
j
i
R
K
i
ijijji
N
j
K
iNK
ϕϕθδ ∏∫ ∫ ∏∏∏
=
∞
===+
⋅Φ= , 
where 
2
),;,,(
ijjiijjiij
ijijji
nvunvu
cwnwvug
δδ
σ
θθδ +−+−++⎟⎟⎠
⎞
⎜⎜⎝
⎛ −= . 
 53 
The above distribution functions involve the nuisance parameters ijδ , so that the test 
statistics are not readily usable unless these parameters are given.   
Next, by taking supremum over all ),( ∞−∞∈ijδ  of the power functions of AT  and MAXT , 
evaluated at 0=θ) , authors obtain the critical values for specified α  by solving the following 
equations for c : 
[ ]∫ ∫∞ ∞∞− ⋅−−Φ= 0 )()( wdudQuuacwnKN ϕα  
for the AVE test statistic, where ),max( NKa = , and the equation 
[ ]{ } [ ]{ } )()()(1
0
42
wdQZcwnEZcwnE∫
∞
+Φ⋅+Φ−=α  
for the MAX test, where E  denotes the expectation and )1,0(~ NZ . When variance is known, 
the authors provide the critical values of both standardized statistics, ATn  and MAXTn , for all 
rectangular designs with 5≤K  and 5≤N  for significance levels of 01.0,05.0,1.0=α . Table 
5 provides some of these values corresponding to the AVE test for 05.0=α . 
Table 5. α -level critical values of ATn ⋅ , provided by Hung et al. (1993) 
 
                                Significance Level 
K        N          1.0=α   05.0=α   01.0=α  
 
1        1               1.81              2.33            3.29 
1        2               1.57              2.01            2.85 
1        3               1.48              1.90            2.69 
2        2               1.11              1.42            2.01 
2        3               1.05              1.34            1.90 
3        3               0.85              1.10            1.55 
 
 
The CPMP/EWP (2002) guidelines, formulated by the European Agency for the 
Evaluation of Medicinal Products state that there are two goals of employing multiple-dose 
factorial designs. These goals include “(i) to provide confirmatory evidence that a combination is 
 54 
more effective than each of its components and (ii) to identify an effective and safe range of dose 
combinations for recommended use.” Hellmich and Lehmacher (2005) consider the problem of 
identifying the minimum effective dose (MED) and do not address goal (i) of the CPMP/EWP 
(2002) guidelines.  
Hellmich and Lehmacher (2005) introduce a definition of a minimum effective dose 
(MED) under the assumption that the response matrix has an isotonic structure. The doses of 
drug A and drug B are coded as Kii ,...,0, =  and Njj ,...,0, =  and the definition of an MED 
is formulated as { }00:),(min μμ >= ijjiMED pp . The problem of identifying the pMED  involves 
the following hypotheses 
),()','(: ''00,0 babaH baab p∀= μμ  versus 
abbaab andbabaH μμμμ <∀≤ 00''00,1 ),()','(: p . 
The estimates for pMED  are given by the smallest grid points ),( ba  for which abH ,0  is 
rejected. The authors construct the closure of family of the above hypotheses, which allows 
applying the Marcus, Peritz and Gabriel principle (Marcus et al. (1976)) to test each hypothesis 
from the closure at a fixed level α . Hellmich and Lehmacher consider the likelihood ratio and 
multiple contrast tests for testing each individual hypothesis. They also provide a tree-graph for 
the 22×  design, illustrating the order in which the hypotheses should be tested.  
In the remainder of this Chapter, we provide a step-down closed testing procedure for 
identifying all minimum efficacious doses (MeD’s). By the efficacious combination we mean 
superiority of the combination, i.e., the combination with positive expected gain. Our 
development begins with the simplest 22×  case in order to present the proposed procedure in 
detail. We then consider the 32×  case, which in turn introduces new complexities of the 
proposed procedure. The method for constructing the procedure for a general NK ×  case is very 
complex and does not have any practical value, so we provide the algorithm for constructing the 
procedure for any specified K  and N  and illustrate the algorithm for the 33×  case.  
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4.2 CRITICAL VALUES FOR NON-RECTANGULAR DESIGNS 
Before our procedure is discussed in detail we discuss non-rectangular designs and the methods 
for obtaining the critical values corresponding to these designs. 
Hung et al. (1993) obtain the critical values of their AVE and MAX statistics for complete or 
rectangular designs. By a “complete” or “rectangular” design we mean the design, in which all 
possible combinations of two drugs are considered, i.e., the combinations 
},...,1,,...,1),,{( NjKijiG ==≡ . Our proposed procedure for identifying the MeD’s which 
involves intersections of null hypotheses results in some of these hypotheses that do not 
correspond to the rectangular designs. So, in order to apply our procedure together with 
rectangular design we have to use some non-rectangular designs of the following form.  
Let Kk ≤' , Nnnn kk ≤≤≤≤ − )1()1'()'( '...''  with )1()'( '' nn k < . Then the non-rectangular 
design is given by  
{ }',...,1,',...,1),,( )( kinjjiI i ==≡ .                                             (4.4) 
The non-rectangular design I  is obtained by the excluding some specified high dose 
combinations from the original grid of points G . Note that if in definition of I we do not require 
)1()'( '' nn k < , then GI ≡ . 
The cardinality of G  is KN  and the cardinality of the lattice corresponding to non-
rectangular design I  is ∑
=
==
'
1
)(')'(''
k
i
inknn , where numbers )(',' ink  depend on the actual 
values of  K  and N  and are to be specified for our testing procedure. Now, let us just mention 
that the simplest case of non-rectangular design corresponds to the case when a single 
combination is omitted from the original set of points. There are KN  possible such non-
rectangular designs, but we are interested only in a single one of them, where the highest drug 
combination ),( NK  is omitted from the original grid G . For the 22×  case, it turns out that this 
form of non-rectangular design is the only one which we need to consider, and is given by 
{ }1',2',2'},',...,1,',...,1),,{( )2()1()()()(22 ======≡× nnkfornjkijjiI iii , i.e., the set of drug 
combinations { })1,2(),2,1(),1,1( . 
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In order to obtain the critical values for the specified non-rectangular design I , we need 
to generalize Hung’s et al. (1993) method for obtaining the critical value for the AVE test. 
Assume that I  is given, so that all of ',...,1,',' )( kink i =  (with 2' )1( ≥n ), 'n  (the total number 
of drug combinations under consideration) and )1('' nkP +=  (the total number of single drug 
doses) are specified. Then the following theorem holds (the detailed proof is given in Appendix 
D). 
Theorem 4.2. Let Kk ≤' , )1()1'()'( '...'' nnn kk ≤≤≤ −  with )1()'( '' nn k <  and ∑
=
=
'
1
)(''
k
i
inn and define 
[ ] )()(')(
0
wdQdxxtxcwnntG ∫ ∫
∞ ∞
∞−
−⋅−Φ= ϕ . Then for non-rectangular design I  of the form (4.4), 
the α -level critical value of the AVE test statistic 
σ
θ
ˆ'
ˆ
).(
⋅=
∑
∈
n
T Iji
ij
A  
is given as the solution c  to the equation α=)( maxtG , where 'max
1
2
max n
m
t
P
s
s∑
==  with sm , 
Ps ,...,1=  non-negative integers subject to constraints:   
{ } PksIksiksim
ksnm
s
ss
,...,1',)',(:)',(
;',...,1,' )(
+=∈−−≤
=≤
 
and '
1
nm
P
s
s =∑
=
, where A  denotes the cardinality of a set A . 
In order to use Theorem 4.2, first one needs to solve the optimization problem of 
maximizing the value of 
'
1
2
n
m
t
P
s
s∑
==  subject to specific constraints on the values of sm , 
Ps ,...,1= . The solution to this problem is given in Appendix E. Next, the equation α=)( maxtG  
must be solved for c , for the specified value of α ; this can be done using MathCAD, Maple or 
another mathematical software package. In the case of known variance, the double integral in the 
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expression for )(tG  reduces to dxxtxcnntG )(]'[)( ϕ−⋅−Φ= ∫∞
∞−
 and can be used to obtain the 
critical values.  
Example 4.1. For the non-rectangular design of the form, 
{ })},{(\},...,1,,...,1),,{()},{(\0 NKNjKijiNKGI ==≡= , the maximum value of 
'
1
2
n
m
t
P
s
s∑
==  subject to above constraints equals 
'
122
max n
babt +−= , where 
},min{ NKa = and },max{ NKb =  and 1' −= KNn . The proof of this fact is given in 
Appendix E. Then, the significance level of the AVE test is given by 
)()(
1
12)1(
0
2
wdQdxxx
KN
babcwKNnLevelceSignifican ∫ ∫∞ ∞
∞− ⎥
⎥
⎦
⎤
⎢⎢⎣
⎡ ⋅−
+−−−−Φ≡ ϕ . 
So the critical values of desired level of significance can be obtained by solving the 
following equation for c : 
)()(
1
12)1(
0
2
wdQdxxx
KN
babcwKNn∫ ∫∞ ∞
∞− ⎥
⎥
⎦
⎤
⎢⎢⎣
⎡ ⋅−
+−−−−Φ= ϕα ,                      (4.5a) 
which simplifies to  
duuu
KN
babcKNn )()
1
12)1((
2
ϕα ∫∞∞− ⋅⋅− +−−⋅−−Φ=                                (4.5b) 
when variance is known.  
This is the only form of the non-rectangular design which is used by us in the 22×  case, 
and the corresponding critical values for this case are given in the Section 4.3. All other higher 
dimensional designs require numerical optimization to compute the critical values. 
4.3 2 BY 2 CASE 
Next, we are going to construct a stepwise procedure for identifying the minimum efficacious 
doses. To illustrate the approach and its complexity we first discuss its details for the 22× case. 
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Our procedure involves the test statistics proposed by Hung et al. (1993). First, for a given 
design all possible MeD-sets must be identified. Next, we identify the corresponding closed 
family of hypotheses. Our procedure uses a graph-theoretic testing order for the hypotheses so 
we can employ the Marcus, Peritz and Gabriel (1976) closed testing principle. This principle 
along with a prescribed step-down testing allows us to estimate the MeD-set.  
In order to test an individual hypothesis for each active compound, the expected gain 
from combining the drugs at the given levels is defined. Next, the appropriate estimator of the 
expected gain is constructed in order to test the hypotheses of the expected gains being zero 
versus at least one positive gain. The pattern of the rejected null hypotheses identifies all the 
combinations, i.e., the MeD’s, such that decreasing at least one component’s dose leads to no-
gain compound.  
Although, we consider a general NK ×  combination drug set up, in most 
biopharmaceutical studies, the number of drug dose levels is not typically bigger than four or 
five, because of the high cost of the study and the large number of participants needed if the 
number of experimental groups is large. We begin with the simplest 22×  case. 
Denote the matrix of unknown expected gains in the case of 22×  design by 
⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
2221
1211
θθ
θθ
. First, the collection of all possible MeD-sets for the 22×  case should be 
identified. This collection is given by (3.1) and consists of the sets represented by the following 
matrices: 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
00
, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
01
, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
10
, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
01
00
,  ⎟⎟⎠
⎞
⎜⎜⎝
⎛
10
00
 and ⎟⎟⎠
⎞
⎜⎜⎝
⎛
01
10
 
Next, we construct a hypothesis family { })1(0)"2(0)'2(0)3(0)4(0 ,,,, HHHHH=Η  where  
0: 22211211
)4(
0 ==== θθθθH , 
0: 211211
)3(
0 === θθθH , 
0: 1211
)'2(
0 ==θθH , 0: 2111)"2(0 ==θθH  
0: 11
)1(
0 =θH  
with the corresponding alternative hypotheses given by 
""0,0,0,0: 22211211
)4(
1 >≥≥≥≥ oneleastatwithH θθθθ  
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"",0,0,0: 211211
)3(
1 >≥≥≥ oneleastatwithH θθθ    
""0,0: 1211
)'2(
1 >≥≥ oneleastatwithH θθ   
""0,0: 2111
)"2(
1 >≥≥ oneleastatwithH θθ    
0: 11
)1(
1 >θH . 
Since, )1(0
)'2(
0
)3(
0
)4(
0 HHHH ⊂⊂⊂ , )1(0")2(0)3(0)4(0 HHHH ⊂⊂⊂  and )3(0")2(0)'2(0 HHH ≡I  
then the intersection of any two hypotheses ,)(0 Η∈sH  ttoidenticalnotissH t ,)(0 Η∈ , is 
given by 
⎪⎩
⎪⎨
⎧
<
>
=
otherwiseH
tsifH
tsifH
HH t
s
ts
,
,
,
)3(
0
)(
0
)(
0
)(
0
)(
0 I  
which belongs to the family; if ,ttoidenticaliss  Η∈≡ )(0)(0)(0 sts HHH I . Hence, the family 
of hypotheses  Η  is closed under intersection. Now the Marcus, Peritz and Gabriel method for 
constructing a procedure that strongly controls the Familywise Error (Marcus et al. (1976)) can 
be applied under the rule that a hypothesis is rejected at level α  if and only if all hypotheses 
implying it, including itself, are significant at level α .  
)3(
0H
")2(
0H
)'2(
0H
)1(
0H
)4(
0H
 
Figure 4. The “implication” tree for the 22×  design 
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The “implication of rejection” tree for the 22×  design is given in Figure 4. A similar 
tree for the 22×  design was first proposed by Hellmich et al. (2005) but for a different problem 
set-up. The tree given in Figure 4 has five nodes and four levels, which we call “hypothesis 
levels”, labeled from bottom to top. The fourth, third and first hypothesis levels consist of a 
single hypothesis, but the second hypothesis level has two hypotheses. This tree defines the order 
in which the hypotheses are to be tested (each hypothesis is tested at level α ). First, we test 
)4(
0H , if 
)4(
0H  is accepted then we stop and conclude that there are no MeD’s, otherwise we test 
)3(
0H . If 
)3(
0H  is accepted then we stop and conclude that the MeD-matrix is estimated as  
⎟⎟⎠
⎞
⎜⎜⎝
⎛
10
00
. 
If )3(0H  is rejected then we test both hypotheses 
)'2(
0H  and 
")2(
0H . If both hypotheses are 
rejected we test )1(0H . If 
)'2(
0H  is accepted and 
")2(
0H  is rejected then we conclude that the MeD-
matrix is estimated as  
⎟⎟⎠
⎞
⎜⎜⎝
⎛
01
00
. 
In the case of rejecting )'2(0H  and accepting 
")2(
0H , the MeD-matrix is estimated as  
⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
10
. 
Finally, in the case of testing )1(0H  if it is accepted than we conclude that there are two 
MeD’s, i.e., the MeD-matrix is estimated as 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
01
10
, 
and if )1(0H  is rejected then it is estimated as  
⎟⎟⎠
⎞
⎜⎜⎝
⎛
00
01
. 
The above conclusions are summarized in Table 6. Note that the case when both )'2(0H  
and ")2(0H  are accepted given that 
)3(
0H  was rejected, does not provide any conclusive result in 
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terms of the estimated MeD’s. In such cases we say that the procedure results in Type A 
ambiguity. This situation is considered in more detail in Section 4.6. 
Each of the hypotheses from the family Η  can be tested using Hung’s et al. (1993) AVE 
test statistic, given by (4.2). The additional critical values are needed only for non-rectangular 
design of testing 0: 211211
)3(
0 === θθθH , so the results (4.5a) and (4.5b) can be used. Applying 
(4.5a), we obtain the critical values by solving the equation below for c  for the specified level of 
significance:  
[ ]∫ ∫∞ ∞∞− ⋅⋅−−Φ= 0 )()(3/53 wdudQuucwn ϕα . 
Table 6. “Decision” sequences with the corresponding estimated MeD-sets for the 22×  case 
(Notation: ACC - “Hypothesis is accepted”, REJ – “Hypothesis is rejected”, NT -“Hypothesis is 
not tested.”) 
)4(
0H  
)3(
0H  
)'2(
0H  
")2(
0H  
)1(
0H  Estimated setMED −  
ACC NT NT NT NT Empty 
REJ ACC NT NT NT )}2,2{(  
REJ REJ ACC ACC NT Type A 
REJ REJ ACC REJ NT )}1,2{(  
REJ REJ REJ ACC NT )}2,1{(  
REJ REJ REJ REJ ACC )}2,1(),1,2{(  
REJ REJ REJ REJ REJ )}1,1{(  
 
In the case of known variance, from (4.5b) it follows that the critical values can be 
obtained from duuucn )()3/53( ϕα ∫∞∞− ⋅⋅−⋅−Φ= . 
For the standardized AVE test, the critical values corresponding to 01.0,05.0,1.0=α  
obtained from the last equation are, respectively, 19.2,55.1,21.1 01.005.01.0 === ccc .  
Example 4.3. Hung et al. (1993) provide data from a factorial clinical trial, which is conducted 
to evaluate the effectiveness of the combination of two antihypertensive drugs, A and B. The 
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subset of observed data of diastolic blood pressure mean reductions (in mm Hg, rounded to the 
nearest integer) is given below. 
 Drug B 
Drug A 0 1 2 
0 0 4 5 
1 5 9 7 
2 5 6 6 
The sample size of each group is 25. The observed blood pressure reductions appear to be 
approximately normally distributed. The pooled estimate for the true variance is 42.  
To illustrate our procedure we consider the above data of diastolic blood pressure mean 
reductions for two active dose levels of each drug. The matrix of estimated gains is  ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
11
24ˆ . 
The AVE test statistics corresponding to )4(0H , 
)3(
0H , 
)'2(
0H , 
)"2(
0H  and 
)1(
0H  and the critical 
values are 
31.0
4222
1124)4( =⋅⋅
+++=AT , 28.025/42.1)4( 05.0 ==c , 
36.0
423
124)3( =⋅
++=AT , 31.025/55.1)3( 05.0 ==c . 
The average of three observed gains is taken to calculate )3(AT  so the expression in the 
denominator, NK ⋅ , is substituted by 3.  
46.0
422
24)'2( =⋅
+=AT , 40.025/01.2")2( 05.0)'2( 05.0 === cc , 
39.0
422
14")2( =⋅
+=AT , 
62.0
421
4)1( =⋅=AT , 47.025/33.2
)1(
05.0 ==c . 
Since )4( 05.0
)4( cTA >  we reject 0: 22211211)4(0 ==== θθθθH . Then, we test 
0: 211211
)3(
0 === θθθH  and since )3( 05.0)3( cTA > , we reject it. Next, we test and reject 
0: 1211
)'2(
0 ==θθH  and test and accept 0: 2111)"2(0 ==θθH . So we stop and conclude that the 
estimated MeD-set is given by the set )}2,1{( .  
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4.4 2 BY 3 CASE 
We next consider the 32×  design, which illustrates some additional complexities not apparent in 
the 22× case. Before we introduce the hypothesis family for this case, all nine possible MeD-
sets must be identified. First, there is an empty set, six different sets of a single element )}1,1{( , 
)}2,1{( , )}3,1{( , )}1,2{( , )}2,2{( , )}3,2{(  and there are three different sets of two elements 
)}2,2(),3,1{( , )}2,1(),1,2{(  and )}3,1(),2,2{( .  
For the matrix of population gains ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
232221
131211
θθθ
θθθ
 we consider the set of null 
hypotheses (the corresponding one-sided alternative hypotheses are parallel to the 22×  case)  
0: 232221131211
)6(
0 ====== θθθθθθH  
0: 2221131211
)5(
0 ===== θθθθθH  
0: 21131211
)'4(
0 ==== θθθθH  
0: 22211211
")4(
0 ==== θθθθH  
0: 131211
)'3(
0 === θθθH  
0: 211211
")3(
0 === θθθH  
0: 1211
)'2(
0 ==θθH  
0: 2111
)"2(
0 ==θθH  
0: 11
)1(
0 =θH . 
The testing order is represented by the “implication” tree of Figure 5. 
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)6(
0H
)5(
0H
")4(
0H
)'4(
0H
)1(
0H
")2(
0H
)'2(
0H
")3(
0H)'3(0H
 
Figure 5. The “implication” tree for the 32×  design 
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We use this tree to show that the family of hypotheses 
{ })1(0")2(0)'2(0")3(0)'3(0")4(0)'4(0)5(0)6(0 ,,,,,,,, HHHHHHHHH=Η  is closed under intersection. Indeed, 
the intersection of any number of hypotheses connected with implication arrows, )(0 1
sH , 
)(
0
2sH ,…, )(0 h
sH  for some 61, ≤< hh  is )(0)(0
1
...21
hi
h
ss
hi
sss
HH =
≤≤
<<<
I . The intersection of any 
hypotheses of the same level is the hypothesis of the higher level, indeed, )5(0
")4(
0
)'4(
0 HHH ≡I ,  
)'4(
0
")3(
0
)'3(
0 HHH ≡I  and ")3(0")2(0)'2(0 HHH ≡I . So the only hypotheses whose intersection is left 
to be considered are the hypotheses which do not imply one another and are of the different 
levels. There are two pairs of such hypotheses, { })'3(0")4(0 , HH  and { }")2(0)'3(0 , HH . Since 
)5(
0
)'3(
0
")4(
0 HHH ≡I  and )'4(0")2(0)'3(0 HHH ≡I  both intersection-hypotheses belong to the family, 
which completes the proof that Η  is closed under intersection.  
Table 7 illustrates that our procedure produces the estimates of all possible MeD-sets. 
Unfortunately, together with these conclusive results, the procedure can result in other “decision” 
sequences of rejected and accepted hypotheses, which lead to ambiguities in terms of the 
estimated MeD-set. These situations are of two kinds, Type A and Type B. One method that can 
be used to deal with Type B ambiguity is presented in Section 4.6. 
In order to test the above hypotheses using the AVE test statistic (4.2), we need to 
calculate the additional critical values for non-rectangular designs in order to test )5(0H , 
)'4(
0H  
and ")3(0H . The critical values for testing 
")3(
0H  based on the AVE test were discussed in the 22×  
case. For testing )5(0H  the results (4.5a) and (4.5b) provide the following equations: 
[ ]∫ ∫∞ ∞∞− ⋅⋅−−Φ= 0 )()(5/135 wdudQuucwn ϕα  (if the variance is not known) and  
duuucn )()5/135( ϕα ∫∞∞− ⋅⋅−⋅−Φ=  if the variance is known. 
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Table 7. “Decision” sequences with the corresponding estimated MeD-sets for the 32×  case 
(Notation: ACC - “Hypothesis is accepted”, REJ – “Hypothesis is rejected”, NT -“Hypothesis is 
not tested”) 
)6(
0H  
)5(
0H  
)'4(
0H  
")4(
0H  
)'3(
0H  
")3(
0H
)'2(
0H  
")2(
0H
)1(
0H  Estimated MeD-set 
ACC NT NT NT NT NT NT NT NT Empty 
REJ ACC NT NT NT NT NT NT NT )}3,2{(  
REJ REJ ACC ACC NT NT NT NT NT Type A 
REJ REJ ACC REJ NT NT NT NT NT )}2,2{(  
REJ REJ REJ ACC REJ NT NT NT NT )}3,1{(  
REJ REJ REJ ACC ACC NT NT NT NT Type B 
REJ REJ REJ REJ ACC ACC NT NT NT Type A 
REJ REJ REJ REJ ACC REJ NT REJ NT )}1,2{(  
REJ REJ REJ REJ ACC REJ NT ACC NT Type B 
REJ REJ REJ REJ REJ ACC NT NT NT )}3,1(),2,2{(  
REJ REJ REJ REJ REJ REJ ACC ACC NT Type A 
REJ REJ REJ REJ REJ REJ REJ ACC NT )}2,1{(  
REJ REJ REJ REJ REJ REJ ACC REJ NT )}3,1(),1,2{(  
REJ REJ REJ REJ REJ REJ REJ REJ ACC )}2,1(),1,2{(  
REJ REJ REJ REJ REJ REJ REJ REJ REJ )}1,1{(  
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For example, for the standardized AVE test the critical values corresponding to 
01.0,05.0,1.0=α  obtained from the last equation are, respectively, 09.11.0 =c , 40.105.0 =c  
and 97.101.0 =c . For testing )'4(0H  the α -level critical value of the AVE test can be obtained as 
the solution to the following equation for the specified level of significance α :     
[ ] )()(4/104
0
wdQdxxxcwn∫ ∫∞ ∞
∞−
−−Φ= ϕα  (if variance is unknown) and from    
duuucn )()4/104( ϕα ∫∞∞− ⋅⋅−⋅−Φ=  (if variance is known). For example, in the case of 
known variance the critical values are given by 20.11.0 =c , 54.105.0 =c  and 18.201.0 =c  for the 
standardized AVE test. 
The details on obtaining the above integrals are considered in Appendix E. 
4.5 3 BY 3 CASE 
In the cases of 22×  and 32×  designs the number of different MeD-sets and the number of 
elements in each set are not relatively large, so it is quite easy to construct a sequence of 
hypotheses which would produce the estimates of all possible MeD-sets configurations and be 
closed at the same time. When the number of drug dose levels increases, the structure of each 
MeD-set becomes more complicated. We consider the case of the 33×  design and illustrate a 
general approach for constructing such a procedure. The same techniques can be used for 
analysis of a combination drug in the 42× , 43× , 44×  trials and trials of higher dimensions.   
First, all possible MeD-sets must be identified and the corresponding hypotheses 
constructed. Then, the proper testing order must be set up. Next, for all non-rectangular types of 
design the additional critical values need to be calculated. Finally, the step-down testing 
procedure can be applied using the MPG principle or any modification of it, which guarantees 
strong control of the FWE. 
Let us look at all possible MeD-sets for the 33×  design. The cardinality, p , of the MeD-
set can be any number such that 3}3,3min{1 =≤≤ p . We use the recursive formula given by 
(3.2) to check that all possible MeD-sets are identified for each p . 
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There are nine different MeD-sets with 1=p , they are )}1,1{( , )}2,1{( , )}3,1{( , )}1,2{( , 
)}2,2{( , )}3,2{( , )}1,3{( , )}2,3{( and )}3,3{( . For 2=p , the formula gives us  
94/))13(3)13(3()3,3,2( =−⋅⋅−⋅=q  
MeD-sets. We identify them as )}1,2(),2,1{( , )}1,3(),2,1{( , )}1,2(),3,1{( , )}2,2(),3,1{( , 
)}1,3(),3,1{( , )}2,3(),3,1{( , )}1,3(),2,2{( , )}1,3(),3,2{(  and )}2,3(),3,2{( .  
Finally, there is a single set )}1,3(),2,2(},3,1{( of cardinality 3=p . Thus, in the 33×  
case there are a total of 19 possible non-empty MeD-sets.  
Now, let us construct the family of the null hypotheses. Each corresponding alternative 
hypothesis states that all gains considered in the null hypothesis are non-negative and at least one 
of them is strictly positive. The null hypothesis of the highest level includes all nine gains. By 
excluding the highest combination )3,3( , we form the hypothesis of the eighth level. The next 
highest combinations are )3,2(  and )2,3( , so we form two hypotheses of the seventh level by 
omitting one of these combinations. Then, we continue to exclude one highest dose at a time 
from each hypothesis, until we are left with the only one gain, corresponding to the null 
hypothesis of the first level 0: 11
)1(
0 =θH . The family of hypotheses constructed in such a way is 
presented below, where the superscript denotes the level from lowest (1) to largest (9). 
0: 11
)1(
0 =θH     
0: 1211
)'2(
0 == θθH     
0: 2111
")2(
0 == θθH    
0: 131211
)'''3(
0 === θθθH    
0: 312111
")3(
0 === θθθH    
0: 211211
)'3(
0 === θθθH    
0: 22211211
)'4(
0 ==== θθθθH   
0: 31211211
")4(
0 ==== θθθθH   
0: 21131211
)"'4(
0 ==== θθθθH   
0: 3122211211
)'5(
0 ===== θθθθθH  
0: 3121131211
")5(
0 ===== θθθθθH  
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0: 2221131211
)'''5(
0 ===== θθθθθH   
0: 323122211211
)'6(
0 ====== θθθθθθH  
0: 322221131211
")6(
0 ====== θθθθθθH   
0: 232221131211
)'''6(
0 ====== θθθθθθH   
0: 32312221131211
)'7(
0 ======= θθθθθθθH   
0: 31232221131211
")7(
0 ======= θθθθθθθH  
0: 3231232221131211
)8(
0 ======== θθθθθθθθH  
0: 333231232221131211
)9(
0 ========= θθθθθθθθθH . 
Again, let Η  be the family of these null hypotheses. Then it can be shown that Η  is 
closed under intersection, so the MPG principle can be used to test the above sequence of 
hypotheses and identify the MeD-set. The order of testing scheme then can be represented by the 
“implication” tree given in Figure 6. There are 20 different MeD-sets (including the empty set) 
for the 33×  design and Table 8 illustrates that our procedure produces the estimates of all 
possible population MeD-sets. As in the 22×  and 32×  cases, the procedure can result in other 
“decision” sequences of rejected and accepted hypotheses leading to ambiguities. Such 
sequences and some suggestions on how to deal with these situations are given in Section 4.6.  
In order to test the above hypotheses using the AVE test statistic (4.2), we need to 
calculate the additional critical values for non-rectangular designs in order to test )8(0H , 
)'7(
0H , 
")7(
0H , 
")6(
0H , 
)'5(
0H , 
")5(
0H , 
)"'5(
0H , 
")4(
0H , 
)"'4(
0H  and 
)'3(
0H . Using the results of (4.5a) and (4.5b), 
we can obtain the critical values for testing )8(0H , 
)'''5(
0H  and 
)'3(
0H . Theorem 4.2 of Section 4.2 
should be used in order to test )'7(0H , 
")7(
0H ,  
")6(
0H , 
)'5(
0H , 
")5(
0H , 
")4(
0H  and 
)"'4(
0H . After all the 
additional critical values are obtained, the step-down testing procedure can be applied using the 
MPG principle or any modification of it, which guarantees strong control of the FWE. 
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)9(
0H
)8(
0H
)'7(
0H
")7(
0H
)'6(
0H
)'''5(
0H
")5(
0H
)'5(
0H
)'''6(
0H
")6(
0H
)'4(
0H
")4(
0H
)'"4(
0H
)"'3(
0H
)"3(
0H
)'3(
0H
)'2(
0H
)"2(
0H
)1(
0H  
Figure 6. The “implication” tree for the 33×  design 
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Table 8. “Decision” sequences with the corresponding estimated MeD-sets for the 33×  case 
(Notation: ACC - “Hypothesis is accepted”, REJ – “Hypothesis is rejected”, NT -“Hypothesis is 
not tested”, Mˆ - “Estimated MeD-set”) 
)9(
0H  ACC REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)8(
0H  NT REJ REJ REJ REJ REJ REJ REJ REJ ACC 
)'7(
0H  NT REJ REJ REJ REJ REJ ACC REJ REJ NT 
")7(
0H  NT REJ REJ REJ REJ REJ REJ REJ ACC NT 
)'6(
0H  NT REJ REJ ACC REJ REJ NT REJ REJ NT 
")6(
0H  NT REJ REJ REJ REJ REJ NT REJ NT NT 
)'''6(
0H  NT REJ REJ REJ REJ REJ REJ ACC NT NT 
)'5(
0H  NT REJ REJ NT REJ REJ NT REJ NT NT 
")5(
0H  NT REJ REJ REJ REJ ACC NT REJ NT NT 
)'''5(
0H  NT REJ REJ REJ REJ REJ NT NT NT NT 
)'4(
0H  NT REJ REJ NT REJ REJ NT NT NT NT 
")4(
0H  NT REJ REJ NT REJ NT NT REJ NT NT 
)"'4(
0H  NT REJ REJ REJ REJ NT NT NT NT NT 
)'3(
0H  NT REJ REJ NT REJ NT NT NT NT NT 
)"3(
0H  NT REJ ACC NT REJ NT NT REJ NT NT 
)'''3(
0H  NT REJ REJ REJ ACC NT NT NT NT NT 
)'2(
0H  NT REJ REJ NT NT NT NT NT NT NT 
)"2(
0H  NT REJ NT NT REJ NT NT NT NT NT 
)1(
0H  NT REJ NT NT NT NT NT NT NT NT 
Mˆ  Empty (1,1) (1,2) (1,3) (2,1) (2,2) (2,3) (3,1) (3,2) (3,3) 
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Table 8 continued 
)9(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)8(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)'7(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ REJ 
")7(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)'6(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ REJ 
")6(
0H  REJ REJ REJ REJ REJ REJ REJ REJ ACC REJ 
)'''6(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)'5(
0H  REJ REJ REJ REJ REJ ACC REJ REJ NT REJ 
")5(
0H  REJ REJ REJ REJ REJ REJ REJ REJ NT REJ 
)'''5(
0H  REJ REJ REJ REJ REJ REJ REJ ACC NT REJ 
)'4(
0H  REJ REJ REJ REJ ACC NT REJ NT NT REJ 
")4(
0H  REJ REJ REJ ACC REJ NT REJ REJ NT REJ 
)"'4(
0H  REJ REJ REJ REJ REJ REJ ACC NT NT REJ 
)'3(
0H  REJ REJ REJ NT NT NT NT NT NT ACC 
)"3(
0H  REJ REJ REJ NT REJ NT REJ REJ NT REJ 
)'''3(
0H  REJ REJ REJ REJ REJ REJ NT NT NT REJ 
)'2(
0H  REJ REJ ACC NT NT NT NT NT NT NT 
)"2(
0H  REJ ACC REJ NT NT NT NT NT NT NT 
)1(
0H  ACC NT NT NT NT NT NT NT NT NT 
Mˆ  
(1,2) 
(2,1) 
(1,2) 
(3,1) 
(1,3) 
(2,1) 
(1,3) 
(2,2) 
(1,3) 
(3,1) 
(1,3) 
(3,2) 
 (2,2) 
(3,1) 
 
(2,3) 
(3,1) 
(2,3) 
(3,2) 
(1,3) 
(2,2) 
(3,1) 
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4.6 ON AMBIGUITIES OF THE PROPOSED PROCEDURE 
We have shown that our procedure provides estimators which include all possible MeD-sets in 
the 22× , 32×  and 33×  cases, but we have also mentioned that there are some “decision” 
sequences of accepted and rejected hypotheses which lead to inconclusive or ambiguous results 
in terms of the estimated MeD-set. Although, we discuss only the types of ambiguities occurring 
in the 22× , 32×  and 33×  cases, we would expect in designs larger than 33×  additional types 
of ambiguities occurring and needing resolutions.  
In the 22×  case, there is only one such situation, when )3(0H  is rejected, indicating that 
there is at least one MeD among the combinations )1,1( , )2,1( , )1,2(  but both null hypotheses 
)'2(
0H  and 
")2(
0H  are accepted, providing contradictory evidence that there is no positive gain 
combinations among )1,1( , )2,1(  and among )1,1( , )1,2( . We call this type of contradiction, i.e., 
the case when a null hypothesis is tested and rejected and all hypotheses of the lower level 
implied by it are accepted, Type A ambiguity.   
Such ambiguities are due to the constructing a closure of the hypothesis family in the 
attempt to use the MPG closed testing approach, and therefore, to guarantee the strong control of 
the FWE. In the 22×  case, for example, we have to include a redundant hypothesis )3(0H  in the 
family, because it corresponds to the intersection of )'2(0H  and 
")2(
0H  and makes the family of 
hypotheses closed. As a consequence, the testing procedure must take into account the decision 
based on that redundant hypothesis. Other researchers who work on constructing closed testing 
procedures by including additional intersections of the hypotheses deal with the same problem. 
For example, Hellmich and Lehmacher (2005) provide an “implication” tree, which specifies the 
order in which the hypotheses are to be tested for the 22×  case. This tree is similar to the one 
presented in Figure 4 but has only 4 hypothesis levels. Nevertheless, they have the same problem 
of making a decision in terms of the pMED -estimate in the case when two individual hypotheses 
are accepted but the corresponding intersection-hypothesis is rejected. 
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While the stepwise procedures discussed by Tamhane et al. (1996) never result in 
ambiguities, the problem of dealing with inconclusive results arises even in the single drug case 
when additional hypotheses are included in the original hypothesis family. Rom et al. (1994) 
consider a problem of identifying the effective doses, i.e., the doses with the response higher 
than the placebo response. Rom et al. (1994) construct a closure of the hypothesis family and 
implement the additional testing rules (other than the ones specified by the MPG principle), 
which allow retaining some of the hypotheses without testing. Even under their testing scheme, 
there are “decision” sequences that lead to contradictory results in terms of identifying the 
effective doses.   
The hypothesis family considered by Tamhane et al. (1996) corresponds to the simplest 
case of an “implication” tree and the minimum effective dose is estimated based on the last 
rejected hypothesis. In order to provide an estimate in the case of Rom et al. (1994) the 
“decision” sequence needs to be considered and the corresponding conclusions about dose 
effectiveness need to be made. 
In order to eliminate the Type A ambiguity, we can make the conclusion about the 
estimated MeD-set based on the hypotheses which produce no contradiction. For example, in the 
22×  case since )4(0H  is rejected we believe that there is an MeD and we estimate it as the 
highest possible combination, i.e., the combination )2,2( . Unfortunately, this approach can 
overestimate the true MeD, so we plan to deal with this case separately from the other cases 
when the reasonable MeD-set estimate is produced by the procedure. We plan to analyze that 
type of inconsistency using the simulation study presented in Chapter 6.0. 
In the 32×  case the Type A result also occurs (see Table 8); however, there are 
“decision” sequences that lead to another type of ambiguity. This kind of ambiguity, Type B, 
happens, when two hypotheses of the same level are tested, one is accepted and the other is 
rejected and the hypothesis implied by the rejected one (of the lower level) is tested and 
accepted. For example, in the case where we deal with rejecting of 
0: 232221131211
)6(
0 ====== θθθθθθH , we test 0: 2221131211)5(0 ===== θθθθθH . If it is 
significant, then we test both 0: 21131211
)'4(
0 ==== θθθθH  and 0: 22211211")4(0 ==== θθθθH . 
Suppose now that )'4(0H  is rejected and 
")4(
0H  is accepted. Then the MPG principle states that the 
next hypothesis to be tested is 0: 131211
)'3(
0 === θθθH  ( ")3(0H is not tested because one of the 
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hypotheses, which implies ")4(0H , is not rejected). The problem arises when we test and accept 
0: 131211
)'3(
0 === θθθH , because it contradicts the conclusion 13222112110 θθθθθ <==== , 
based on the rejected )'4(0H  and accepted 
")4(
0H . There are two “decision” sequences in terms of 
accepting and rejecting hypotheses that lead to Type B ambiguity and they are noted in Table 8.  
To handle the Type B ambiguity we propose to modify the MPG principle, so the testing 
procedure never results in a Type B situation. If at least one hypothesis of a certain level is 
accepted, we continue testing only hypotheses of that level and stop testing. The MeD-set is 
estimated accordingly. In the case considered above, since )5(0H  and 
)'4(
0H  are rejected and 
")4(
0H  
is accepted, we could conclude that 13222112110 θθθθθ <==== , i.e., the MeD-set is given by 
)}3,1{(  without further testing of )'3(0H . These ideas are summarized in the “Modified MPG 
Principle” given below. 
Modified MPG principle. Test and reject any hypothesis at level α  if and only if all hypotheses 
implying it, including itself, are significant at level α  and all hypotheses of the higher 
hypotheses levels are significant at level α . 
It is straight forward to show that the modified MPG principle leads to strong control of 
the FWE. Note that the probability of rejecting of at least one true hypothesis under the modified 
MPG principle is at most the probability of rejecting of at least one true hypothesis under the 
original MPG principle (because the modified procedure rejects less often). Since the MPG 
guarantees the strong control of the FWE, the modified principle also guarantees the strong 
control of the FWE. 
Even more complicated cases arise in the 33×  case. Testing under the modified MPG 
principle stated for the 32×  case eliminates Type B ambiguity. However, in the 33×  case, the 
MPG principle introduces a new ambiguity, Type C, and while the modified MPG method again 
eliminates Type B ambiguities, it does not change Type C ambiguity. All possible “decision” 
sequences for the 33×  case are summarized in the Table 9. If there are three hypotheses of the 
same level are tested and exactly two of them are accepted, then Type C ambiguity happens if 
one of the following is true: 
1) The two accepted hypotheses are not implied by the same rejected hypothesis of the 
higher level,  
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Table 9. “Decision” sequences (under the modified MPG principle) leading to ambiguities for 3 
by 3 case 
(For some “decision” sequences there are partial ambiguities while some of the MeD’s are 
identified) 
)9(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)8(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)'7(
0H  ACC REJ REJ REJ REJ REJ REJ REJ REJ 
")7(
0H  ACC REJ REJ REJ REJ REJ REJ REJ REJ 
)'6(
0H  NT ACC ACC ACC REJ REJ REJ REJ REJ 
")6(
0H  NT ACC ACC REJ ACC REJ REJ REJ REJ 
)'''6(
0H  NT ACC REJ ACC ACC REJ REJ REJ REJ 
)'5(
0H  NT NT NT NT NT ACC ACC ACC REJ 
")5(
0H  NT NT NT NT NT ACC ACC REJ ACC 
)'''5(
0H  NT NT NT NT NT ACC REJ ACC ACC 
)'4(
0H  NT NT NT NT NT NT NT NT NT 
")4(
0H  NT NT NT NT NT NT NT NT NT 
)"'4(
0H  NT NT NT NT NT NT NT NT NT 
)'3(
0H  NT NT NT NT NT NT NT NT NT 
)"3(
0H  NT NT NT NT NT NT NT NT NT 
)'''3(
0H  NT NT NT NT NT NT NT NT NT 
)'2(
0H  NT NT NT NT NT NT NT NT NT 
)"2(
0H  NT NT NT NT NT NT NT NT NT 
)1(
0H  NT NT NT NT NT NT NT NT NT 
∧
M  
Type 
A 
Type 
A 
Type 
A, 
(2,3) 
Type 
C 
Type 
A, 
(3,2) 
Type 
A 
Type 
C 
Type 
C 
Type 
C 
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Table 9 continued 
)9(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)8(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ 
)'7(
0H  REJ REJ REJ REJ REJ REJ REJ REJ REJ 
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2) All three hypotheses are implied by the same rejected hypothesis of the higher level. 
 
For example, if we reject all hypotheses of the 6th level, accept 
0: 3122211211
)'5(
0 ===== θθθθθH , reject 0: 3121131211")5(0 ===== θθθθθH  and accept 
0: 2221131211
)'''5(
0 ===== θθθθθH  then we stop. In this case all three hypotheses of the 5th 
level follow from the same hypothesis ")6(0H  so this is the Type C ambiguity. Acceptance of 
)'5(
0H  and 
)'''5(
0H  leads to the conclusion that none of the combinations )1,1( , )2,1( , )3,1( , )1,2( , 
)2,2( , )1,3(  belongs to the MeD-set but rejection of ")5(0H  indicates that at least one of )1,1( , 
)2,1( , )3,1( , )1,2( , )1,3(  belongs to the MeD-set. Thus, no meaningful conclusion in terms of the 
estimated MeD-set can be made.  
The Type C ambiguity is certainly different from the Type A inconclusive result. In the 
example above, Type A ambiguity would occur if all hypotheses of the 5th level are accepted, 
because Type A ambiguity occurs if a certain hypothesis is rejected but all hypotheses of the 
lower level implied by it are accepted.  
Also in the 33×  case some “decision” sequences lead to the combination of the 
reasonable MeD-estimate together with Type A inconclusive result (see Table 9). For example, 
suppose we reject both hypotheses of the 7th level, 
0: 32312221131211
)'7(
0 ======= θθθθθθθH  and 
0: 31232221131211
")7(
0 ======= θθθθθθθH , and we accept both 
0: 323122211211
)'6(
0 ====== θθθθθθH  and 0: 322221131211")6(0 ====== θθθθθθH , and 
reject 0: 232221131211
)'''6(
0 ====== θθθθθθH . Since both accepted hypotheses )'6(0H  and 
")6(
0H  are implied by rejected 
)'7(
0H  and they are the only ones implied by it, Type A ambiguity 
occurs. At the same time, based on acceptance of ")6(0H  and rejection of 
)'''6(
0H  and 
")7(
0H , we can 
conclude that )3,2(  belongs to the MeD-set. Although, in this case we can not provide a proper 
estimate for the whole MeD-set, there is enough evidence to believe that a combination dose 
)3,2(  belongs to the MeD-set. 
To summarize the above results, we can claim that in the considered designs a Type A or 
Type C ambiguity happens if and only if at least two hypotheses of the same level are accepted. 
We use the simulation studies to approximate the probabilities of occurring Type A ambiguity 
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for 22×  and 32×  designs. We also consider testing under the modified MPG principle for the 
32×  design and provide the results in Chapter 6.0, where the simulation studies are discussed. 
Again, we would expect in designs larger than 33×  additional types of ambiguities 
occurring and needing resolution. 
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5.0 CRITERIA FOR EVALUATING TESTING PROCEDURES 
5.1 ON PARAMETER ESTIMATION 
In the case of a single drug study with K  active doses, we consider the problem of identifying an 
MED. The following facts are true about the MED in a single drug case: 
1) The population parameter of interest, the MED, has a simple structure; if the MED exists 
then it is unique and is a single element. 
2) Under the assumption of non-decreasing mean dose-response function, the MED 
provides the full information about the drug effectiveness. All doses to the left of the 
MED are non-effective and all doses to the right are effective. 
3)  If the dose-response is not assumed to be monotone, then the MED identifies the 
effectiveness of only lower doses than the MED. All doses with lower dose levels than 
the MED are identified as non-effective.  
4) The performance of the testing procedure can be measured by using Familywise Error, 
Power, Lack of Power and Bias. These values can be easily obtained by simulation. 
Now let us consider the analogs of the above statements for the case of the NK ×  
combination drug study regarding the MeD-set. 
1) The population parameter of interest is the MeD-set. If it exists (non-empty) then it is 
unique, but it may have a very complicated structure. 
The cardinality of the set can be any number from 0  to { }NK ,min . Moreover, the 
single element of the set does not provide the information about other possible elements 
of the MeD-set, unless it is the smallest combination, (1, 1), or the largest combination, 
),( NK . For example, for the 33×  design, if (1, 3) belongs to the MeD-set then it does 
not specify the cardinality of the set (it can be 1, 2 or 3) and it does not provide any 
information about other combinations that, possibly, belong to the set. We can only 
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conclude that the MeD-set is one of the following four sets: 
{(1, 3)}, {(1, 3), (2, 2)}, {(1, 3), (3, 1)}, {(1, 3), (2, 2), (3, 1)}. 
2) Under the assumption of an isotonic structure of the indicator gain matrix the MED 
provides the full information about the drug effectiveness in terms of the combination 
gains. All doses with at least one index smaller than the MeD’s are no-gain 
combinations and all doses with both indexes bigger than the MeD’s are positive gain 
combinations. 
3) If a general structure of an indicator gain matrix is assumed, then MeD’s provide the 
information only about combinations with at least one index smaller than the MeD’s; all 
such combinations are identified as no-gain doses. 
4) A performance of the testing procedure can not be measured using the same notions as 
in a single drug case. The measures such as the Familywise Error, Power, Lack of Power 
and Bias must be generalized to the combination drug setting.  
Section 5.2 illustrates how the Familywise Error, Power and Lack of Power can be 
generalized to measure the performance of the testing procedures in the combination drug 
setting, and how to obtain these by simulations.  
While Bias is well defined for a single drug study, the problem of defining it for the 
combination drug design is not trivial. It lies in the definition of the expected value of the 
estimator and measuring the distance from this expectation to the true parameter, the MeD-set. 
Hellmich and Lehmacher (2005) just mention that the notion of Bias can be extended to the 
combination drug case but do not provide any Bias-like measure.  
Intrinsically, to measure bias, one has to compare two sets of, perhaps, different 
cardinality. Instead of the Bias, we consider the loss functions defined in Section 5.3 which can 
be used to measure the “distance” between the estimated MeD-set and the true MeD- set.  
In addition to the measures described above we define two notions which are related to 
overestimating and underestimating the population MeD-set. These notions are discussed in 
Section 5.4. 
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5.2 FAMILYWISE ERROR, POWER AND LACK OF POWER 
In this section we illustrate how to measure the performance of testing procedures constructed to 
identify the MeD-set in terms of the estimated Familywise Error (FWE), Power and Lack of 
Power (LOP). These measures can be used in the combination drug case even when the isotonic 
structure of the indicator gain matrix is not assumed.  
First, we provide the statistical definitions of the above measures and then discuss the 
rules for estimating these measures by simulation. We use the following definitions which are 
suitable for assessing performance of any closed testing procedure. Familywise Error is defined 
as in a single drug case, i.e., it is the probability of rejecting at least one true null hypothesis. 
Power is defined as the probability of rejecting the set of all false and only false null hypotheses. 
Lack of Power is the probability of accepting at least one false null hypothesis. Care must be 
taken in specifying the parameter configurations under which these probabilities are computed. 
Following Tamhane et al. (1996) we measure the performance of an MED estimation 
procedure in the case of a single drug using the above notions. In the single drug case these 
measures were obtained by simulation and applying formulas (2.25). The proportion of 
replications for which a lower dose than the true MED is estimated as an MED corresponds to 
the estimated Familywise Error of the procedure. The proportion of replicates for which the 
MED is estimated correctly provides the estimated Power of the procedure. The Lack of Power is 
estimated by the proportion of cases when the doses with higher indexes than the true MED’s are 
estimated as the MED’s including the cases when none of the doses is declared as the MED. 
Note, that in the single drug case, we can write that FWE is the probability that lower doses than 
the true MED is estimated as an MED. Power is the probability that the MED is estimated 
correctly. And LOP is the probability that the doses with higher indexes than the true MED’s are 
estimated as the MED’s. 
First, let us illustrate why the rules for obtaining the simulated FWE, Power and LOP 
need to be generalized for the combination drug setting. Let us consider a simple example, when 
the true MeD-set is given by )}2,1{(  and it is estimated as )}1,2{( . Since these two doses are 
incomparable, it is not clear whether the estimate provides a higher or a lower dose combination 
than the true MeD, so some modifications are needed in order to use these measures. 
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Hellmich and Lehmacher (2005) use some modifications of these notions to measure the 
performance of their procedure to identify the minimum effective doses (MED’s) in the 
combination drug case. The authors consider the combination drug design under the assumption 
of an isotonic structure of the mean response matrix, which makes it possible for them to classify 
each combination as non-effective, effective but not minimum effective, or as an MED. Using 
this information, they simulate the FWE, Power and LOP using the following statements: FWE 
is given by the proportion of cases when non-effective doses are estimated as the MED’s. Power 
is obtained as the proportion of replications corresponding to the correctly estimated MED’s. 
Lack of Power is the proportion of cases when effective doses but not MED’s are estimated as 
the MED’s.  
We propose a generalization of the estimated measures used by Hellmich and Lehmacher 
(2005). We obtain the estimated measures by utilizing all available information about dose 
effectiveness provided by the true and estimated MeD-sets. The advantage of such a 
reformulation is that it introduces these concepts to situations where the isotonic structure of the 
gain matrix is not assumed. 
In order to simulate the values of our generalizations of the estimated FWE, Power and 
Lack of Power, we consider the following proportions. The proportion of replications for which 
at least one no-gain dose is estimated as an MeD corresponds to the estimated FWE of the 
procedure. In this case at least one true MeD is underestimated. The proportion of replicates for 
which the exact MeD-set is estimated correctly provides the estimate of the Power of the 
procedure, including the cases when an empty MeD-set is estimated correctly as an empty one. 
The Lack of Power is estimated by the proportion of all cases when a combination with unknown 
true effectiveness is estimated as the MeD, including the cases when none of the combinations is 
declared as the MeD but the true MeD-set is not empty. If the population MeD-set is non-empty 
and it is estimated as an empty set, then all combinations are estimated as no-gain doses, 
meaning that the MeD, if it exists, has higher indexes than the doses considered in the study, 
hence, at least one true MeD is overestimated.  
Next, we provide an approach to translate the FWE, Power and LOP in terms of 
probabilities involving the true and estimated MeD-sets.  
Let the population MeD-set, M , and the MeD-set, Mˆ , estimated by a statistical 
procedure be denoted by  
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respectively, where Kii ≤≤ ',1 , Njj ≤≤ ',1 . If the MeD-set is empty then there are no 
efficacious combinations in the grid NK × , but there may be efficacious doses in the larger grid 
so it makes more sense to use )}1,1{( ++ NK  to represent the empty MeD-set than )}0,0{( . 
Next, let −M  denote a set of all combinations which are identified by the MeD-set as no-
gain combinations. These are the combinations with at least one index lower than the true 
MeD’s. And let +M  denote a set of all combinations with both indexes higher than the true 
MeD’s. This latter set may consist of efficacious and/or no-gain combinations if the isotonic 
structure of the population indicator gain matrix is not assumed. If the isotonicity is assumed 
then the set +M  consists of efficacious doses. Based on the given MeD-set each element ),( ji , 
NjKi ,...,2,1,,...,2,1 ==  of the matrix 'Θ  can be allocated to one and only one of the sets: 
MeD-set, M , no-gain dose set, −M , or the set of all other combinations, +M .  
Similarly, based on the estimated MeD-set, Mˆ , and the corresponding indicator gain 
matrix, 'Θˆ , each combination ),( ji , NjKi ,...,2,1,,...,2,1 ==  can be allocated to one and only 
one of the sets: estimated MeD-set, Mˆ , estimated no-gain dose set, −Mˆ , or the estimated set 
+Mˆ , which contains the combinations with higher dose indexes than the estimated MeD’s. 
Using the preceding notation, we rewrite the definitions of the FWE, Power and Lack of 
Power as follows. 
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Statistical Measure Statistical Definition Alternative Definition 
Familywise Error (FWE) Probability of rejecting at least one true null hypothesis )
ˆ( ∅≠−MMP I  
Power 
Probability of rejecting all 
false and only false null 
hypotheses 
)ˆ( MMP =  
Lack of Power (LOP) Probability of accepting at least one false null hypothesis )
ˆ( ∅≠+MMP I  
 
Note that measures defined in such a way add up to 1. In the case when a closed testing 
procedure results in ambiguity, the alternative definitions can not be used, but if each type of an 
ambiguity corresponds to a single and known “decision” sequence then the statistical definitions 
can be used in order to obtain the FWE, Power and LOP. Such situations are discussed in detail 
later on in this section. In the cases when a procedure results in some MeD-set estimate, it is 
more convenient to use the alternative statements.  
We do not provide an explicit proof that these definitions are equivalent other than in the 
22×  and 32×  cases, as they involve tedious enumerations. Our judgment is that these 
definitions would extend to the NK ×  case, but we have not yet obtained the necessary complex 
graph-theoretic proof.  
Now let us come back to the above example when the true MeD-set is given by )}2,1{(  
and it is being estimated as )}1,2{( . Then this case results in FWE, because a no-gain 
combination )1,2(  is estimated as the MeD.  
Some procedures may produce no meaningful MeD-set estimate. Then these cases should 
be considered separately in detail to figure out what kind of error this outcome corresponds to. 
For example, the proposed step-down procedure can result in some type of ambiguity. Let us 
consider the case when it results in Type A ambiguity. Other types can be considered similarly.  
The proportion of cases when Type A ambiguity happens, should be included in 
calculating the FWE or LOP. In the case of Type A ambiguity our procedure stops due to 
acceptance of at least two hypotheses of some level, both implied by the same rejected 
hypothesis. For example, this happens in the 22×  case, when )3(0H  is rejected but both 
hypotheses )'2(0H   and 
")2(
0H  are accepted. These situations should be analyzed in more detail, 
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because depending on the true responses they may lead to the different types of error committed 
by the testing procedure. For example, if the true gains are 0211211 === θθθ  then the 
proportion of cases when Type A ambiguity happens contributes to the FWE, because the 
procedure fails to reject the true )3(0H . If the true gains are not all equal to zero, then the 
procedure rejects the false )3(0H  (no error made) but it fails to reject at least one false hypothesis 
( )'2(0H  or 
")2(
0H ). The last corresponds to the LOP and the proportion of such cases should be 
allocated to this measure.  
Example 5.1. Suppose, for the 22×  case the true MeD-set is given by )}2,1{( . Then the 
population MeD-matrix and the population indicator gain matrix are given by  
⎟⎟⎠
⎞
⎜⎜⎝
⎛=Λ
00
10
 and ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
*0
10
' . 
Suppose that the simulation studies based on 10,000 replications produce the results 
given in Table 10. Then 8.0000,10/000,8 ==Power . Combinations )1,1(  and )1,2(  are known 
to be no-gain combinations, so 07.0000,10/)300200200( =++=FWE . 
Table 10. Estimated MeD-set with the corresponding hypothetical frequency 
Result in Terms of Estimated MeD-set Frequency 
Empty 600 
)}2,2{(  400 
Type A: )4(0H , 
)3(
0H  are rejected and 
)'2(
0H , 
")2(
0H  are accepted 
300 
)}1,2{(  200 
)}2,1{(  8,000 
)}2,1(),1,2{(  200 
)}1,1{(  300 
 
Next, the Type A result indicates that the false null hypotheses )4(0H  and 
)3(
0H  are 
rejected (no error made), the true )"2(0H  is accepted (no error made), but the false 
)'2(
0H  is also 
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accepted (type II error made). So the replications corresponding to this case should be included 
in the computations of Lack of Power. Also, the proportion of cases when the estimated MeD-set 
is given by a single combination )2,2(  together with the replications corresponding to the 
“Empty” outcome should contribute to the Lack of Power: 
13.0000,10/)300400600( =++=PowerofLack . 
To reiterate, this example is based on hypothetical simulation data and the frequencies are 
given for pure illustration of the methods for obtaining the simulated FWE, Power and Lack of 
Power. 
5.3 LOSS FUNCTION 
To measure the performance of an estimator of the MeD-set, we define several loss 
functions and describe their properties. Let the population MeD-set and the MeD-set estimated 
by a statistical procedure be denoted by (5.1) of Section 5.2. In order to define a loss function 
)ˆ,( MML  we use the key feature of any loss function: ),0[)ˆ,( ∞∈MML  with the property 
0),( =MML . 
We propose several definitions of the loss functions based on the distances between the 
dose combinations that belong to M  and the dose combinations that belong to Mˆ . Since both 
sets can be represented uniquely by the NK ×  MeD-matrices, we can introduce the notion of 
distance based on the relative locations of two combinations in the NK ×  matrix. By the 
distance, ),( 21 aad , between two dose combinations ),( 111 qpa =  and ),( 222 qpa = , where  
},...,2,1{, 21 Kpp ∈ , },...,2,1{, 21 Nqq ∈ , we mean 212121 ),( qqppaad −+−= . Note that if 
21 aa =  (i.e., 21 pp =  and 21 qq = ), then 0),( 21 =aad . We also use the notion of the distance 
between a dose combination *)*,(* qpa =  with },...,2,1{* Kp ∈ , },...,2,1{* Nq ∈  and a set 
}),min{1),,({ NKiqpaA iii ≤≤== , defined as )*,(min)*,(* i
iall
aadAad = . Note that if 
Aa ∈* , then 0)*,(* =Aad . 
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Definition 5.1 for the loss function does not require additional knowledge of the drug 
combinations other than whether or not they are included in the given MeD-sets and is given 
below. 
Definition 5.1. Let M  and Mˆ  denote, respectively, the true and estimated MeD-sets. Further, 
let ( )MMMM ˆˆ1 I−≡  and ( )MMMM ˆ2 I−≡ . Then the loss function, 1L , is defined as 
)ˆ,(*),'(*)ˆ,(
21'
1 McdMcdMML
McMc
∑∑
∈∈
+= .  
In the case when Mˆ  is not identical to M , each element Mc∉'  increases the value of 
the first sum, and each element Mc ˆ∉  increases the value of the second sum in the expression 
for )ˆ,(1 MML . 
Example 5.2. For simplicity of calculations, we consider the 22×  design with the true MeD-set 
)}2,1{(=M  and two estimated sets, )}2,2{(ˆ 1 =M  and )}1,1{(ˆ 2 =M . Let us compare these 
estimates based on the values of the loss functions given in Definition 5.1. Since iMM ˆI , 
2,1=i  is empty then iMM ˆ1 ≡ , 2,1=i  and MM ≡2 in both cases. So 
211)ˆ,()ˆ,( 2111 =+== MMLMML .  
Next, let us look at the drawbacks of the loss function, defined above. First of all, 
)ˆ,(1 MML  does not take into account whether the combination, estimated as an MeD is indeed 
an efficacious (but not minimum efficacious) combination or it is a no-gain combination. 
Example 5.2 illustrates that the estimators )}1,1{(ˆ 1 =M  and )}2,2{(ˆ 2 =M  have the equal loss 
functions, although, the second estimator provides either an efficacious or no-gain dose as an 
MeD-estimate, while the first estimator provides a no-gain dose )1,1(  as an MeD. So if no more 
information is given about the other combinations, it is logical to have )ˆ,()ˆ,( 21 MMLMML ≠ .  
Whether we want )ˆ,()ˆ,( 21 MMLMML >  or )ˆ,()ˆ,( 21 MMLMML <  depends on the 
particular drugs under study. If one prefers overestimating an MeD to underestimating it, then it 
is desirable to have )ˆ,()ˆ,( 21 MMLMML > . This situation can arise when the administration of 
the higher drug dose combinations is not harmful and it is more important to see the effect than 
to control the amount of the administered drug. If administering the higher drug doses is not safe 
then one favors underestimating an MeD, rather than overestimating it. Hence, it is preferable to 
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have )ˆ,()ˆ,( 21 MMLMML < . The loss function given in Definition 5.1 does not take into 
account those different cases and treats them equally.  
More flexible loss functions can be constructed in the case when additional information 
about the combination effectiveness is taken into account.  
Table 11. Possible allocations of a single dose with the corresponding errors 
Estimated Property of a Dose ),( ji  Population 
Property of a 
Dose ),( ji  −Mˆ  Mˆ  +Mˆ  
−M  No Error Error C* Error D* 
M  Error B* No Error Error A* 
+M  Error F* Error E* No Error 
 
Using the notation introduced in Section 5.2, we can allocate each dose ),( ji , 
Ki ,...,2,1=  and Nj ,...,2,1=  to one and only one set based on its true and estimated property. 
Table 11 summarizes the possible dose allocations with the corresponding conclusions whether 
or not a statistical procedure makes an estimation error. The table uses the following notation.  
By “No Error” for dose ),( ji , we mean the correct estimation. “No Error” corresponds to 
the cases when there is no information available about how a combination with unknown true 
effectiveness is estimated. And since it is correctly allocated to +Mˆ  set, the procedure does not 
make an estimation error in terms of the dose allocation.  
Now, let us consider the cases when the estimation of the dose effectiveness leads to an 
error. There are six types of errors. We say that A* error occurs when +∈ MMji ˆ),( I , in this 
case the true MeD is underestimated and as the result, it is estimated as an +Mˆ -dose. We say 
that B* error occurs when −∈ MMji ˆ),( I , i.e., the effectiveness of the true MeD is not detected 
by a procedure and it is estimated as a no-gain combination. In this case the MeD is either 
overestimated or the estimated MeD-set is empty. C* error corresponds to the case when 
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MMji ˆ),( I−∈ , i.e., a no-gain combination is estimated as an MeD, so all lower no-gain 
combinations are estimated correctly. D* error occurs when +−∈ MMji ˆ),( I . In this case the 
true MeD is misclassified. If we compare the cases related to last two errors then there is the 
larger number of misclassifications associated with the error D*. Finally, if MMji ˆ),( I+∈  or 
−+∈ MMji ˆ),( I  then the true MeD is overestimated and these cases denoted by errors F* and 
E*, respectively. There are more misclassifications happening in a case resulting in F* error than 
resulting in E* error.  
The above classification provides a better understanding of the desirable properties of a 
loss function. Clearly, the different types of errors should have different impact on the value of 
the loss function and can be weighted depending on the researcher’s preference. The following 
definition of the loss function allows assigning the different values, 
****** ,,,, FEDCBA wwwwww , to these types of errors.  
Definition 5.2. For each drug combination ),( ji , Ki ,...,1= , Nj ,...,1=  consider its unique 
allocation to one of the classes presented in Table 12 with the assigned value of error ijw , where 
},,,,,,0{ ****** FEDCBAij wwwwwww ∈ , NjKi ,...,1,,...,1 ==  are some fixed positive constants. 
Then the loss function is defined by ∑∑
= =
=
K
i
N
j
ijwMML
1 1
2 )ˆ,( . 
Table 12. Possible allocations of a single dose with the assigned values of errors 
Estimated Property of a Dose ),( ji  Population 
Property of a 
Dose ),( ji  −Mˆ  Mˆ  +Mˆ  
−M  0 *Cw  *Dw  
M  *Bw  0 *Aw  
+M  *Fw  *Ew  0 
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Since the function defined in such a way is equal to zero if and only if all of the errors ijw  
are zero (i.e., all combinations are estimated correctly), it is a proper definition of the loss 
function. Obviously, the more the number of incorrectly estimated combinations, the higher the 
value of )ˆ,(2 MML .  
Example 5.3 illustrates one of the possible assignments of the values to the constants 
****** ,,,,, FEDCBA wwwwww . 
Example 5.3. Suppose that a dose-response study deals with the drugs such that the higher drug 
dose combinations are not as safe as the lower ones, and it is preferable to underestimate the 
MeD than to overestimate it. Among the cases presented in Table 12, there are three cases that 
deal with overestimating the true MeD (and result in B*, E* or F*error) and three cases that 
correspond to underestimating the MeD (and result in A*, C* or D* error). Since error F* is the 
worst in terms of the number of misclassified combinations, and the errors B* and E* are 
relatively the same, we require *** FEB www <= . Similarly, among the cases when the true MeD 
is underestimated we can order the types of errors as *** DCA www <=  and so that we choose the 
error values such that ****** FEBDCA wwwwww <=≤<= . Using this fact we could use, for 
example, 5.2,2,5.1,1 ****** ====== FEBDCA wwwwww  as one of the possible 
assignments.  
Next, we illustrate how the loss function )ˆ,(2 MML  can be calculated based on these 
error values for the MeD-sets given in Example 5.2. The MeD-sets are given by )}2,1{(=M , 
)}2,2{(ˆ 1 =M  and )}1,1{(ˆ 2 =M . Obviously, 1Mˆ  overestimates the MeD and 2Mˆ  underestimates 
the true MeD. While 1'Θˆ  is uniquely identified by 1Mˆ , there are a number of different 'Θ  and 
2'Θˆ  corresponding to M  and 2Mˆ , respectively. The following are the steps that allow to 
calculate 2L . 
Let +m  represent a combination whose effectiveness is not uniquely identified by the 
true MeD-set ( ++ ∈Mm ), or by the estimated MeD-set ( ++ ∈Mm ˆ ). Then we obtain 
⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ +m0
10
' , ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
10
00
'ˆ 1  and ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ ++
+
mm
m1
'ˆ 2 . 
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Let us first calculate the loss function corresponding to the 1Mˆ . Based on the first two 
matrices, each dose combination is classified as follows: −−∈ MM ˆ)}1,2(),1,1{( I , 
−∈ MM ˆ)2,1( I , MM ˆ)2,2( I+∈ . Then, using the above assignment of the misclassification 
errors, we obtain 02111 == ww , 2*12 == Bww , 2*22 == Eww  and, therefore, 
4)ˆ,(
2
1
2
1
12 == ∑∑
= =i j
ijwMML .  
Next, let us calculate the loss function )ˆ,( 22 MML . Since MM ˆ)1,1( I−∈ , 
+∈ MM ˆ)2,1( I , +−∈ MM ˆ)1,2( I  and ++∈ MM ˆ)2,2( I  with the corresponding errors 
1*11 == Cww , 1*12 == Aww , 5.1*21 == Dww  and 022 =w , then 
)ˆ,(5.3)ˆ,( 1222 MMLMML <= . So 2Mˆ  provides a better estimation than 1Mˆ  in terms of the 
loss function )ˆ,(2 MML . This concludes the example. 
Now, let us consider a special case of 2L , where we do not differentiate among all the 
error types. First of all, any true (estimated) MeD-set defines uniquely both sets, −M  ( −Mˆ ) and 
+M  ( +Mˆ ), and, therefore, we can consider no-gain doses separately from the other doses, i.e., 
we can consider only two sets, −M  ( −Mˆ ) and += MMU U  ( += MMU ˆˆˆ U ). Then, if 
UMji ˆ),( I−∈  and the population MeD-set is not empty then at least one true MeD is 
underestimated. If UMji ˆ),( I−∈  and the population MeD-set is empty then at least one true 
no-gain combination is identified as an MeD by the procedure. In any case, the true MeD is 
underestimated.  
If −∈ MUji ˆ),( I  and ∅=Uˆ  then all combinations are identified as no-gain 
combinations. Hence, no MeD is detected by the procedure. If −∈ MUji ˆ),( I  and ∅≠Uˆ  then 
a larger dose combination than the true MeD is declared as an MeD. In any case, at least one true 
MeD is overestimated.  
All other allocations of a combination ),( ji  can be viewed as the correct ones with the 
corresponding allocation errors being zero.  
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Table 13. Possible single dose allocation with the corresponding conclusion about the true MeD 
and the assigned errors 
Estimated Property of a Dose ),( ji  Population 
Property of a 
Dose ),( ji  −Mˆ  
+= MMU ˆˆˆ U  
−M  
No Error, 
0=ijw  
Underestimated, 
uij ww =  
+= MMU U  
Overestimated, 
oij ww =  
No Error, 
0=ijw  
 
All of the above cases are presented in Table 13. Using this logic we need to assign only 
two error values, one is for overestimating, ow , and the other is for underestimating, uw , the true 
MeD. Then, the following loss function can be defined. 
Definition 5.3. For each drug combination ),( ji , Ki ,...,1= , Nj ,...,1=  consider its allocation 
presented in Table 13 with the assigned value of error ijw , where },,0{ uoij www ∈  for all 
Ki ,...,1=  and Nj ,...,1= . Then the loss function is defined by ∑∑
= =
=
K
i
N
j
ijwMML
1 1
3 )ˆ,( . 
The loss function defined in such a way involves fewer numerical computations than the 
one defined in Definition 5.2, and at the same time it allows assigning different misclassification 
error values. Let us illustrate how )ˆ,(3 MML  can be calculated for the set-up of the Example 
5.2.  
Example 5.4. Consider the set-up of the Example 5.2 with  
⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ +m0
10
' , ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
10
00
'ˆ 1  and ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ ++
+
mm
m1
'ˆ 2 . 
Let us first calculate the loss function for )}2,2{(ˆ 1 =M . Since −∈ MU ˆ)2,1( I  is the only 
misclassified combination, owMML =)ˆ,( 13 . Similarly, for )}1,1{(ˆ 2 =M  we have 
UM ˆ)}1,2(),1,1{( I−∈  so uwMML 2)ˆ,( 23 = . If the values of ow  and uw  are specified then the 
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loss functions can be compared. If we choose 1== uo ww  then 
2)ˆ,(1)ˆ,( 2212 =<= MMLMML . Based on these values, one would rather use a procedure 
resulting in the first MeD-set. This concludes the example. 
We have considered three definitions of the loss functions which can be used to measure 
the distance between the true MeD-set and the estimated one and, therefore, to allow comparison 
among estimated MeD-sets. As Examples 5.2-5.4 show, the same estimated MeD-sets can result 
in different values of the corresponding loss functions, depending on what definition of the loss 
function is used. Moreover, which estimator is preferred depends on the available information 
and assumptions that can be made.  
While Definition 5.1 does not require any information about the dose combinations other 
than the true MeD’s and the estimated MeD’s, Definitions 5.2 and 5.3 use all available 
information about possible structure of the indicator gain matrix. Definitions 5.2 and 5.3 provide 
some flexibility in assigning the misclassification errors and can be easily modified to handle 
different cases. In general, these loss functions are not symmetric with respect to the true and 
estimated MeD-sets, while the first loss function is symmetric. In the special case when 
uo ww = , the third loss function becomes also symmetric.   
Table 14 and Table 15 present the values of the first and third loss functions for all 
configurations of the true and estimated MeD-sets in the 22×  case. Both loss functions are used 
in the simulation studies as an analog of Bias to measure the performance of the proposed 
procedures. These simulation studies are described in Chapter 6.0. 
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Table 14. Values of the loss function )ˆ,(1 MML  for all configurations of the true and estimated 
MeD-sets in the 22×  case 
        
∧
M   
   M  
Empty )}2,2{(  )}1,2{(  )}2,1{(  )}2,1(
),1,2{(
 )}1,1{(  
Empty 0 4 6 6 9 8 
)}2,2{(  4 0 2 2 3 4 
)}1,2{(  6 2 0 4 2 2 
)}2,1{(  6 2 4 0 2 2 
)}2,1(),1,2{(  9 3 2 2 0 3 
)}1,1{(  8 4 2 2 3 0 
 
Table 15. Values of the loss function )ˆ,(3 MML  for all configurations of the true and estimated 
MeD-sets in the 22×  case 
        
∧
M   
    M  
Empty )}2,2{(  )}1,2{(  )}2,1{(  )}2,1(
),1,2{(
 )}1,1{(  
Empty 0 uw  uw2  uw2  uw3  uw4  
)}2,2{(  ow  0 uw  uw  uw2  uw3  
)}1,2{(  ow2  ow  0 uo ww +  uw  uw2  
)}2,1{(  ow2  ow  uo ww +  0 uw  uw2  
)}2,1(),1,2{(  ow3  ow2  ow  ow  0 uw  
)}1,1{(  ow4  ow3  ow2  ow2  ow  0 
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5.4 ADDITIONAL MEASURES TO ASSESS PERFORMANCE OF TESTING 
PROCEDURES 
Next, we define two additional measures that characterize the estimate in terms of overestimating 
and underestimating the true MeD-set. Let the true MeD-set and the estimated one be 
represented by (5.1).  
We say that the population MeD-set }{ scM = , is underestimated by }'{ˆ tcM =  if for any 
element Mct ˆ'∈  there exists an element Mcs ∈  such that st cc ≤'  with at least one strict 
inequality.  
Similarly, we say that the population MeD-set }{ scM =  is overestimated by }'{ˆ tcM =  
if for any element Mcs ∈  there exists an element Mct ˆ'∈  such that 'ts cc ≤  with at least one 
strict inequality.  
For example, in the 32×  case if the true MeD-set is given by )}3,1(),2,2{(=M  then it 
is underestimated by each of the following sets: )}1,2{( , )}2,1{( , )}3,1(),1,2{( , )}2,1(),1,2{( , 
)}1,1{( . And it is overestimated by an empty set, {(3,4)}, and by a set )}3,2{( . For the 32×  case 
these are the only sets that overestimate and underestimate the given true MeD-set.  
Next, let us define two measures which use the notions of overestimation and 
underestimation. The first measure, UND, represents the probability of underestimating the true 
MeD-set by a procedure. It is defined as  
UND = Probability{M is underestimated}.. 
Similarly, the second measure, OV, is defined as  
OV = Probability{M is overestimated}. 
Both measures can be obtained by simulation. A proportion of replications when a 
procedure results in underestimating the true MeD-set, i.e., it returns an estimated MeD-set 
which overestimates the true one, corresponds to the UND -measure. A proportion of cases when 
a procedure returns a set underestimating the true one corresponds to the estimated OV -
measure.  
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We use the estimated UND -measure and OV -measure in addition to the estimated FWE, 
Power, LOP and loss functions to assess the performance of the proposed procedures in our 
simulation studies presented in Chapter 6.0.  
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6.0 SIMULATION STUDIES 
6.1 GOALS OF THE SIMULATION STUDIES 
Since our procedure is based on computing a number of the AVE test statistics, the power of the 
procedure depends on the power of each single test statistic. As it is shown in Hung et al. (1993) 
(for rectangular designs) and in Appendix D (for non-rectangular designs), the power function of 
a single AVE test ( )θδ )),cTP A >  depends on the parameters ijθ  only through AVEθ  and on a 
nuisance parameter ),...,,( 1211 KNδδδδ =) , where σμμδ /)( 00 jiij −=  and ),( ∞−∞∈ijδ .  
To facilitate the understanding of our simulations we note two results, which are stated 
by Hung et al. (1993) about the power function of a single AVE test for a rectangular design: 
Result 6.1. For any given δ)  with ),( ∞−∞∈ijδ  and any fixed number ),( ∞−∞∈c , power 
increases in AVEθ . 
Result 6.2. For any given AVEθ  and c , the power function increases in each ),0( ∞∈ijδ  and 
decreases in each )0,(−∞∈ijδ  when the remaining lmδ  are fixed. Hence, power increases in each 
ijδ  when the remaining lmδ  are fixed.  
Result 6.2 does not have any practical value due to the fact that δ)  is a vector of the 
control mean differences. In the designs with 1>K  and 1>N , it is impossible to change just a 
single component of the vector δ)  and keep remaining components fixed. So we illustrate the 
fact that power depends on the values of the control mean differences by changing several 
components of the vector δ)  while keeping remaining components fixed. 
Our procedure involves simultaneous calculations of several AVE test statistics, and 
overall power depends on conditional rejection and acceptance of the hypotheses. For example, 
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in the 22×  case when the true MeD-set is )}2,2{(  in order to estimate the set correctly, it is not 
enough to reject the first tested hypothesis; the procedure must also accept the second tested 
hypothesis.  
The first goal of the simulation study is to confirm an analog of Result 6.1 in terms of the 
overall power, i.e., to illustrate that the overall power increases in each gain average, 
The second goal of the simulation study is related to a special case where our procedure 
is based on a single AVE test. When the true MeD-set is empty and the first tested hypothesis is 
accepted, then the procedure correctly estimates the MeD-set as an empty one. In the NK ×  
case it involves calculating a single test statistic  
σ
θ
ˆ
ˆ
2,1.
KN
T ji
ij
A
∑
== . 
Since )ˆ( MMPPower == , in the case when the true MeD-set is empty, the power can 
be viewed as the probability of accepting the true null hypothesis. Hence, power defined in such 
a way decreases with increasing ijδ ’s when the remaining lmδ  are fixed. And the second goal of 
the simulation study is to illustrate this fact.  
Table 16. Cases corresponding to familywise error (FWE), lack of power (LOP) and power in 
the 22×  case 
             
∧
M  
    M  
Empty )}2,2{(  )}1,2{(  )}2,1{(  )}2,1(
),1,2{(
 )}1,1{(  Type A 
)}2,2{(  LOP Power FWE FWE FWE FWE FWE 
)}1,2{(  LOP LOP Power FWE FWE FWE LOP 
)}2,1{(  LOP LOP FWE Power FWE FWE LOP 
)}2,1(),1,2{(  LOP LOP LOP LOP Power FWE LOP 
)}1,1{(  LOP LOP LOP LOP LOP Power LOP 
 
The third goal of the simulation studies is to describe the performance of the proposed 
procedures based on the regular and modified MPG principle. For this purpose the summary 
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statistics presented in Chapter 5.0 are computed. Table 16 illustrates which proportions should be 
included in the estimated FWE, Power, Lack of Power and Type A ambiguity for the 22×  case. 
Although, these three summary statistics add up to 1, we report the results in terms of all of these 
measures. We do not present the table for the 32×  case, because it is constructed in a similar 
manner as for the 22×  case. 
In addition to these measures two loss functions, 1L  and 3L , are computed, which are 
defined in Section 5.3. To specify the values of the misclassification errors for the loss function 
3L , we assume the case when it is more desirable to overestimate the true MeD-set than to 
underestimate it. The weights are set to be uo ww =5 .  
Since a sum of all errors corresponding to 1L  is the fixed number for each design, the 
error values of 3L  are rescaled so that they also add up to this value. For example, Table 14 
provides the error values of the first loss function for the 22×  design. The sum of all errors 
equals 118 , so the errors of 3L  are rescaled so that their total sum is also 118 .  
In order to simulate the values of 1L  and 3L  for each given true MeD-set, the proportion 
of replications corresponding to each estimated MeD-set is multiplied by its misclassification 
error and then added up to produce a single value. The estimates of the loss functions obtained in 
such a way are the analog of bias defined in a single drug case.  
In addition to all of the above measures, the UND -measure and the OV -measure, 
presented in Section 5.4 are simulated.  
The design of the simulation studies and their results are discussed separately for the 
22×  and 32×  case. In each case the proposed step-down procedure (based on the regular MPG 
principle) is used for different configurations of the true mean response matrix. In the 32×  case, 
a testing procedure based on the modified MPG principle is also considered. In each case the 
relationship between the overall power and the average gain is examined and the special case of 
an empty MeD-set is considered. The performance of the procedures is assessed using the 
simulated measures discussed above. In the 32×  case the proposed regular and modified step-
down procedures are compared. To check the validity of the program code the results of the 
simulation studies are compared with the numeric computations given by Hung et al. (1993) for 
some specific configurations of the population parameters.  
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6.2 DESIGN OF THE SIMULATION STUDIES 
Throughout the study, the significance level α  is fixed at 05.0 , 1=σ  and the common sample 
size, 30=n , is assumed per group. The critical values used in the studies are the critical values 
given in Table 5 and Sections 4.3 and 4.4, divided by 30 . 
To illustrate the relationship between the overall power and gain averages, we consider 
0=δ) , where jiij 00 μμδ −= , so that only settings involving ji 00 μμ =  with 2,1, =ji  for the 
22×  case and 2,1=i , 3,2,1=j  for the 32×  case are considered. Without loss of generality, all 
single drug mean responses, 0iμ  and j0μ , are taken to be zero. For the special case of an empty 
MeD-set other values of δ)  are considered, which are specified later on.  
The single simulation run is performed as follows. For each specified value of the global 
gain average 4/
2
1,
4 ∑
=
==
ji
ijAVEAVE θθθ  ( ∑∑
= =
==
2
1
3
1
6 6/
i j
ijAVEAVE θθθ ) for the 22×  ( 32× ) case, all 
possible configurations of the MeD-sets are considered. These configurations are given in 
Sections 4.3 and 4.4.  
In the 22×  case among possible values of the global gain average we consider 
2.1,8.0,4.0,0=AVEθ . Since 0=AVEθ  corresponds to only a single MeD-set (empty one) and 
each of positive 2.1,8.0,4.0=AVEθ  corresponds to five different MeD-sets, there are 16 
simulation configurations in total in the 22×  case. These configurations are presented in Table 
17. 
In the 32×  case we consider 2.1,4.0,0=AVEθ . Since there are nine different MeD-sets 
can be constructed for each of the positive gain average, there are 19 simulation configurations in 
total.  
The performance of the procedure depends not only on the true global average AVEθ  but 
also on all partial averages. For example, in the 22×  case the partial gain averages are given by 
3/)( 211211
3 θθθθ ++=AVE , 2/)( 1211"2 θθθ +=AVE , 2/)( 2111"2 θθθ +=AVE  and 111 θθ =AVE . Ideally, it 
would be desirable to see how the performance of the procedure depends on a single gain 
average when the rest of the averages are fixed. But changing the value of one gain average leads 
to changing the value of at least one other average, so it is impossible to construct such a study.  
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Next, we explain how the population mean dose-response matrix is constructed. For each 
specified value of the global gain average AVEθ  we construct the population mean dose-response 
matrix such that the corresponding gain matrix has equal positive values for efficacious doses 
and zero-values for no-gain doses. Such assignment of the mean dose-responses does not 
differentiate between the cases where the true MeD-sets are given by )}2,1{(  and )}1,2{(  (and in 
addition by )}3,1{(  and )}2,2{(  in the 32×  case). So the results should be similar for these 
configurations. 
A matrix, constructed in such a way, has an isotonic structure, but this specific design 
should not necessarily improve the results, because the performance of our procedure does not 
depend on any particular structure of the matrix other than on δ)  and the gain averages.  
Example 6.1. To illustrate how such mean dose-response matrix can be constructed for some 
non-zero ),,,( 22211211 δδδδδ =
)
 with jiij 00 μμδ −= , consider )1,1,0,0(=δ
)
 where 010 =μ , 
120 =μ , 001 =μ , and 002 =μ . Suppose, that the global gain average is 4.0=AVEθ  and consider 
two MeD-sets )}2,2{(1 =M  and )}2,1{(2 =M . Then, in the 22×  case the mean dose-response 
matrices are given by  
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛×
6.211
000
00
 and 
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛×
8.111
8.000
00
,  
where ""×  indicates that this dose is not evaluated. The corresponding gain matrices are 
⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
6.10
00
1  and ⎟⎟⎠
⎞
⎜⎜⎝
⎛=Θ
8.00
8.00
2 . 
Note, that although, 04 == AVEAVE θθ  in both cases, the partial gain averages are different: 
01"2'23 ==== AVEAVEAVEAVE θθθθ  in the first case, and 27.03 =AVEθ , 4.0'2 =AVEθ , 01"2 == AVEAVE θθ  in 
the second case . This concludes the example. 
Next, for the specified sij 'μ  the group sample means  
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛×
=
222120
121110
0201
yyy
yyy
yy
Y  or 
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎝
⎛×
=
23222120
13121110
030201
yyyy
yyyy
yyy
Y  
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are generated depending on the design, where the ijy  are independent random variables such that 
)30/1,(~ ijij Ny μ . Then, the step-down procedure is applied to these data. In the 32×  case, 
both proposed procedures, regular and modified, are applied to these same data. The result of 
each procedure is noted and the above steps are replicated 000,100  times for the specified value 
of δ)  and AVEθ . 
To illustrate the fact that power depends on the values of the control mean differences, in 
addition to the simulation studies described above, we consider a special case when the true 
MeD-set is empty ( 0=AVEθ ) and so that the correct estimation involves only a single step 
procedure. In the 22×  case we consider this situation for two configurations of the nuisance 
parameter δ) , )1,1,0,0(=δ)  and )1,1,1,1(=δ) . The results corresponding to these configurations 
are then combined with the results of the first simulation study where 0=AVEθ  and 0=δ) , and 
are analyzed together. Table 17 presents all configurations of the population parameters used in 
the 22×  case. 
In order to check the validity of the program, in the 32×  case we consider four 
additional cases with non-zero nuisance parameter δ)  given by Hung et al. (1993). These authors 
calculate the exact power for the case of different global gain averages and specified values of 
the control mean differences. We consider just some of these cases given in Table 18. 
These special cases are discussed in more details when the results of the corresponding 
simulation runs are presented. 
For all the combination drug studies 100,000 simulations are used for estimating the 
measures involving probabilities, this leads to a maximum standard error of estimation of 
002.0000,100/)5.0(5.0 = . Since the loss functions, 1L  and 3L , are not based on probabilities, 
no standard errors are herein provided. 
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Table 17. Population parameters configurations used in the simulation studies in the 22×  case  
MeD-Set AVEθ  δ
)
 
Empty 0 
)0,0,0,0(=δ)
)1,1,0,0(=δ)
)1,1,1,1(=δ)  
)}1,1{(  
0.4 
0.8 
1.2 
)0,0,0,0(=δ)  
)}2,1{(  ( )}1,2{( ) 
0.4 
0.8 
1.2 
)0,0,0,0(=δ)  
)}2,1(),1,2{(  
0.4 
0.8 
1.2 
)0,0,0,0(=δ)  
)}2,2{(  
0.4 
0.8 
1.20 
)0,0,0,0(=δ)  
 
Table 18. Additional population parameters configurations used in the simulation studies in the 
22×  case  
AVEθ  10μ , 20μ  01μ , 02μ , 03μ  
0=AVEθ  0.1, 1.0 0.1, 0.3, 1.0 
0=AVEθ  0.1, 0.3 0.1, 0.2, 0.3 
2.0=AVEθ  0.1, 0.3 0.1, 0.2, 0.3 
6.0=AVEθ  0.1, 0.3 0.1, 0.2, 0.3 
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6.3 DETAILED RESULTS OF THE 2 BY 2 SIMULATION STUDIES 
First, we discuss the simulation results regarding the relationship between the value of the gain 
average and the power of the procedure. Table 19, Table 20 and Table 21 summarize the results 
of the studies. Note, that in the cases where the true MeD-sets are given by )}2,1{(  and )}1,2{(  
the procedure produces very similar results, as expected.  
Table 19 contains the sample FWE (upper entry) and sample power (lower entry) for 
each configuration of the gain average and the population MeD-set. Since all FWE’s are less 
than 051.0000,100/95.005.096.105.0 =⋅+  the procedure again demonstrates the theory that 
the FWE is strongly controlled at 05.0 . Since configurations with MeD-set given by )}1,1{(  
involve no FWE, Table 19 has no upper entry for such configurations.  
The power of the procedure greatly depends on the value of AVEθ . If 0=AVEθ  then the 
procedure correctly estimates the empty MeD-set with a high probability.  
The proposed procedure has the average power of 366.0  for 4.0=AVEθ , 833.0  for 
8.0=AVEθ  and 983.0  for 2.1=AVEθ . So for all non-zero effect averages, the power of the 
procedure increases with the value of the gain average.  
Among the considered designs, our procedure identifies the true MeD-set )}1,1{( , )}2,1{(  
( )}1,2{( ), )}2,1(),1,2{(  and )}2,2{(  with the average power of 675.0 , 671.0 , 485.0  and 866.0 , 
respectively. Hence, among the non-empty sets, the MeD-set given by )}2,2{(  is correctly 
identified with the highest probability. The procedure performs the worst in the case when the 
true MeD-set is “diagonal”, i.e., is given by )}2,1(),1,2{( .  
Table 20 contains the sample probabilities of Type A ambiguity (upper entry) and LOP 
(lower entry). Probability of Type A outcome decreases in AVEθ  and it is very small, 001.0 , 
when the MeD-set is empty. The average probability of Type A outcome is 068.0  for 
4.0=AVEθ , 042.0  for 8.0=AVEθ  and 002.0  for 2.1=AVEθ . Configurations with MeD-set 
)}1,1{( , )}2,1{(  ( )}1,2{( ), )}2,1(),1,2{(  and )}2,2{(  have the average probability of Type A 
outcome of 028.0 , 009.0 , 140.0  and 002.0 , respectively. So the configurations with true 
“diagonal” MeD-set correspond to the greatest frequency of Type A ambiguity. 
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As expected, similar conclusions can be drawn based on the estimated lack of power. The 
proposed step-down procedure has the average lack of power of 630.0  ( 4.0=AVEθ ), 162.0  
( 8.0=AVEθ ) and 013.0  ( 2.1=AVEθ ). Independent of the gain average, cases where )}2,2{(=M  
correspond to the smallest value of the lack of power. Configurations with the “diagonal” MeD-
set, )}2,1(),1,2{(=M , correspond to the greatest value of the lack of power.  
Table 21 contains the estimated values of the loss functions, discussed in Section 5.3. 
Two loss functions behave similarly: their values decrease with increasing gain average. 
Moreover, if one function increases (decreases) then the other also does. The procedure has the 
average losses values of 727.21 =L , 813.03 =L  (when 4.0=AVEθ ); 287.01 =L , 119.03 =L  
(when 8.0=AVEθ ); and 035.01 =L , 027.03 =L  (when 2.1=AVEθ ). Again, independent of the 
value of the gain average, the cases where the MeD-set is )}2,1(),1,2{(=M  correspond to the 
largest loss among possible configurations of the MeD-sets. For all considered non-zero gain 
averages, the true )}2,2{(=M  is identified with the smallest loss. 
Finally, let us mention the results of additional simulation studies, summarized in Table 
22. When there is no MeD ( 0=AVEθ ) there is a decrease in “power” of the procedure associated 
with the increased values of components of δ) . 
 
Summary of the 2×2 Simulation Results 
1) The estimation quality of the procedure increases with the increased positive gain 
average. If the non-zero gain averages are relatively large then the procedure correctly 
identifies the MeD-set with high power.  
2)  Among possible configurations in the 22×  case, the empty MeD-set and the set 
containing the highest combination, )}2,2{( , are correctly identified with the highest 
probability.  
3) The “diagonal” configuration of the MeD-set, )}2,1(),1,2{(=M , is the most difficult to 
be estimated by the procedure.  
4) Additional simulation studies indicate that the results of the estimation depend on the 
values of the mean dose-response differences of the single drugs.  
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Table 19. Estimated familywise error (the upper entry) and power (the lower entry) for 0~ =δ  
AVEθ  MeD-set Step-Down 
0 Empty Not Defined 0.996 
)}1,1{(   
0.170 
)}2,1{(  0.004 
0.191 
)}1,2{(  0.004 
0.189 
)}2,1(),1,2{( 0.009 0.044 
0.4 
)}2,2{(  0.005 
0.608 
)}1,1{(   
0.859 
)}2,1{(  0.004 
0.831 
)}1,2{(  0.004 
0.828 
)}2,1(),1,2{( 0.012 0.488 
0.8 
)}2,2{(  0.005 
0.995 
)}1,1{(   
0.997 
)}2,1{(  0.004 
0.992 
)}1,2{(  0.004 
0.992 
)}2,1(),1,2{( 0.012 0.923 
1.2 
)}2,2{(  0.004 
0.996 
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Table 20. Proportion of cases resulted in Type A ambiguity (upper entry) and lack of power 
(lower entry) 
AVEθ  MeD-set Step-Down 
0 Empty 0.001 Not Defined 
)}1,1{(  0.078 
0.830 
)}2,1{(  0.024 
0.805 
)}1,2{(  0.023 
0.807 
)}2,1(),1,2{( 0.213 0.947 
0.4 
)}2,2{(  0.002 
0.388 
)}1,1{(  0.006 
0.141 
)}2,1{(  0.002 
0.165 
)}1,2{(  0.002 
0.168 
)}2,1(),1,2{( 0.199 0.500 
0.8 
)}2,2{(  0.002 
0.001 
)}1,1{(  0.000 
0.003 
)}2,1{(  0.000 
0.004 
)}1,2{(  0.000 
0.004 
)}2,1(),1,2{( 0.009 0.065 
1.2 
)}2,2{(  0.002 
0.000 
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Table 21. Estimated values of the loss functions based on Definition 5.1 (upper entry) and 
Definition 5.3 (lower entry) of Section 5.3 
AVEθ  MeD-set Step-Up Step-Down 
0 Empty 0.126 0.204 
0.018 
0.020 
)}1,1{(  3.299 
1.334 
4.097 
1.651 
)}2,1{(  2.719 
0.783 
3.124 
0.842 
)}1,2{(  2.726 
0.786 
3.134 
0.845 
)}2,1(),1,2{( 4.304 1.214 
4.433 
1.236 
0.4 
)}2,2{(  1.607 
0.415 
1.558 
0.286 
)}1,1{(  0.326 
0.120 
0.356 
0.141 
)}2,1{(  0.100 
0.119 
0.338 
0.135 
)}1,2{(  0.098 
0.112 
0.342 
0.138 
)}2,1(),1,2{( 0.660 0.267 
0.660 
0.267 
0.8 
)}2,2{(  0.060 
0.142 
0.010 
0.013 
)}1,1{(  0.008 
0.002 
0.008 
0.002 
)}2,1{(  0.028 
0.092 
0.016 
0.023 
)}1,2{(  0.029 
0.093 
0.015 
0.024 
)}2,1(),1,2{( 0.149 0.082 
0.149 
0.082 
1.2 
)}2,2{(  0.054 
0.135 
0.007 
0.013 
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Table 22. Estimated power of the procedure in the case of 0=AVEθ  for different values of the 
mean control differences 
δ)  
Estimated Power 
of the Step-Down 
Procedure 
)0,0,0,0(=δ)  0.996 
)1,1,0,0(=δ)  0.986 
)1,1,1,1(=δ)  0.949 
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6.4 DETAILED RESULTS OF THE 2 BY 3 SIMULATION STUDIES 
Tables 23-25 summarize the results of the simulation studies for the 32×  case. 
First, let us compare the performance of the regular and modified step-down procedures. 
The modified procedure uses the generalized MPG testing principle presented in Section 4.6. 
The only difference between the procedures is that the regular MPG procedure may result in 
Type B ambiguity (6th or 9th “decision” sequences of Table 7) but the modified procedure 
provides meaningful estimates of the MeD-set ( )}3,1{(  or )}1,2{( , respectively) in such cases.  
Since the probability of Type B ambiguity outcome is very small for 8.0=AVEθ  and 
2.1=AVEθ , the simulated measures corresponding to the modified procedure are given for 
0=AVEθ  and 4.0=AVEθ  only. These are presented in Table 23. Since the occurrence of Type A 
ambiguity does not change whether or not the regular or modified MPG principle is used, Table 
23 presents a single entry of simulated probability of Type A ambiguity for each population 
configuration.  
The modified procedure strongly controls the FWE at 05.0=α . The performance of this 
procedure is very similar to the one of the regular procedure in terms of estimated values of 
power, FWE and lack of power. When the true MeD-set is given by )}3,1{(  or )}1,2{(  the power 
(lack of power) of the modified procedure is greater (less) than the power (lack of power) of the 
regular procedure. On the other hand, when the true MeD-set is given by )}3,1{(  or )}1,2{( , Type 
B ambiguity occurs in less than %1 of the replications so the difference in power for the regular 
and modified procedures is not significant. For example, when the true MeD-set is given by 
)}3,1{( , the power is 151.0  and 157.0  for the regular and modified procedures, respectively.  
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Table 23. Simulation results of the regular and modified procedures for 0=AVEθ  and 
4.0=AVEθ  in the 32×  case 
Population 
MeD-Set Empty (2,3) (2,2) (1,3) (2,1) 
(2,2) 
(1,3) (1,2) 
(2,1) 
(1,3) 
(2,1) 
(1,2) (1,1) 
Power  0.999 0.670 0.165 0.151 0.075 0.041 0.079 0.022 0.025 0.147
mPower  0.998 0.670 0.165 0.157 0.081 0.042 0.078 0.022 0.025 0.146
LOP  0.000 0.328 0.833 0.845 0.924 0.955 0.918 0.975 0.968 0.853
mLOP  0.000 0.328 0.833 0.839 0.918 0.954 0.918 0.975 0.967 0.854
FWE  0.000 0.002 0.002 0.004 0.001 0.004 0.004 0.004 0.008 0.000
mFWE  0.000 0.002 0.002 0.004 0.001 0.005 0.003 0.004 0.008 0.000
1L  0.007 1.317 2.969 2.972 4.384 3.998 3.922 4.614 5.276 4.750
mL ,1  0.009 1.317 2.968 2.976 4.369 4.004 3.944 4.798 5.648 4.881
3L  0.004 0.102 0.350 0.355 0.564 0.501 0.681 0.645 0.795 0.988
mL ,3  0.005 0.103 0.350 0.356 0.562 0.503 0.696 0.679 0.886 1.043
UND  0.001 0.001 0.001 0.001 0.000 0.002 0.002 0.004 0.008 0.000
mUND  0.001 0.002 0.001 0.001 0.000 0.003 0.002 0.004 0.008 0.000
OV  0.000 0.328 0.827 0.826 0.911 0.616 0.754 0.509 0.572 0.741
mOV  0.000 0.328 0.828 0.827 0.910 0.619 0.758 0.510 0.572 0.797
AType  0.000 0.000 0.006 0.012 0.008 0.250 0.153 0.233 0.157 0.056
BType  0.000 0.000 0.000 0.008 0.005 0.006 0.011 0.063 0.131 0.056
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Table 24. Simulation results of the proposed procedure for 8.0=AVEθ  in the 32×  case 
Population 
MeD-Set (2,3) (2,2) (1,3) (2,1) 
(2,2) 
(1,3) (1,2) 
(2,1) 
(1,3) 
(2,1) 
(1,2) (1,1) 
Power 0.998 0.832 0.826 0.553 0.466 0.526 0.317 0.364 0.859
LOP 0.000 0.166 0.170 0.446 0.529 0.470 0.679 0.624 0.141
FWE 0.002 0.002 0.004 0.001 0.005 0.004 0.004 0.012 0.000
1L  0.005 0.334 0.343 0.920 0.444 1.260 0.891 0.733 0.389
3L  0.003 0.052 0.059 0.142 0.073 0.157 0.111 0.133 0.065
UND  0.001 0.001 0.001 0.000 0.003 0.002 0.004 0.012 0.000
OV  0.000 0.165 0.167 0.444 0.014 0.434 0.056 0.154 0.135
Type A 0.000 0.001 0.003 0.002 0.319 0.036 0.361 0.237 0.005
Type B 0.000 0.000 0.001 0.000 0.002 0.000 0.020 0.061 0.002
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Table 25. Simulation results for 2.1=AVEθ  in the 32×  case 
Population 
MeD-Set (2,3) (2,2) (1,3) (2,1) 
(2,2) 
(1,3) (1,2) 
(2,1) 
(1,3) 
(2,1) 
(1,2) (1,1) 
Power 0.998 0.996 0.994 0.937 0.916 0.914 0.805 0.847 0.997
LOP 0.000 0.003 0.003 0.062 0.079 0.082 0.191 0.141 0.003
FWE 0.002 0.002 0.003 0.001 0.004 0.004 0.004 0.012 0.000
1L  0.004 0.008 0.012 0.126 0.114 0.250 0.387 0.262 0.008
3L  0.003 0.003 0.008 0.022 0.021 0.033 0.048 0.052 0.001
UND  0.001 0.001 0.001 0.000 0.003 0.002 0.004 0.012 0.000
OV  0.000 0.003 0.003 0.062 0.000 0.081 0.022 0.054 0.003
Type A 0.000 0.000 0.001 0.000 0.028 0.001 0.059 0.027 0.000
Type B 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000
 
Table 26. Estimated average loss 
Average Loss  0=AVEθ  4.0=AVEθ  8.0=AVEθ  2.1=AVEθ  
1L  0.007 3.800 0.591 0.130 
mL ,1  0.009 3.878 0.615 0.129 
3L  0.004 0.553 0.088 0.021 
mL ,3  0.005 0.575 0.094 0.022 
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Type B ambiguity happens the most frequently when the true MeD-set is given by the 
“diagonal” set )}1,2(),2,1{( . When 4.0=AVEθ  the probability of Type B outcome is about 
%13 , this percentage is a sum of two percentages. The first percentage corresponds to the cases 
when the regular procedure results in the 6th “decision” sequence of Table 7 (about %3 ) and the 
second percentage corresponds to the cases when it results in the 9th “decision” sequence ( %10 ). 
The estimated probability of Type B ambiguity is relatively high for the MeD-set )}1,2(),2,1{(  
due to two reasons. The first reason is that the diagonal designs require the testing of more 
hypotheses. The second reason is the small value of the gain average. Indeed, when the 
8.0=AVEθ , the percentage of Type B outcomes reduces to %6  and when 2.1=AVEθ  it reduces 
to %1.0 . 
The power of each procedure depends on the value of the gain average. In the case of a 
zero gain average, the estimated power is greater than 99.0 . The estimated values of the average 
power are 246.0 , 638.0  and 934.0  for 4.0=AVEθ , 8.0=AVEθ  and 2.1=AVEθ , respectively.  
The estimated averages of the loss functions are summarized in Table 26, where iL , 
3,1=i  denotes the average loss corresponding to a regular procedure and miL , , 3,1=i  denotes 
the average loss of the modified procedure. 
The loss averages seem to be higher for the modified procedure than for the regular one 
in the case of 4.0=AVEθ . These higher values are due to the increased proportion of cases 
corresponding to the meaningful MeD-set estimates. 
In terms of underestimating the true MeD-set, both procedures perform similarly. There 
are technical reasons for why this happens. The only true sets that can be underestimated by the 
set )}3,1{(  are the set )}3,2{(  and an empty set. But Type B outcome almost never happens for 
such configurations (proportion of Type B outcome is less than %1.0 ). Similarly, the only true 
sets that are underestimated by the set )}1,2{(  are the sets )}2,2{(  and )}3,2{( . Again, Type B 
ambiguity happens in less than %1.0  of the cases for such configurations. 
In terms of overestimating the true MeD-sets, the results of the procedures are slightly 
different when the true MeD-set is given by )}1,1{( . In such cases )}1,1{(  is overestimated by 
both sets, )}3,1{(  and )}1,2{( , and type B outcome happens about %6  of the time, so the 
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modified procedure results in higher values of the estimated measureOV −  than the regular 
procedure does.  
Tables 23-25 also contain the frequencies of Type A ambiguity. When there is no MeD, 
the proposed procedure almost never results in such outcome (the proportion of such cases is less 
than %1.0 ). The average frequency of Type A ambiguity is 097.0  for 4.0=AVEθ , 107.0  for 
8.0=AVEθ  and 013.0  for 2.1=AVEθ . Among possible configurations, the configurations with 
the true “diagonal” MeD-sets, )}3,1(),2,2{( , )}2,1(),1,2{(  or )}3,1(),1,2{( , correspond to the 
highest average frequency of Type A ambiguity. Among those, configurations with the true 
MeD-set )}3,1(),1,2{(  correspond to the highest probability of Type A outcome. The 
configurations with the true MeD-sets given by )}3,2{( , )}2,2{( , )}1,2{(  and )}3,1{(  correspond 
to the lowest average frequency of Type A ambiguity, less than %1 , followed by the set )}1,1{(  
( %2 ) and )}2,1{(  ( %5 ).  
These conclusions are summarized at the end of this section. 
Table 27. Simulation probability and the exact power of a single AVE test statistic given by 
Hung et al. (1993) 
AVEθ  10μ , 20μ  01μ , 02μ , 03μ  Simulation Probability  
Power of a 
Single AVE Test 
0=AVEθ  0.1, 1.0 0.1, 0.3, 1.0 0.990 0.01 
0=AVEθ  0.1, 0.3 0.1, 0.2, 0.3 0.996 0.005 
2.0=AVEθ  0.1, 0.3 0.1, 0.2, 0.3 0.822 0.18 
6.0=AVEθ  0.1, 0.3 0.1, 0.2, 0.3 0.009 0.99 
 
To confirm the correctness of our simulation program we consider four special cases 
given in Table 18. Table 27 presents the simulation probabilities for such configurations and the 
exact power obtained by Hung et al. (1993). In the first two cases with 0=AVEθ  the simulated 
probabilities provide the estimated “power” of the procedure, both simulated values agree with 
Hung’s exact power of a single AVE test, i.e., HUNGPowerMMPPower −=∅=∅== 1)|ˆ( . 
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Based on the simulated probabilities for the last two cases we can conclude that the first tested 
hypothesis is rejected with estimated probabilities of 178.0822.01 =−  and 991.0009.01 =− . 
Again, both values agree with Hung’s values, 18.0  and 99.0 .  
6.5 SUMMARY OF THE RESULTS 
We summarize the conclusions presented in Section 6.3 for the 22×  case and Section 6.4 for the 
32×  case as follows. 
1) The quality of the proposed procedures improves with increasing positive gain average.  
2) Our proposed procedures perform the best in the case when there is no MeD. 
3) Among possible non-empty true MeD-sets, the set containing the highest combination is 
correctly identified with the highest probability. The “diagonal” configurations of the 
MeD-set are correctly identified with the lowest probability. 
4) The regular and modified step-down procedures perform very similarly. The modified 
procedure results in a slightly greater average loss but provides a meaningful MeD-set 
estimate in the cases when the regular procedure results in ambiguities.  
5) While the theory demonstrates that our procedure controls the FWE rate, the simulations 
reinforce this. 
6) The probability of Type A ambiguity is small when the gain averages are relatively large. 
The population configurations with “diagonal” MeD-set correspond to the highest 
frequency of Type A ambiguity. Configurations with true MeD-set containing the highest 
combination correspond to the smallest probability of Type A ambiguity.  
7) Additional simulation studies indicate that the results of the procedures depend on the 
values of the mean dose-response differences of the single drugs. 
8) The program validation is checked using the exact power values presented by Hung et al. 
(1993).  
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7.0 DISCUSSION 
7.1  DISCUSSION OF THE RESULTS 
In the biopharmaceutical industry in order for a new drug to be marketed, efficacy and safety 
studies are required. One of the main goals of the efficacy study is to identify the effective dose 
range, i.e., all doses which are superior to placebo. This applies to both a single drug and 
combination drug setting.  
In addition to identifying all effective doses, clinicians are interested in selecting the 
minimum effective dose. Such a dose is especially desirable when increasing the dose level leads 
to the serious side effects. In a single drug case, the minimum effective dose, if it exists, is 
unique.  
We propose a closed testing procedure for identifying the minimum effective dose in a 
single drug study. Our procedure uses the assumption of non-decreasing mean dose-response, 
which is the most popular shape of the mean dose-response function. The proposed procedure is 
based on the closed testing principle applied to a family of hypotheses and involves constructing 
simultaneous confidence bands. Our procedure performs better than its competitors when the 
population mean dose-response function is rapidly rising near zero, i.e., when the true minimum 
effective dose is relatively low, which is often the case in biopharmaceutical trials. 
In the case of a combination drug, in addition to demonstrating safety and efficacy the 
FDA requires demonstrating that each component makes a contribution to the claimed effects. A 
combination which satisfies the last requirement is called an efficacious combination. The 
efficacious combinations with the lowest doses are called the minimum efficacious 
combinations. Since the minimum efficacious combination may not be unique, we introduce the 
notion of the minimum efficacious dose set (MeD-set). 
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The problem of identifying the MeD-set is very complex. The more dose levels of each 
drug, there are more different structures of the population MeD-sets that will need to be 
identified by a procedure. 
We propose a closed testing procedure for identifying the MeD-set. Our procedure 
requires first, identifying all possible patterns of the population MeD-set for a given design. 
Next, the closed hypothesis family is constructed and the proper step-down partial testing order 
is specified. Then, the hypotheses are tested using the closed testing scheme. The pattern of 
rejected and accepted hypotheses provides the estimated MeD-set. 
The main advantage of the procedure is the strong control of overall error at a specified 
level of significance. This feature is crucial in multiple testing because when the number of 
hypotheses to be tested is large, the familywise error can rapidly increase. As a consequence, a 
procedure involving multiple testing results in false conclusion about the drug effectiveness with 
high probability.  
The other advantage of the proposed procedure is that in the case of a combination 
consisting of approved single drugs, our procedure demonstrates effectiveness and efficacious of 
the combination drug, so the two regulatory problems stated by the FDA can be solved at once. 
That is because in the case of approved component drugs, it is known that each single drug is 
superior to placebo, and therefore, all efficacious combinations are also superior to placebo, i.e., 
they are effective by implication. So the proposed procedure identifies the minimum efficacious 
and therefore, effective combinations.  
There are some complexities associated with the hypothesis testing approach used to 
identify the MeD-set. First, when the number of active doses of each drug is high, there are a 
large number of hypotheses to be tested. While in the case of four combinations (two active 
doses of one single drug and two active doses of the other single drug) there are five hypotheses 
in the hypothesis family; in the case of nine combinations (three active doses of one single drug 
and three active doses of the other single drug), there are nineteen hypotheses in the family.  
The other technical complexity of our procedure is related to a complicated structure of 
the parameters for the population MeD-set. The procedure is constructed so that all possible 
patterns of the parameters can be identified, but together with those estimates it may result in 
ambiguities. We describe three types of ambiguities that may be present in the designs with up to 
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nine combinations. One type of these ambiguities can be eliminated by generalizing the testing 
scheme; others require additional research. 
These two complexities, large number of hypotheses to be tested and possible resulting in 
ambiguity, are of primary concern when the number of combinations is large. But the modern 
biopharmaceutical combination drug studies usually do not involve more than four or six drug 
combinations, and for such designs our proposed procedure is quite effective. 
Since there are no other procedures for identifying the minimum efficacious doses in the 
combination drug case, the performance of the proposed procedure can not be compared with the 
performance of any other procedure. Instead, Monte-Carlo simulations are used in order to 
describe the properties and goodness of the estimation. 
The simulation studies reinforce the applicability of the proposed procedure. Among 
possible structures of the population MeD-set, the sets containing the highest dose combinations 
are identified by the procedure the best. Also, if there are no efficacious combinations in the 
study, the procedure detects this case with high power.  
7.2 FUTURE RESEARCH  
The primary goal of our future research is to continue developing statistical techniques that can 
be used in the analysis of the efficacy studies of the combination drug. The problems related to 
this goal are discussed in this section. 
The first goal is to construct a similar step-down testing procedure based on the MAX 
test statistic. The proposed procedure is based on the closed testing principle, which allows 
testing a single hypothesis at a fixed level of significance. The testing of a single hypothesis 
involves constructing the AVE statistic proposed by Hung et al. (1993). As it is mentioned in 
Section 4.1, Hung et al. (1993) consider one more test statistic, the MAX statistic, for testing 
individual hypotheses.  
In order to implement the MAX test, we need to obtain the distribution function 
corresponding to non-rectangular designs; then define the power function; and finally, provide 
the formula for calculating the critical values for non-rectangular designs. Using Hung’s et al. 
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(1993) results for testing the hypotheses corresponding to the rectangular designs, we can test all 
of the hypotheses under the closed testing principle.  
Finally, the two procedures, based on the AVE and MAX test statistics, can be compared 
by simulation. We plan to obtain the conditions and identify the population patterns, when one 
procedure dominates the other in terms of the measures presented in Chapter 5.0. 
The long term research goal is to develop the confidence bands techniques similar to the 
ones introduced in the single drug case and presented in Section 2.4. By constructing the 
simultaneous lower bands for the dose-response surface we could estimate the population mean 
dose-response function. To construct such bands we can start with the simplest case of monotone 
mean dose-response surface. Based on the knowledge obtained in this case a general setting can 
be considered. 
In this dissertation we present a testing procedure for identifying all minimum efficacious 
doses in the combination drug study. This procedure uses an assumption of approved single 
drugs. So the regulatory problems stated by the FDA, requiring demonstration that the 
combination is superior to placebo, and that the combination is superior to each component drug 
taken alone, can be handled by our procedure. That is because in the case of approved 
component drugs, it is known that each single drug is superior to placebo, and therefore, all 
efficacious combinations are also superior to placebo. The other long term research goal is to 
construct a procedure for identifying the minimum efficacious doses, similar to the one proposed 
in this dissertation, but without the assumption that each component drug is superior to placebo.  
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APPENDIX A 
R CODE FOR SIMULATION THE UPPER CRITICAL VALUES FOR THE TWO-
SIDED AND ONE-SIDED SIMULTANEOUS MAX-MIN CONFIDENCE BANDS FOR 
THE CASE OF EQUAL SAMPLE SIZES AND KNOWN VARIANCE 
sd1<-(1/(2^(0.5))); 
max1<-500000; 
k<-6; alp<-0.95; 
c1<-as.array(k); 
c2<-as.array(k); 
t<-as.array(max1); 
w<-as.array(max1); 
for (r in 1:k){ 
                      A<-matrix(0,r,r); 
                      s<-(r+1); 
                      y<-as.array(s); 
                      z<-as.array(r); 
                      for (l in 1:max1){  
                   y<-rnorm(s, mean=0,sd=sd1); 
                       for(n in 1:r){ 
                       z[n]<-(y[n]-y[s]); 
                                    } 
                       for (b in 1:r) { d<-b; A[b,d]<-z[b]; 
                                       } 
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for (i in 1:r){ 
for (j in i:r){ 
if (i<j) {A[i,j]<-((((j-i)^0.5)*(A[i,(j-1)])+z[j])/((j-
i+1)^0.5));  
               A[j,i]<-A[i,j]}    
                             }  
                 }    
               w[l]<-max(A); t[l]<-max(abs(A)); 
       } 
               c1[r]<-quantile(w,alp); c2[r]<-
quantile(t,alp);  
                       } 
print(c1); print(c2); 
 
Comments:   
sd1 specifies the standard deviation of the group sample mean; 
max1 stores the number of replications; 
k defines the number of active doses;  
alp specifies the level of significance; 
c1 is a vector of length max1 of the upper one-sided critical values, c1[i] stores the critical value 
based on i active doses; 
c2 is a vector of length max1 of the upper two-sided critical values, c2[i] stores the critical value 
based on i active doses. 
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APPENDIX B 
R CODE FOR THE SIMULATION STUDIES FOR THE SINGLE DRUG CASE 
     sd1<-1; 
N<-matrix(0,6,15); 
 
for (t in 1:5) { 
   N[5,t]<-3; 
} 
for (t in 6:10) { 
   N[5,t]<-4; 
} 
for (t in 11:15) { 
   N[5,t]<-5; 
} 
N[4,2]<-1.5; 
N[3,3]<-1; 
N[4,3]<-2; 
N[2,4]<-0.75; 
N[3,4]<-1.5; 
N[4,4]<-9/4; 
N[1,5]<-0.6; 
N[2,5]<-1.2; 
N[3,5]<-1.8; 
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N[4,5]<-2.4; 
N[4,7]<-2; 
N[3,8]<-4/3; 
N[4,8]<-8/3; 
N[2,9]<-1; 
N[3,9]<-2; 
N[4,9]<-3; 
N[1,10]<-4/5; 
N[2,10]<-8/5; 
N[3,10]<-12/5; 
N[4,10]<-16/5; 
N[4,12]<-5/2; 
N[3,13]<-5/3; 
N[4,13]<-10/3; 
N[2,14]<-5/4; 
N[3,14]<-10/4; 
N[4,14]<-15/4; 
N[1,15]<-1; 
N[2,15]<-2; 
N[3,15]<-3; 
N[4,15]<-4; 
print(N); 
T<-5; 
Delta<-3; 
POPMEAN<-as.array(6); 
lee<-as.array(10); 
korn<-as.array(10); 
wilm<-as.array(10); 
"Critical values for up to 10 active doses are given" 
"Only first five are used by the program" 
lee[1]<-1.645; 
lee[2]<-2.12; 
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lee[3]<-2.45; 
lee[4]<-2.72; 
lee[5]<-2.98; 
lee[6]<-3.18; 
lee[7]<-3.39; 
lee[8]<-3.59; 
lee[9]<-3.76; 
lee[10]<-3.94; 
korn[1]<-1.645; 
korn[2]<-1.92; 
korn[3]<-2.06; 
korn[4]<-2.16; 
korn[5]<-2.23; 
korn[6]<-2.29; 
korn[7]<-2.34; 
korn[8]<-2.38; 
korn[9]<-2.42; 
korn[10]<-2.72; 
wilm[1]<-1.645; 
wilm[2]<-1.716; 
wilm[3]<-1.739; 
wilm[4]<-1.750; 
wilm[5]<-1.756; 
wilm[6]<-1.760; 
wilm[7]<-1.763; 
wilm[8]<-1.765; 
wilm[9]<-1.767; 
wilm[10]<-1.768; 
y<-as.array(6); 
z<-as.array(5); 
M<-0; 
E<-as.array(1); 
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E0<-as.array(1); 
E1<-as.array(1); 
E2<-as.array(1); 
E3<-as.array(1); 
E4<-as.array(1); 
E5<-as.array(1); 
E6<-as.array(1); 
G<-as.array(1); 
Q<-as.array(1); 
t<-as.array(5); 
LEST<-as.array(6); 
LDFEST<-as.array(6); 
KEST<-as.array(6); 
WEST<-as.array(6); 
X<-matrix(-100,5,5); 
A<-matrix(0,5,5); 
V<-matrix(0,5,5); 
B<-as.array(5); 
set.seed(100) 
max1<-10000; 
for (n in 1:15) { 
   if ((n==1)||(n==6)||(n==11)) {T<-5}; 
   if ((n==2)||(n==7)||(n==12)) {T<-4}; 
   if ((n==3)||(n==8)||(n==13)) {T<-3}; 
   if ((n==4)||(n==9)||(n==14)) {T<-2}; 
   if ((n==5)||(n==10)||(n==15)){T<-1}; 
   if ((n==6)||(n==7)||(n==8)||(n==9)||(n==10)){Delta<-4}; 
   if ((n==11)||(n==12)||(n==13)||(n==14)||(n==15)){Delta<-
5}; 
   for (u in 1:6) { 
      POPMEAN[u]<-N[u,n] 
   } 
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   LEXP<-0; 
   LDFEXP<-0; 
   KEXP<-0; 
   WEXP<-0; 
   LBIAS<-0; 
   KBIAS<-0; 
   WBIAS<-0; 
   LDFBIAS<-0; 
   for (k in 1:6) { 
      WEST[k]<-0; 
      LEST[k]<-0; 
      KEST[k]<-0; 
      LDFEST[k]<-0; 
   } 
   LMED<-as.array(max1); 
   KMED<-as.array(max1); 
   WMED<-as.array(max1); 
   LDFMED<-as.array(max1); 
   E<-0; 
   E0<-0; 
   E1<-0; 
   E2<-0; 
   E3<-0; 
   E4<-0; 
   E5<-0; 
   E6<-0; 
   G<-0; 
   Q<-0; 
   for (l in 1:max1) { 
      for (i in 1:6) { 
         y[i]<-rnorm(1,mean=POPMEAN[i],sd=sd1) 
      } 
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      "LEE PROCEDURE" 
#Generating A (needed to calculate maximums) 
      for (b in 1:5) { 
         A[b,b]<-(y[b]-y[6]); 
      } 
      for (r in 1:5) { 
         for (j in r:5) { 
            if (j>r) {h<-(j-r+1);A[r,j]<-((((j-r)*(A[r,j-
1]))+y[j]-y[6])/h)} 
            } 
      } 
      "Step-down Lee" 
      p<-1; # to break the while loop 
       j<-5; 
      while ((j>=1)&(p>0)) { 
         M<-(y[1]-y[6]-lee[j]*(2^0.5)); 
         for (k in 1:j) { 
            for (h in 1:k) { 
               w<-(k-h+1); 
               F<-(A[h,k]-(lee[j])*((2/w)^0.5)); 
              if (F>M) {M<-F} 
              } 
         }  
         if (M>=0) {j<-(j-1)} else {p<-0} 
     } 
        LMED[l]<-(j+1); 
      h<-LMED[l]; 
      LEST[h]<-(LEST[h]+1); 
"Step-down fixed" 
     p<-1; # to break the while loop 
     j<-5; 
     while ((j>=1)&(p>0)) { 
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         M<-(y[1]-y[6]-lee[5]*(2^0.5)); 
       for (k in 1:j) { 
            for (h in 1:k) { 
               w<-(k-h+1); 
               F<-(A[h,k]-(lee[5])*((2/w)^0.5)); 
               if (F>M) {M<-F} 
               } 
         } 
        if (M>=0) {j<-(j-1)} else {p<-0} 
      } 
      LDFMED[l]<-(j+1); 
      h<-LDFMED[l]; 
      LDFEST[h]<-(LDFEST[h]+1); 
      "WILM PROCEDURE" 
      r<-1; 
      for (contrj in 0:4) { 
         j<-(5-contrj); 
         FMax<-1; 
         for (u in 1:j) { 
            FMin<-1; 
            for (v in j:5) { 
               summ<-0; 
               for (i in u:v) { 
                  summ<-(summ+y[i]); 
               } 
               trymin<-(summ/(v-u+1)); 
               if (FMin==1) {FMin<-0;curmin<-trymin} 
               else { 
                  if (trymin<curmin) {curmin<-trymin;} 
               } 
            } 
            if (FMax==1) {FMax<-0;curmax<-curmin} 
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            else { 
               if (curmin>curmax) {curmax<-curmin;} 
            } 
         } 
         if (((curmax-y[6])/sqrt(2))<wilm[j]) { 
            r<-j+1; 
            break; 
         } 
      } 
      WMED[l]<-r; 
      WEST[r]<-(WEST[r]+1); 
      "KORN PROCEDURE" 
      j<-5; 
      p<-1; 
      while ((j>=1)&(p>0)) { 
         M<-(y[1]-y[6]-(korn[j]*(2^0.5))); f<-1; 
         for (i in 1:j) { 
            z[i]<-(y[i]-y[6]-(korn[j]*(2^0.5))); 
            if (z[i]>M) {M<-z[i]; f<-i} 
            } 
         if (M>=0) {j<-(f-1)} else {p<-0} 
      } 
      KMED[l]<-(j+1); 
       
      h<-KMED[l]; 
      KEST[h]<-(KEST[h]+1); 
   } 
   for ( i in 1:6) { 
      LEXP<-(LEXP+i*LEST[i]); 
      LDFEXP<-(LDFEXP+i*LDFEST[i]); 
   } 
   LEXP<-(LEXP/max1); 
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   LDFEXP<-(LDFEXP/max1); 
   LBIAS<-(LEXP-T); 
   LDFBIAS<-(LDFEXP-T); 
   if (T>1) { 
      for (f in 1:(T-1)){ 
         E<-(E+LEST[f]); 
         E1<-(E1+LDFEST[f]); 
      } 
   } 
   for(f in (T+1):6) { 
                  E2<-(E2+LEST[f]); 
                  E4<-(E4+LDFEST[f]); 
                  } 
   LFWE<-(E/max1); 
   LDFFWE<-(E1/max1); 
   LLACK<-(E2/max1); 
   LDFLACK<-(E4/max1); 
   LPOWER<-(LEST[T]/max1); 
   LDFPOWER<-(LDFEST[T]/max1); 
   print("Delta"); print(Delta); 
   print("True MED"); print(T); 
   print("LEE"); 
   print("LEST"); 
   print(LEST); 
   print("LEXP"); 
   print(LEXP); 
   print("LBIAS"); 
   print(LBIAS); 
   print("LFWE"); 
   print(LFWE); 
   print("LPOWER"); 
   print(LPOWER); 
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   print("LLACK"); 
   print(LLACK); 
print("LEE DOWN FIXED"); 
   print(LDFEST); 
   print(LDFEXP); 
   print(LDFBIAS); 
   print(LDFFWE); 
   print(LDFPOWER); 
   print(LDFLACK); 
   for ( i in 1:6) { 
      KEXP<-(KEXP+i*KEST[i]); 
   } 
   KEXP<-(KEXP/max1); 
   KBIAS<-(KEXP-T); 
   if (T>1) { 
      for (f in 1:(T-1)){ 
         G<-(G+KEST[f]) 
      } 
   } 
   for (f in (T+1):6) { 
                 E5<-(E5+KEST[f]) 
                 } 
   KFWE<-(G/max1); 
   KLACK<-(E5/max1); 
   KPOWER<-(KEST[T]/max1); 
   print("KORN"); 
   print(KEST); 
   print(KEXP); 
   print(KBIAS); 
   print(KFWE); 
   print(KPOWER); 
   print(KLACK); 
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   for ( i in 1:6) { 
      WEXP<-(WEXP+i*WEST[i]); 
   } 
   WEXP<-(WEXP/max1); 
   WBIAS<-(WEXP-T); 
   Q<-0; 
   if (T>1) { 
      for (f in 1:(T-1)) { 
         Q<-(Q+WEST[f]) 
      } 
   } 
   for (f in (T+1):6) { 
                  E6<-(E6+WEST[f]) 
                  } 
   WFWE<-(Q/max1); 
   WLACK<-(E6/max1); 
   WPOWER<-(WEST[T]/max1); 
   print("WILM"); 
   print(WEST); 
   print(WEXP); 
   print(WBIAS); 
   print(WFWE); 
   print(WPOWER); 
   print(WLACK); 
} 
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APPENDIX C 
R CODE FOR RECURSIVE ALGORITHM FOR IDENTIFYING THE POPULATION 
MINIMUM EFFICACIOUS DOSE SET FOR A GIVEN RESPONSE MATRIX 
The notation is given in Section 3.3.2, with the only changes: matrix F is substituted by F1 and 
matrix 'F  is substituted by F2. The MeD-matrix is denoted by MED. 
# Recursive Function for step 4 
recur<-function(W,A,B) { 
result<-matrix(0,A,B); 
l1<-0;l2<-0; m1<-0;m2<-0; 
# looking for (l1,l2) 
for(a in 1:A) { 
              for(b in 1:B) { 
              if(W[a,b]==1) {l1<-a;l2<-b;break} 
                            } 
              if(l1>0) break 
              } 
# looking for (m1,m2) 
for(b in 1:B) { 
              for (a in 1:A){ 
              if(W[a,b]==1) {m1<-a;m2<-b;break} 
                            } 
              if(m1>0) break 
              } 
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              if(m1>0) { # non-zero entries present 
              if(((m1-l1)>1)&&((l2-m2)>1)) {  
# another run is needed 
              W1<-matrix(,m1-l1-1,l2-m2-1); 
              for(a in 1:(m1-l1-1)) { 
              for(b in 1:(l2-m2-1)) { 
              W1[a,b]<-W[l1+a,m2+b] 
                                    } 
                                    } 
              result1<-recur(W1,m1-l1-1,l2-m2-1); 
              for(a in 1:(m1-l1-1)) { 
              for(b in 1:(l2-m2-1)) { 
              result[l1+a,m2+b]<-result1[a,b]; 
                                            } 
              } 
              } 
result[l1,l2]<-1; 
result[m1,m2]<-1; 
      } 
result 
} #recur 
# The Main Function of the Algorithm of Identifying the 
Population MeD-set 
algorithm<-function(M,K,N) { 
 
#STEP 1. Constructing the Indicator Effect Matrix (IEM)  
            IEM<-matrix(0,K,N); 
            for(k in 1:K) { 
                          for(n in 1:N) { 
     if(M[k+1,n+1]>max(M[1,n+1],M[k+1,1])) IEM[k,n]<-1 
else IEM[k,n]<-0; 
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                                                } 
                                     } 
 
#STEP 2. Constructing the Matrix F1 (MED for fixed doses 
of drug A) 
F1<-matrix(0,K,N); 
for(k in 1:K) { 
               n<-1; 
               if(IEM[k,n]==1) F1[k,n]<-1; 
               while((n<N)&&(IEM[k,n]==0)) { 
               n<-n+1; 
               if(IEM[k,n]==1) F1[k,n]<-1; 
                                           } 
              } 
#STEP 3. Constructing the matrix F2 (MED for fixed doses 
of drug B) 
F2<-matrix(0,K,N); 
for(n in 1:N) { 
               k<-1; 
               if(F1[k,n]==1) F2[k,n]<-1; 
               while((k<K)&&(F1[k,n]==0)) { 
               k<-k+1; 
               if(F1[k,n]==1) F2[k,n]<-1; 
                                          } 
              } 
 
#STEP 4. 
MED<-recur(F2,K,N); 
MED 
}  #algorithm 
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To illustrate how the above algorithm works we have considered the following test 
procedure. It generates a 66×  matrix M of standard normal responses and applies the algorithm. 
 
#TEST 
K<-5 
N<-5 
M<-matrix(0,K+1,N+1) 
for (k in 1:(K+1)) { 
  for (n in 1:(N+1)) { 
     M[k,n]<-rnorm(1, mean=0, sd=1) 
                     } 
                   } 
M 
Algorithm(M,K,N) 
 
The results of this test are given below. The generated matrix of population responses is given by 
 
 -0.2799251 -1.6213077 0.1028200 1.7159707 2.4321761 -3.1145317 
 0.5636922 0.0620111 -1.9548860 -0.5171184 0.1749682 0.1311853 
 -0.3697043 0.6650670 0.9565387 0.2911767 0.7744501 0.0178395 
 0.4097249 -0.8624360 0.3079037 0.2320736 -0.1868923 -1.4978265 
 -0.3652390 -1.5065386 1.4905473 -1.9176413 -0.3723691 -0.3778648 
 0.5745144 0.5821338 1.3091003 1.4995865 0.5130860 0.4909296 
 
Then, the indicator gain matrix obtained at the 1st step, together with the matrices F (F1) and 'F  
(F2) are given by the following matrices, respectively: 
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 0    0    0    0    0 
 1    1    0    0    1 
 0    0    0    0    0 
 0    1    0    0    0 
 1    1    0    0    0 
 
 0    0    0    0    0 
 1    0    0    0    0 
 0    0    0    0    0 
 0    1    0    0    0 
 1    0    0    0    0 
  
 0    0    0    0    0 
 1    0    0    0    0 
 0    0    0    0    0 
 0    1    0    0    0 
 0    0    0    0    0 
   
And the final MeD-matrix is obtained as   
 
 0    0    0    0    0 
 1    0    0    0    0 
 0    0    0    0    0 
 0    0    0    0    0 
 0    0    0    0    0 
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APPENDIX D 
ON OBTAINING THE ADDITIONAL CRITICAL VALUES FOR THE AVE TEST 
STATISTIC 
In order to prove Theorem 4.2 of Section 4.2, we need to generalize the method, introduced by 
Hung et al. (1993) for obtaining the critical values for the AVE test. Let I  be the specified non-
rectangular design of the form (4.4). Assume that 2' )1( ≥n  and 'n  is the total number of drug 
combinations under consideration.  
Since for non-rectangular design (4.4) 
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The power function depends on the parameters ijθ  only through AVEθ  and for any given 
δ)  with ),( ∞−∞∈ijδ  and any fixed number ),( ∞−∞∈c , it is increasing in AVEθ . So the 
significance level is defined as 
( )0,sup
),(
=>≡
∞−∞∈
θδ
δ
))
cTPLevelceSignifican A
all ij
. 
Similar to Appendix B of Hung et al. (1993), it can be shown that for any given AVEθ  and 
c , the power function is increasing in each ),0( ∞∈ijδ  and is decreasing in each )0,(−∞∈ijδ  
when the remaining lmδ  are fixed. To prove it, consider the following cases. 
Case D.1. ),0(11 ∞∈δ  and 011 >+− δnvu ji , then 
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Case D.2. ),0(11 ∞∈δ  and 011 ≤+− δnvu ji , then  
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Combining the final results of Cases D.1 and D.2 for ),0(11 ∞∈δ , we obtain  
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Then, the derivative with respect to ),0(11 ∞∈δ  is given by 
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when the remaining lmδ  are fixed.  
Since ),0(11 ∞∈δ  is arbitrary, the same conclusion holds for any other ),0( ∞∈ijδ . 
Similarly, it can be shown that the derivative is negative in the case of each )0,(−∞∈ijδ , when 
the remaining lmδ  are fixed. So we can conclude that the power function is increasing in each 
),0( ∞∈ijδ  and is decreasing in each )0,(−∞∈ijδ  when the remaining lmδ  are fixed.  
Therefore, since any bounded monotone function converges, the significance level can be 
evaluated as 
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To evaluate the limit, let us first consider the limit when a single ∞→11δ  by 
considering separately the cases when ∞→11δ  and −∞→11δ . 
Case D.3. ∞→11δ  
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Case D.4. −∞→11δ  
Then, the first term of ( )0, => θδ ))cTP A  goes to zero and the second term becomes 
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Combining the above cases we can conclude that  
( )0,lim
11
=>∞→ θδδ
))
cTP A  
)(......)()(
'
)1(
)0,..,(
)1(
)1(
'1'1
'
1
'
10
111111
)11(0 wdQdvdvduduvun
vuwvuh nkj
n
j
i
k
iRP
ϕϕππδ ΠΠ∫ ∫ ==
∞
⎥⎦
⎤⎢⎣
⎡ −+−Φ= ) , 
where  
⎪⎩
⎪⎨⎧ −∞→
∞→=
.,0
,1
11
11
11 δ
δπ
if
if
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To simplify the limit expression, let us consider the numerator of the second term in q , 
that is  
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)(tG  can be written as  
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Next, we substitute a new variable xx −='  in the first double integral, then the limits of 
integration change from )0,(−∞  to )0,(∞ , since the density function of the standard normal 
random variable is even, )'()( xx ϕϕ = and 'dxdx −= , so by switching the limits of integration to 
),0( ∞  we obtain 
[ ] )(')'('')(
0 0
wdQdxxtxcwnntG ∫ ∫∞ ∞ +⋅−Φ= ϕ [ ] )()('
0 0
wdQdxxtxcwnn∫ ∫∞ ∞ −⋅−Φ+ ϕ  
        [ ] [ ]( ) )()(''
0
wdQdxxtxcwnntxcwnn∫ ∫∞ ∞ +⋅−Φ+−⋅−Φ= ϕ  
Next, our goal is to show that )(tG  is an increasing function in t , then the significance 
level can be obtained as the value of )(tG , evaluated at the largest possible t . To show that, we 
will consider the derivative of )(tG with respect to t  for any fixed 0>c  and any given 0>w , 
and prove that it is positive.  
Since the outer integral does not depend on t , the order of integration and differentiation 
can be changed and we obtain: 
[ ] [ ]( ) )()('')()('
0 0
wdQdxxtxcwnnxtxcwnnxtG t ∫ ∫∞ ∞ +⋅−+−⋅−−= ϕϕϕ  
           [ ] [ ]( ) 0)()(''
0 0
>+⋅−−⋅= ∫ ∫∞ ∞ wdQdxxxtxcwnntxcwnn ϕϕϕ , 
because for 0,0,0,0 >>>> twcx , 0' >+⋅ txcwnn . If 0' >−⋅ txcwnn  then 
txcwnntxcwnn +⋅<−⋅ ''  and )'()'( txcwnntxcwnn +⋅>−⋅ ϕϕ . If 0' <−⋅ txcwnn  then 
txcwnntxcwnn +⋅<−⋅ ''  and )'()'( txcwnntxcwnn +⋅>−⋅ ϕϕ . So the function 
difference in the double integral is always positive, which proves that 0)(' >tGt  and, hence, 
)(tG  is increasing in t . 
The last fact allows us to claim that the significance level can be obtained as the value of 
)(tG , evaluated at the largest possible t , subject to the constrains, specified above. This 
completes the proof of the theorem.  
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APPENDIX E 
THE OPTIMIZATION PROBLEM OF SECTION 4.2 
In Section 4.2 we formulate Theorem 4.2 which provides the equation for obtaining the critical 
values for the non-rectangular designs of the form (4.4). The proof of Theorem 4.2 is given in 
Appendix D. We also have mentioned that before the result can be applied, one should solve the 
following optimization problem.  
Problem. Let Kk ≤' , Nnnn kk ≤≤≤≤ − )1()1'()'( '...''  with )1()'( '' nn k < . Consider the non-
rectangular design of the form { }',...,1,',...,1),,( )( kinjjiI i ==≡ , where ∑
=
==
'
1
)(')'(''
k
i
inknn  
denotes the cardinality of I  and )1('' nkP += . Then, the problem is to find the maximum value 
'
max 1
2
max n
m
t
P
s
s∑
== ,
 
where the non-negative integers sm , Ps ,...,1=  are subject to the following constraints: 
{ } PksIksiksim
ksnm
s
ss
,...,1',)',(:)',(
;',...,1,' )(
+=∈−−≤
=≤
 
                                              
'
1
nm
P
s
s =∑
=
, 
where A  denotes the cardinality of a set A .    
We provide the solution to this problem for the specific form of the non-rectangular 
design, when a single highest dose combination is excluded from the rectangular design. This 
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result is presented in the Example 4.1 of Section 4.2 and states that for a non-rectangular design 
of the form, { })},{(\},...,1,,...,1),,{()},{(\0 NKNjKijiNKGI ==≡= , the maximum value  
'
max 1
2
max n
m
t
P
s
s∑
== , 
where sm , Ps ,...,1=  are non-negative integers subject to constraints:   
{ } PksIksiksim
ksnm
s
ss
,...,1',)',(:)',(
;',...,1,' )(
+=∈−−≤
=≤
 
                                               
'
1
nm
P
s
s =∑
=
,  
equals 
'
122
max n
babt +−= , where },min{ NKa = , },max{ NKb =  and 1' −= KNn .  
We now prove this fact. Since the non-rectangular design II ≡0  with 1' −= KNn , 
NKP += , NnKk s == )(','  for 1−≤ Ks  and 1' )( −= Nn K , the above constraints reduce to 
the following conditions: 
1
1,...,1,
1
;1,...,1,
−≤
−++=≤
−≤
−=≤
+ Km
NKKsKm
Nm
KsNm
NK
s
K
s
 
                                               and 1
1
−=∑+
=
KNm
NK
s
s . 
Next, consider the case when KNK =},max{  and NNK =},min{ , so KN ≤ . Note 
that t  is increasing in each sm , and there are 1−N  numbers  
KmK ≤+1 , KmKm NKK ≤≤ −++ 12 ,..., , 
that can be evaluated at the maximum possible value, K . The sum of these 1−N  numbers is 
equal to 1)1( −<−=− KNKKNNK  for 1>K . Hence, to satisfy the condition 
1
1
−=∑+
=
KNm
NK
s
s , 
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we should consider additional sms ' , as few of them as possible, which sum to S , such that 
1)1( −=+− KNSNK , i.e., 1−= KS . There is a single number 1−≤+ Km NK  which can be 
evaluated at its maximum possible value and the rest of the numbers are taken to be zero. Then  
11)1(0
1
111
−=−+−+=++= +
−+
+==
+
=
∑∑∑ KNKNKmmmm NKNK
Ks
s
K
s
s
NK
s
s . 
Numbers, chosen in such a way provide the combination which maximizes t  and   
1
12
1
)1()1( 222
max −
+−=−
−+−=
KN
KNK
KN
KNKt . 
Similarly, in the case when NNK =},max{  and KNK =},min{  we obtain  
1
122
max −
+−=
KN
NKNt . 
The results of both cases can be combined by letting },min{ NKa =  and 
},max{ NKb =  to obtain the final expression in the form  
'
122
max n
babt +−= , where 1' −= KNn . 
■ 
In Section 4.4 we provide the equation for obtaining the critical values for the AVE test 
for testing 0: 21131211
)'4(
0 ==== θθθθH , which corresponds to the design   
)}1,2(),3,1(),2,1(),1,1{('=I . 
Let us illustrate how the result is obtained. The design II ≡'  with 4'=n , 
1',3',2' )2()1( === nnk , then 5'' )1( =+= nkP . So the problem becomes: to maximize  
4
5
1
2∑
== s
sm
t , 
where 1,3 21 ≤≤ mm , { } 2)}1,2(),1,1{(')1,(:)1,(3 ==∈≤ Iiim , 
{ } 1)}2,1{(')2,(:)2,(4 ==∈≤ Iiim  and { } 1)}3,1{(')3,(:)3,(5 ==∈≤ Iiim , such that  
4
5
1
=∑
=s
sm . 
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Since t  is increasing in each sm , it is maximized when a single sm  (or a few of them) is  
evaluated at its maximum and the rest are taken to be zero. First, we rewrite the non-negative 
integers, sms ' , according to the maximum possible value: ,3max11 =≤m  2max33 =≤m , 
5,4,2,1max ==≤ tm tt . Next, since 45maxmax 31 >=+  we should decrease the value of  
3m  and consider 13 =m . Then 4max 31 =+ m  and we can take ,31 =m  13 =m  and 
5,4,2,0 == tmt . Thus, we obtain the maximized value  
4
10
max =t . 
■ 
The same method can be used to obtain the solution to the optimization problem for any 
other non-rectangular design I . 
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